var title_f9_7_9328="Tuberous breast deformity";
var content_f9_7_9328=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F86171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F86171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Tuberous breast deformity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 230px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    16-year-old with bilateral tuberous breast deformity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The breast: Examination and lesions. In: Emans, Laufer, Goldstein's Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_7_9328=[""].join("\n");
var outline_f9_7_9328=null;
var title_f9_7_9329="Roseola rash";
var content_f9_7_9329=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Characteristic roseola rash",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The rash of roseola appears as the fever abates. It starts on the neck and trunk and spreads to the extremities. As depicted above, it is erythematous, blanching, and macular or maculopapular.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Brady, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_7_9329=[""].join("\n");
var outline_f9_7_9329=null;
var title_f9_7_9330="Warfarin-induced skin necrosis on thighs";
var content_f9_7_9330=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F51999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F51999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Warfarin-induced skin necrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sharply demarcated, purpuric lesions are present on the thighs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_7_9330=[""].join("\n");
var outline_f9_7_9330=null;
var title_f9_7_9331="Pelvic binder";
var content_f9_7_9331=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Pelvic binders for open book fractures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 365px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hemorrhage from a pelvic fracture may be controlled by binding with a sheet or specialized binder that is centered over the greater trochanter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_7_9331=[""].join("\n");
var outline_f9_7_9331=null;
var title_f9_7_9332="Neomycin and polymyxin B: Drug information";
var content_f9_7_9332=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Neomycin and polymyxin B: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/5/34899?source=see_link\">",
"    see \"Neomycin and polymyxin B: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/14/4324?source=see_link\">",
"    see \"Neomycin and polymyxin B: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F200576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Neosporin&reg; G.U. Irrigant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F200577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Neosporin&reg; Irrigating Solution",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F200589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Topical;",
"     </li>",
"     <li>",
"      Genitourinary Irrigant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F200578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bladder irrigation:",
"     <b>",
"      Not for I.V. injection",
"     </b>",
"     ; add 1 mL irrigant to 1 L isotonic saline solution and connect container to the inflow of lumen of 3-way catheter. Continuous irrigant or rinse in the urinary bladder for up to a maximum of 10 days with administration rate adjusted to patient's urine output; usually no more than 1 L of irrigant is used per day.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F200585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/14/4324?source=see_link\">",
"      see \"Neomycin and polymyxin B: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F200579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F200565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution, irrigation: Neomycin 40 mg and polymyxin B sulfate 200,000 units per 1 mL (1 mL, 20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neosporin&reg; G.U. Irrigant: Neomycin 40 mg and polymyxin sulfate B 200,000 units per 1 mL (1 mL, 20 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F200552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F200568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bladder irrigant: Do not inject irrigant solution; concentrated irrigant solution must be diluted in 1 L normal saline before administration; connect irrigation container to the inflow lumen of a 3-way catheter to permit continuous irrigation of the urinary bladder",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F200567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term as a continuous irrigant or rinse in the urinary bladder to prevent bacteriuria and gram-negative rod septicemia associated with the use of indwelling catheters",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F200587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Contact dermatitis, erythema, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Bladder irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Neuromuscular blockade",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Ototoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Nephrotoxicity",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F200571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to neomycin, polymyxin B, or any component of the formulation; pregnancy (GU irrigant)",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F200559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acarbose: Neomycin may enhance the adverse/toxic effect of Acarbose. Neomycin may enhance the therapeutic effect of Acarbose. Neomycin may decrease the metabolism of Acarbose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Aminoglycosides may enhance the hypocalcemic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Polymyxin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CARBOplatin: Aminoglycosides may enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Aminoglycosides may decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (2nd Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (3rd Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (4th Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CISplatin: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Polymyxin B may enhance the neuromuscular-blocking effect of Colistimethate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Aminoglycosides may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gallium Nitrate: Aminoglycosides may enhance the nephrotoxic effect of Gallium Nitrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Polymyxin B may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Aminoglycosides may enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillins: May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: Neomycin may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Neomycin may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F200561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7413693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Because of several reports of total irreversible bilateral congenital deafness in children whose mothers received streptomycin during pregnancy, the manufacturer classifies neomycin and polymyxin B as pregnancy risk factor D. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F200581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F7413696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if neomycin or polymyxin B are excreted into breast milk. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Neosporin GU Irrigant Irrigation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40-200000 (1 mL): $28.55",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F200572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alosol (MX);",
"     </li>",
"     <li>",
"      Maxitrol (MX);",
"     </li>",
"     <li>",
"      Statrol (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IL, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TW, TZ, UG, YE, ZA, ZM, ZW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F200555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F200570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     See individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Topical: Clinically insignificant amounts of neomycin and polymyxin B are absorbed following irrigation of an intact urinary bladder. Systemic absorption may occur from a denuded bladder.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2007, 64(16):1711-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/7/9332/abstract-text/17687059/pubmed\" id=\"17687059\" target=\"_blank\">",
"        17687059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9687 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-AA4CF5E739-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_7_9332=[""].join("\n");
var outline_f9_7_9332=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200576\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200577\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200589\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200578\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200585\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200579\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200565\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200552\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200568\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200567\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200587\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200571\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299752\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200559\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200561\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7413693\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200581\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7413696\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323487\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200572\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200555\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200570\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9687\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9687|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/5/34899?source=related_link\">",
"      Neomycin and polymyxin B: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/14/4324?source=related_link\">",
"      Neomycin and polymyxin B: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_7_9333="HeartMate II";
var content_f9_7_9333=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F86142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F86142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 493px\">",
"   <div class=\"ttl\">",
"    The HeartMate II axial flow left ventricular assist device",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 473px; height: 526px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with the permission of: Thoratec Corporation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_7_9333=[""].join("\n");
var outline_f9_7_9333=null;
var title_f9_7_9334="RBC membrane model";
var content_f9_7_9334=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F79183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F79183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 607px\">",
"   <div class=\"ttl\">",
"    Multiprotein complexes in the red cell membrane",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 587px; height: 335px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFPAksDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6nk7UynydqZQAUUUUAFFFFABRRRQAUUUUAFFFFABRRQBk0AFFO2e9Gz3oAbRTtnvRs96AG0U7Z70bPegBtFO2e9Gz3oAbRTtnvRs96AG0U7Z70bPegBtFKRg0lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFSr0FAEVFS0UARUVLRQBFRUtFAEVFS0UARUVLRQBFRUtRUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUtRVLQA2TtTKfJ2plABRRRQAUUUUAFFFFABRRRQAUUUUAFKvUUlKvUUASVzfjnxlpnguwtrvVluZFuJTEqW6B3ACM7yEEjCIiszHsB3rpK5DxV4FsvFWvW95rVzdPY29nLbRWlvPLbENIR5jtJG6lgVULtIxjOc54ANm68S6FaanFp13rWmQahMVWO1kuo1lct90KhOTntgc1l6N430u6tLmbVLmy0oxX95ZIlzdqvmi3maIuN2OuASOcbgMnrXPW/wvkGj31nd639pnuY9OiFy9oAwWzkDrn5/mLAAE5HPPPSlsPhlHpl74gujfNf2ut/bRf2MkAJljmlkkWOJy/wC6I8xgedrdSqnmgDtr/wARaLp8ksd/rGnWskRxIs90iFDsMnIJ4+RS3+6CegrO/wCE48NxW/nahrWl6ejTSxRm6v7dfN8t9jMpDkYzjjORkBgp4rmfB/w/uodO8K3uv3Qk1uzvH1TUPMRZDPO9u0KqWBwDGrIAwz/qxjrmp7f4ZpFf39y+prJ9qg1WEKbX7n264WbOd3OwAr23Zzx0oA7nUdTsNMsHvtSvbW0skALXFxKscag9MsSAKzk8XeG3lsYk8Q6O0l+N1ogvYybkZK5jG75+QRxnkGs/WPCMl74a0HT7XUEgvNGlt57e4lt/NjaSFdo3x7gSpBPAYEHBByKxtU+H+p6pe3c91rtkF1NbUaksemEFzA5ZfIZpT5WRgHd5mDkjBNAHR3Xjnwla3Fxb3XijQoZ7clZo5NQhVoiG2kMC2QQ3Bz34qw/izw6l7a2b6/pK3d0Ea3gN5GHmDjKFFzltwIxjr2rB0zwBFZapYXr3iTG11TUdT2m2A3m6LnZnccbd4Ge+3oK4/RfhVqts9zos2pW6aAtrpcElx9kBnvPsxLHYRL+55AzlW68HjNAHd6N490e50a2vtZvtP0Z7m7urWGG7vEUymG4eHKltuSdgOAON2Oep3U1vSpJ1hj1OxaZp2tRGtwhYzKNzR4zneByV6gV5lqPwbNxGgh1sbmju4LhJo7lYpop7qW42lYLmInHmlTuZgwAOBXSab4DksfHh8UJqUJuHjNrJB9jG024VQihixcSAoMyEncOCoAXaAds/3qbTn+9TaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKlXoKYqginjgUAMmljhheWZ1jijUs7ucBQOSSewrn/BHjDTfGdpqN1o63It7K8ayLzx7PNIRHDoM5KFZFIJwT6VpeIdFsPEWjXWlavC01hcqFljWV4ywBBxuQhhyB0PtXLeGPAMvhiXU30bXLuNb/VY7+UXBkucwKiqYMyyNy205lGGxtByFXABeuvHml28nixHt9Rz4asxe3m62MfmIVlbEW/G/wD1Lc8KcjDHnE/hHxfb+JLu9tBp2oadeWkUM8kN55RJjmDGNgYndedjcEgjHI6Vi6t4G1TU9R8Yyz63ZLaeIdM/szyk05g9uqrMsbbzNhiPPbd8o3YGNvOdHwb4Jt/CN7MdFlit9MuIUE9iluFTz1AXzUIPybgPmXBBPIwc5ANebxNoMGpzadNrelx6hDGZZbV7uMSogXcWZM5AC8kkdOarnxp4WGmpqJ8S6INPeQwrc/b4vKLgZKh92Mgc4znFc7ffD+8uLHxHpUes26aLrU8128bWBa4jmkwc+b5gVkDKDtMedvy56ELYfD+5/wCEos9f1fVra6v4b77ZIlvYeRE4Fq9uiqpkYqRv3FiWJwBgDGADo7Xxh4Zu0uXtfEWjTpaxiWdo76JhEh6MxDfKDkcn1qlJ430ubUdAg0e6stVtdUvJrRrq1u0kSBo7eSY5K5BP7sDGRjdn2PFa/wDCy5t/By2mj3Ed3eWuiz6VFD5CxiYy3EUu8kvgY8s/Lnnd1HfTn+F8mo6jNqGta0kt5c3EstybO0NvGUayktAsamRyhAkLbiWyRjA7AHZWPizw7frusdf0m5Xz1tsw3kbjzmztj4P3zg4XqcVpWN7a38BmsbmC5hDsheGQOu5SQwyO4III7EV5jp3wkkg0e/0681mKdL2G3tJrgQ3LzG3iYtsUz3Mqo2SNrKq7DkgZI2994Q0eXw/4bsNJmuY7r7HGIUljtxBlBwuVBIzjGSMAnJwOlAGxUVSk4FRUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUtRVLQA2TtTKfJ2plABRRRQAUUUUAFFFFABRRRQA2WRIYnkldY40UszscBQOSSewrDj8WaRKoeB72eJuVkh0+4kRh6qyoQR7g4rQ1nTYtWsvslyW8hpI3kUYxIFYNsbPVTjBHcZFXs0AYf/CU6b/d1P8A8Fd1/wDG6B4p03+7qf8A4K7r/wCN1uZozQBif8JXp393U/8AwV3X/wAbo/4SvTv7up/+Cu6/+N1t5ozQBif8JXp393U//BXdf/G6P+Er07+7qf8A4K7r/wCN1t5ozQBif8JXp393U/8AwV3X/wAbo/4SvTv7up/+Cu6/+N1t5ozQByUuv6u+rxX9rpt43huONopla3K3EkjEETJERvKJtKkYDNvJAIUZ0v8AhK9O/u6n/wCCu6/+N1t0ZoAxP+Er07+7qf8A4K7r/wCN0f8ACV6d/d1P/wAFd1/8brbzRmgDE/4SvTv7up/+Cu6/+N0f8JVp393U/wDwV3X/AMbrbzRmgDDPinTT1XU//BXdf/G6P+Ep03+7qf8A4K7r/wCN1uZozQBh/wDCU6b/AHdT/wDBXdf/ABukbxXpSKXlN/GijLPJp1yiqPUkx4A9zW7mjJ9aAI7eeK5gjntpUmglUOkkbBldTyCCOCKkqjpGmw6VBPDbFvJknknVD0jLncyr6DcSce5q9QAUUUUAFFFFABRRRQAUUUUAFZuqa5p2mXEcF3OftMil0giieaQqDjdsQFtueM4xWlVKx06KzvdQu0ZnnvZFeRmxkBVCqg/2RgnHqzHvQBQ/4SnTf7up/wDgruv/AI3R/wAJTpv93U//AAV3X/xutzJozQBiDxVpo6Lqf/gruv8A43R/wlenf3dT/wDBXdf/AButvNGaAMT/AISvTv7up/8Agruv/jdH/CV6d/d1P/wV3X/xutvNGaAMT/hK9O/u6n/4K7r/AON0f8JXp393U/8AwV3X/wAbrbzTJJ4omCySojEZAZgCR/kigDBu/FCPA8ek2WpXd84KwxtYzQpu7F3kQKqjqSTnHQE8VDpPiG5sbCG08TQXq6rAgjmmt7GWWG4IGPNQxqQA3XacEZwR3PRC5gZlUTxFmOAA4JJ9BUtAGJ/wlenf3dT/APBXdf8Axuj/AISvTv7up/8Agruv/jdbeaM0AYn/AAlenf3dT/8ABXdf/G6P+Er07+7qf/gruv8A43W3mjNAGJ/wlWnf3dT/APBXdf8Axuk/4SnTf7up/wDgruv/AI3W6M0YPvQBhf8ACU6b/d1P/wAFd1/8bo/4SnTf7up/+Cu6/wDjdbuD70YPvQBl6brunajdNa207C6VPMME0LwyFem4K4BIz3AxWnVHUtNiv57CaRmSaynE8TpjIOCpX6MrEEVeoAKKKKACiiigAooooAKKKKACiiigAqWoqloAbJ2plPk7UygAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiuY8R6tqUOsW+naS9pAxgNxLNcRNLxuCqqqGXvkkk9unORg6Z4u12e3g1G8i01LQ3n2SS1iR2fHn+QZFlLDnd820p04znmpc0nYrlbVz0WiuY1LxpFbanf2Wn6HrWsf2eVW9msIo2SBmUME+eRWdgrKxWMMQCO5AqonxEsTeTLPpGsW+mxai+ltqbpCbcTrJ5WDtkMiqXwAzIByMkVRJ2VFKR82K5fQvF9tf6Dqeq3sf2O3srua3Pzby6o2EYADJLgoQoycsAM0AdWvQUuK878XXdzHrPgLWbzS9SSG3uLiS6itrSW8e3D2siqGWFWP3mA4BGe/euK1nT9Vm8RX91pWl6tJpOnXP/AAlVnmzlieaZvJD26owUlyFu/lI3fvV45BoA92fqKbXNfDfTLjSvBOlxX6FNQnVry7UjBE8zmWQHPOQzkfhXS0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAU4LkZzTa8Y8faZI/iDxNLrGgnVriaOJtEnuNFn1S3SMRAPCoiIMEhl3HeSv3gcnGAAe1bPejZ714vp5ubeHxppN1pOrQXus2dtBaCPTbqWAubCOLaZgjKoV8qS78YJJ4Jq/ounQeMPEPh0ap4eun0vTdCltbyLWNNaOPz3e3KoFlXDkeSx3LlRxzzQB6zs9683+JqKfEui5AP+h3P/AKMgrj7/AMIWmn/s6Xdpb+Hru11u9s2RodNspkuJ5x5nliZYV3Mo3HiTK8811fj66jvtY0C5hWZY5bG5ZVnheFwN8H3kcBlPsQDUy2Jn8LMjSkX/AISfw8cD/j/9P+mMtew14/pf/Iz+Hv8Ar/H/AKJlpLHxX4jk+JMtpJf3yab/AMJBJpy+fFaix8pbcP5QZV87zyTldxCnpkkEUobEUvhPYaK8x+EvizVbuz0HSNctNzXunz3lvfm9aeSYRSojearINp/eKRhm4HOOleh/2laLrK6UZR9va3N0Isc+WGClvzIFWaluivOYPFGoP4rS7a5P9iy3p09bbau0LuMazZxncZR642sOMjNdpresW2kxReaJJrmdtlvawjdLO/8AdUfqScBRySBzVSi42v1JjNTvboaanDCvP9D+JsGs3t5b2tjGqaXPdDV7iS62xWEMMsiK7Nt5dxGXCcYXJLDjd0Ok6VdTX8era+6PfJn7PbRMTDZgjBC9N7kHBcj1ChQTnHk+GOgyW80Kvexm4a7+1OjqrXMVy7vJDJ8vzJlzt/iXAwwOSZKK+sfEi1eTSk8Pt5sk9+ttcx3tnPA6RtbXEyOqyBDhjAMNgqQGxz06jwVqs+veCdA1e8SJLnUNPt7uVYgQivJGrEKCScZJxkmuW0b4SaDpK24t5p/3FylyhjtbO3JZYpYgGMMCFxtnY/Nk5AOeue08P6TBoXh/TdHs3le2sLWK0iaUguUjQKCxAAzgDOAKALdFB60UAFFFFABRRRQAUUUUAFFFFABRRRQAVLUVS0ANk7UynydqZQAUUUUAFFFFABRRRQAUUUUAFc54m8Qy6PrWgWUVvHLHqE5jld3IKLlFBUAcndIvXsDXR15x8ULyCx8QaDeXTbYLNTcSH0UXFuT/ACNVBXdiZOyudvq+tabo0cbapewWvmZCK7fM5HXavVvwFZ8PjPw7LII/7Wt4nPAFxmHP03gZrkI50063fWtaz/al8V8wKpeTJ5S3jA5wo4AHUhmPUmkfVdUnQg6InktwY57xQ5HuoVl/8eNeVPMbS0WnrY7o4S61evoenoyuisjBkYZDA5Bpa8diurXS2MlvFqfhmUnJkhQPak+rqu6PHuwU+4rsNE8YEGCLXTbCOchINTtWzazMeAp5JjYngAkqTgBsnFdVHFQq+T/rqY1KMoHZUjMqkBiAScDJ6mlryn4qW0V3qerm4Te1rookt2J5gcmcl0P8LZRPmGD8o9K6krmUVd2Ol1ohvGalSCP7OxkHPPm1yun/APIqR/8AYW/9yNR+GbG1sfGFwtnBHAr6TAXEYwGIlcZI9ffqe9PsP+RUj/7C3/uRrnmrVLeh0JWjb1OuufCutW2s6vd+G/EUOnW2qyLPcQz6f9paOUIqF4W8xQpKouQyuMjOO1YepeELnTba9XV9eibwvcawdTntoNPKzEyXAkCPMZWHlh9u4hFO0HkDNZPjLRfGNx8U/DOrzWtpeaZbatstFt7uYLbQGCQO8yCEqGJ/jLEZCIANxY5virQrOx1zVdc03w7Y6RbQSLo8BWwSFrszMDczH5RuUr+7UnI5dhnIroSbdkcrdlc9zYgEk9BzXmXwz0tLxUuLqQtFbLb3MdqeV897dP3599vCjsdzdSNvGap4l1zStNur+DW72T7HA8oikKvFIqKcBgVzhlAzzkEnBr0n4coIXuIVGFXT9PYf9+mX/wBlFTWhKlUgpdU/0CMlJOx24YgUu80xiFUkkADkk9q4bWPGbT27yaNNa2mmjhtXvP8AVt/1xQkb/ZiQvpvqZ1IwV5MuMXJ2R3FxNHDC0s8iRRIMs7sFUD3JrAfxp4cViE1WCbHU24aZR+KAivPzPbXsomaw1PX5wcrc34CRg+qLJtVfqiVpDWNSgQNNoxMI6i1ulkdR7Kyrn6A59K4KmYpO0V97SOqOEbV2/wAD0PStUsNXtzPpd5Bdwg7S0Thtp9D6H2NZHhDxDLrs+spNbxwiyu2gj2MW3xjIDHI4PB6e1cqb2CI2/ifSnB8vAuWUEefbhsSI467k+ZgDyrKRxlgbnwoZTPrm1g4eRJgw5yGaXB/Su3DVlXg5Ws0ctaDpyUe56DRRRWpIUUUUAFFFQX13BYWU93dyCK3gRpJHPRVAyTQBPRXDf2jrWpETyXcmlwtzHawRoZFXt5jsG+b1CgAdMnrVLUYfEMzI+n+Kry2Kj/VyWsEiN9TsDfr+FcTzCipWudCwtRq56NRXli+KfFehjOrx217bL1nMZ249TJGMp9TFj1auq0bxvpt+9vFdh9PnnwIfPZWimJ6eXKpKNnsMhj6VvDEU6mzM5UpR3R1NFFFbGYUUUUAFPUjb1qteXMNnaTXV1KkNvChkkkc4VFAyST6ACuO/4SLXNRHnafb2mn2jcxfbYnlmdezMisoTPoST64PFZ1a0KSvN2LhCU3aKO8yKTI9a4uHX9ftgPtFnp1+uefs7tbvj2VtwJ+rCtHTfFumXt3HaTmbT7+Q4S2vU8tnPojcq/wDwFjSp16dT4HcJU5w+JHR7h615x8TDnxJov/Xnc/8AoyCvQ687+JX/ACMmjf8AXnc/+jIKuWxlP4WYel/8jP4e/wCv7/2jLXo+rw6NaaPqM9zp9lLaktezxiBG8+RAG3EHhn+ReTz8o9K8f8RSPDYpJC7JIplKspwR+4l6HtTdd0LSw/ieIWMCww6YjRRquFjYibLIBwrHYmSME7RnpTpxugw8OaJ29jqWowi0mtfDnh62kgiaOCNJmDQo5DNGrCLgEquccEgHnFVrXXUvNTXxYkZiiGbIhyCUQQM7KT7TfL+FaMR5T8K5P7O1j8L/ALLBatPB5c99PPIcKmZ3kIHdnJ4A6ADLHorOuuXlt3McPVlO/MQyMtp4Wt7Rg0l1HZpOyocFNoDeYx52jcpI6liMAHnHaG4bRNe0WRwmpX+sZFzfS5UpHlAqQryEQNIp255xklmOawpLOOGwuoIgT5itvZjuaRiuNzHuccew4AAAFT6leLHH4KuJd0jixgkREG55m3wEqijlmwCf54612YqLTi5GWDkmpKJ6hXIeKfGK6douoano7293BpEivf7lba8QJEiRSZCmYdQvzcgKQCwItHTdS187teLWWnHppsEnzyD/AKbyL1/3EO3sWcVqXmg6XfW9jb3VnGbaxmjnt4FJSNHT7h2KQCFPIBBAIBxkCuM7TzTUvirqOlWHh3UruzspbTXY7qe2hh3ZiVTEIBLLuKJ/rCZHIwvQcj5vVdHF+NMt/wC15bWXUNmZmtI2SIt/shmJwOmSeevGcDKt/Bvh+2uRPFpyZVrlgjSO0Y+0bTMBGTtAcqCRjGcnHJzqaNptpo2mW+n6erpaW67IkeV5Ci9lDMScDoBngYA4FAFk9TSUp6mkoAKKKKACiiigAooooAKKKKACiiigAqWoqloAZIcDJ6VX8/uVOz1qS8/1DfSq78Ix9qaQiQzkk7FDKO+ev0o+0KR8oZvXA6VFDhYk7AD8qbCf3II7jNOyAnNwv8ALD1FBnBPyAsB3zUUQxEmPSkhPyED+8TRZATGcH7gLHv2xQZxgYU7/AO7npUUf3pAMdR/Kkjx50nrgUWAmE4GQ4w3YDnNHnqOCGDdl7moVINxjjKr+WaX/AJbt64GKLICU3CgfdO7+73ry/wCLMcN7q1vBdJmIW0JdfUG6Q/8AslelOR58eeuDzXmnxKfOuXGekVjbtn/tvIf/AGWrhG7+T/JmdR2XzX5oln/03xTcSv8ANHp8awxjsJZBudvrsMYH1b1q/Wfo/wA/9oznGZr+4Yn1CuYx+iCr9fEVn79u2h9NSXu37igkHjism90SCUTvZbbOeYES7UDRTgjkSxH5XB79G9CK1aKiM5Qd4sqUVJWY/wCHPiG6W7ufDesxyLfWsQntXLF1nt87Ttc8tsJA5+bDJnJ+Y53xGdZNQ8QlTx/Yag+3/HxTtShndYrmwIXUbRvOtmPA345Q/wCywyp9jnqBWf4qvodUttWv7YERXPh9JVDdVz9oOD7jofpX1WXYr6xDX4lueRWoexqabMs6L/yOUn/YIh/9HPUVjkeE48f9Bb/3I1Lov/I5S/8AYIh/9HPUVj/yKaf9hb/3I1pU/ifcJ7P5nq5nHI2nfnG2uJ+LUhbwzbBgAft9vjBzn5jXXsR9rb/dxn8a434skf8ACOWoPUX8BH/fRrspr316o4pfCzyXxd/yKOu/9g+4/wDRTV7N4PZbfV7yM9tMsMAd/wDXD+leNeLBnwnrY9bGcf8AkNq9SuNR/sW+1K7jjEtwNNso4Iz0eVnmRAfbcwz6DNPM2liKd+0v0M8N8L+RX8fa3davrB8MaXErRwosuoySE+UN3KRPjlsj5mQY3DaCQpOa9ppEENwl1clr2+UYFxcYLJ7IB8sY9lA981Y060+x22xpGmndjJPM33pZG5Zz9T27DAHAFWa+QxmMlXm+XSJ9Dh8MqUddwooorhOooabGsHiC8tCP9G1GE3Gzt5i4ST/vpWjP1BPej4KKlnZPaqWkKabY4J6sAJRk/lTNSPk6npFz02zSxH6NC5/mi1N8KTi6dcEFtKtGwfYyf419Pk/vUpt/3fza/I8PMPdqwXr+SPS/PU/dBLdx6UhuAcBFLN3HpUUWSXI67jmmqR50nvivSscpZEylSTkEcEd6POTazc8dsc1XfH2hfXaTRLgPEScHdj68UWC5MZyvMihV9Qc1zHjudp7fS9PKYjvL1PM56xxgykH2JRQfrXRXBAVQTyxAFcv4nbzPFWkR9orO5l/EvCo/TdWGJlyUpSXY0ormmkBpKKK+XPaFzjpXOavoYhSe40m2ikWXJutOYDyboHrhTwsnv0bo3Zh0VFVGViWrmZ4O8RDT/scEtxJc6FeER2s0pJktZCcLE5PJUn5Ru5VvlOcjHoTygY2DcSM9e1eU3ljEmr32nTL/AKDqkLXAUHG2QELLj0zujb67jXaeC9Qk1DRUa6cPfQMbe5PTMiEqWx23AB/+BV7mAruonTk7tbea/wCBsediaSjaa6/mdALj+Er+89B396XzwAQykN2HrUCkGdh3Cih/9fGPY16Nkchz3jqV7mPS9LdV8u8uRJMAc5iiHmEH2LCMH2Jrmby5udV1C4tbS5ltbG1by55oTiSaTAJRW/hVQRkjkk4BG053PEkyL4stnlIEdnpssrZ7b5F5/KI1g+G0ZdDs3l/10yfaJf8AfkJdv1Y14GZ1OWpp0sv1PTwcLx1EGjQrzHdapG/99dQmJ/ViD+IpLm11E27wSS2ur2j/AH7bUIlVmH++ox+aH61qUV5SrzXW53ulF9CloHittDultLx7v7Bglra9O6e0UdXjfJ86Id+SyDnp8ou/EcpJr+iyRuGU2dzgg5BBeHkVBfWdvfweTdxiRMhhyQVYdGUjlWHYjBFcnFHe2Go2OkXrtcQWdvcmzuSoG6BpISI2x/EhBHAAK7cY5A93A41Vl7Oe55GNw3s4uUdiLxR/yDB9ZP8A0RLWnr3/AB8eK/8AsFp/K4rM8Uf8g0fWT/0RLWnr3/Hz4s/7BafyuK9aj8JzYX4WdbH1T8KypwP+FT3P/XjL/Nq1Y+qfhWXP/wAknuf+vGX+bVGL+x6nFhftDb8z4IthECSd0kuSEHqFH3j7ZA9T2NO0gtrUaDNEkoea0064keVt7fNcR7VBwAFUDAVQAPStGfpL9DVLIOn6Jn/lnpOkt/5Hz/7LXqYyPvJ+pjgX7rXoerCZCGOSMdQRg0wzso3SKFT1z0+tRXIAKk8Ycfzpbgjyxk8ZA/WvPsejck8/oShCetHnkklEyo755NRykiJ/pgUIwWIEdAOKLAS/aFxlQzDuQKPtCn7oLKOpFQxcQKV/u54+lOjwETHTA5osgJDOCfkXcPUGnecmAck57Ac1Wg/1eOmCePxoiwJJceoz+VFgLDTKFBT5iegpv2g52lPm6jB4qHAFwcdSucfjSqR5rjvtGPzosgJhOBkOMHsBzn6UfaVxghg3Ze5qHgz4PVVzilP+vPqF4osguSmdRwVIb+6e9KkwzhxsOM8nioHOJos9eaS4xhc9NwxRYCykyMccg9eRjNM889QmU/WopxmJgTwBmnMQE3fw4zRYC0DkAjoalqvCCsKg9QBVipGV7vkKn948/SqYQ92JHVBnpzVy64kj+h/pUJx5UJ7jisJt3di0tiD5WKHkq7EkZ4oClQAGIUsRig8RkjtJx+dEwwj/AOywNZ88t7lWQIhGUDERg4x9aMYCEE7mOMj07VI3+rlPsD+Wab0kiHYDP8qblLTUSSGrHt3FCwOSWOeozTiBu2c8AsOfWpLbDFs/xKf51GD88R9QRQ5SsncLK4xEz5bKdrEHJ9aTazbJFY+Y3y5p8Zxt/wB4ilh4Df7L/wBaSnLuOyEVQxGWJGMn6/5zXmXjx86xq7uSVTT4Dk9sGVv8K9Pk+Uz+3/668r8fNtvvE7nkR2KjH0hZv612YK8qrT7M5sU7U7+aLnhznRLWT/nrum/77dm/rWjWZ4WGPC+j4GM2cJx6ZQGtOviqjvNvzPp4fCgooqI3EAuhbedH9pKGQRbhv25xux1xkgZqBktcVMwT/hNLIdLWybaPRZFmlH6yNXa1x2rQCPVvGso6zaNAT+C3Ir1smlbENd0zlxcbwT7G9ov/ACOUn/YIh/8ARz1DZ5/4RBcf9BU/+nGp9E/5HKX/ALBEP/o56i0/nwpH/wBhb/3I17VX+I/kcD2fzPTWA3hDnDEsDnmuL+KgB8MWjc7v7RgyT9TXaycOns5H4c1xnxU58Mw8dNRgx+dFCTdWKb6o5pr3WeV+JBu8O6qPW0lH/jhru/EMob4g6fY5/wCYct2w9fLeRF/WbP4Vw3iEZ0DUx620g/8AHDXoWrWv/FwvtRAyujpCD35nYn+QquIZcrg/KX42FlyvO3mi5RRmivjT6QKKbI6xRs8jKiKCzMxwAB1JNJDLHPDHNBIkkUih0dCCrKRkEEdRQIyvFbiLSknOB5NxG4J7ZO3/ANmq58PyYdYMYJVv7Lj6D+64H/s1ZHxIk8nwLrMwODFCJAfQhlOa3PCICeKzD3bT5R/3zJF/jX0+Tf7nWku6PDzL/eaa8md3tKO3lkjPzMf5/jQw2o7An5T8p7+9S2/zCPPdcH8qizmJQe7Y/WtuaVk7mdkOK/MVDHcSG3GmsGcZkI47D0p38Up+gH5VLMuGwOgT/GmpycXqFlcgKBvNBBJXkZNcrqeW8ZuGOTFpseMnpvlkP/sgrrEH71vUxg1yd983jHUW7ixtF/8AHpj/AFrmxMn7GXy/M2oJe0RNRRRXiHpBRTZHSKN5JHVEUFmZjgADqSaSCWOeGOaCRJYZFDo6MGVlIyCCOoPrTAyPEgKXGjXA6peeWf8Adkjdf/Qtv5VoeDW8vXddtc4WRILxcHB3MrRt/wCilqj4qXdp1qe639qR/wB/kH9at+G/l8aN/wBNNOIPvtlGP/QzXVhJNVY27NfqYV1enL1X+R2MablDJ8rngHv/AJ60uB8gJOHI5zzmliyPIx0DYP5GllBGcdRIMfnXsXfLe551lc868buy3XiplY7k0mKFSTnBYz4/9CFXVQRKEHAUbR9BWf4xG688SjP+suLCAewJj/8AizWkxyxNeFmDvP8Arsj1cGrR/rzEoopk0scEMk08iRxRqXd3ICqoGSST0FeedY+uf1z/AJGGw/685/8A0OGt6N1kjWSNldGAZWU5BB6EGsHW/wDkYbD/AK9J/wD0OGu3L/8AeI/P8mceP/3eXy/MxvFP/IMHuZP/AERLWpr3/Hz4r/7BafyuKzPFHOmDPrJ/6IlrT17/AI+fFn/YLT+VxX1VHZnk4X4GdbH1T8Ky5/8Akk9z/wBeMv8ANq1I+qfhWXP/AMknuf8Arxl/m1TjPsepw4T7Q+fpL9DWavzaJbjJymjaWc+nzMf6VpT9Jfoayg5/4Ri4ZBho9FsMH6RFv616mM+KPzMMDtL5Hqku92fcRwTgAdaZsVpNvLDAIyc8VamADoPY/wAxUEf3lPqleHOUr2ueukgVD1yx/iQGmqASh5KsSSM8ZqVciG3PfGKiHEa+0nH50SlJdQSBBtVV3EIWIx+dCoR8mSIwduKJB8pP9181LL/q5v8AZAaiM5PqDSIscxncQzdSPTFLyBlDgrxz35707H71B/sk0tv8wjz/ABEk/wA6IzleyYNIYFLMpcnJ444waaiK2xud2Dk55qaT7zY7P/Wo4j8+O4Yj8KTlK+4JIai58pgSrc5PrRhm2yBjvJ25pydB7ORSoNobH8L/ANRQpvuOyEC7mG4k5GW+o/yaRfuqTliQQM09/lkm9B/+umqPmiHopNNzkm9RWTFwzEozfL2OOppqqMoDkgg8Z4zU+P3Ubdy2f51C3Dr/AL5FE5S6sEkXIDmJfUcGrFVbf7rf71Wq6Iu6RD3K97gKjE4INVN+1mzkgfdwO5q3d/fj/GqsY4UdMNWFX4i47C7Mw5ZlB7duaZgPEy/KoAyeeppynBcnqGwPak7RfnU3XYY0yBiQCPLI5PpTogJBvBA2r1pMfLDx7mh+FbHXdj+VJPuAFsEsOCTtIHXHrT4/nf5SAAOMim/8vOe2AKByIQehPNC8wE4SVgCpHY56UjMIy6hgzE7vapB95iegGKYgAUj+6v8AjQ2AAhmZc5Zhz7H3ry7xggfVfFiA7sjyz/4Cp/jXqQXiPI65B968w1ICXW/EIP8AFdshz7Qxr/SvQy3Ws/RnHjv4fzOK8dWb6h4K8EGOzF1BHc2ssytp8l9Gkf2WQbnhT5mXJUduSK5433ijQ/C0djoNjq8DQm7ktpIrJljnG/cgMDW8rx8sQsZMYwPvdMeofD6Zp/Afh6STPmfYIVfP95UCn9Qa36+Q9v7P3JK9mz6T2XN7ydro85ivPF73sl75l7sGqR2yWDWiLEYGt0ZnLbN+BIzDduwMEHPaPwE2rXviy3vtXOryTnSSlwbyw+zRQTmVC0UZ2LuA5wctkDqea9KorN11ZrlRfs9b3POdStorn4jaVdafos0NxBdMLqddMaF5B5br5rXf3HjwVHl/eJA54xW3rf8Ax/eLf+wLF/K6rqxXKa3/AMf3i3/sCxfyuq78rnz4mPkmYYiPLB+bNjRf+Ryk/wCwRD/6OeobIkeEFI6jVT/6cam0X/kcpP8AsEQ/+jnqKx48JJ/2FT/6ca9mr/EfyOF7P5nqA/eShVOApIywPJrjPiwqr4dt9rBgb+3798muxkJAHu/9TXH/ABXH/FNW3bF/B/OjD/xI+qOap8LPLNf/AOQFqX/XtJ/6Ca9L1f8A5G8/9g5P/Rr15pr/APyAdR/69pP/AEE16Xq//I4H/sHJ/wCjXpcSfY9H+aHlfx/12Z4jpem3tj4vl1CDSJpL2PXL2UrHpMsMskDtIN7Xbfu3TBBVO5xzV/S9a8b3jzQD+14oZZLHy557EGSEPPtmBzbRKcJyflYDGQxHT2Givm5YpS3ime0qNtmeU6vd+KBDc6fez619iBvYUu7XTVlnuSNghVwsRVVYM/zhVB29R36aSOGH4daVbatpT3g+yQRPA+nm7ETiMYZ4R8zBWAyBz9Oo7Cis3Wulpaxap2vqeZWtlJb/AAb1a0ubaW2RmnWNJIjCCjz/AClYjzEp3cIeQMZz1r0bwyR/wm0C5AL2lyMn2eE1g/EaQp4VaNfvT3lpAB6hriPP6ZrX0E48XWHq8Nyv6I3/ALLX02Ue/hK031f+R4eY+7iaUeyPQkfbsVDkr8pp0IWTCKRw3XNI/wDq2I6k0rYDMcY+XP41KfcYbhvIJHzdD604kyoW4yx2imr92Pd/d6flTQoCKTkHd2NFwJZQIWGSCzDHpXG3BI8Y6mrZP+h2pB9RumH9K7BjuMgbnC9T+NcnrCmHxdbHoLnT2T8YpR/SascUr05WNaGk1c8N0rTL7T/GMuowaNPJexa9fSlYtHmglkgkeUb2vG/dyJtIKp3O3mtDStc8dXjzwD+2YYZZLDy57ixDSwB7jbODm1iU7U5PysBjIYjp7PRXmvEc28bnaqVtmeSaxeeKhDc6dfXGufYQb6FLu00xZZ7kjYIVcLEVVGDP84RQdvUd+okigg+G2kWur6TJeL9jt4nt5NPa8ETiMYaSAfMwVgMgc/TqOzoqHVvbSxShbqedeFLSay+H9pBNay2oGrK0aSRGHKG8BUrEeYkIPEZ5UYznrXdeHEMnjVMHAGnS/rLH/hVTxR/yDYP+v21/9HpVvw4SPGYwcH+zZMf9/UrbDy5sRGT8/wAjOsrUpJeR2BPlmRVxlTlaVW3sqjIOcksD1pindGjY7k/zpzkhHIPO7/CvVvr5HnnnPi75dX1aMHJbU9OJ/Hyv/ia8c0DTr/TNbjv7bRp3v4b7UGkjh0iW3maNzKVZrp/3co+7tTH8S9cV7L47XytfuVPyq/8AZk499tyUb/2X860DXk4uq6c2raP/AC/4J6GGhzxT7HkWiav40vnuIJG1aGF7myEVxNZDzI43ZxMPmtolO0BSTsIXP3iDSa7eeKZtMv8ATr+TWvs/lX8EU9ppqyS3jBysSyYjIRWQ53Kqg8/MMV67RXJ9YV7qCOn2TtZyZymrpbp4JsYNT0w3qmKKMxSac16sL7OHeFfmYAjBxzz25IwvBttNZ6XodvcW01syW97tSVDGdpuEKkIeY1IIIQ8qMLzjNekVz+uf8jFYf9ec/wD6HDW+AqXrRj5t/gznx8LUZP8ArdGN4p/5Bg69ZP8A0RLWpr3/AB8eK/8AsFp/K4rM8U/8g0fWT/0RLWnr3/Hz4s/7BafyuK+mo7M8vC/AzrY+qfhWXP8A8knuf+vGX+bVqR9U/Csu4/5JPc/9eMv82qcZ9j1OHCfaHz9JfoayIX3eD9SYdY9Jtl/KzVv/AGateb/lr+NZGm4bwXqR9NPiU/hYxH+tetivjj8/0OfA/DL5fqesbjIrN6fKPeiVPK8tiwz0P0qvb7WtI5ORkK3B9QKnJzMFbkBTjP1rwLqzvueyJ5m0kckD7uBmlKfuAS657DpzTYuAg9/6UqHG/PXdj6ChPuAMA0RGQoHPXqaa0gYuAcRsOTTiCBF7Dmgf8sh7c0r9gHJhwZAcBR1pqSbATkAoc4pG4HH9/H4UsgyXGOeMUX2sA8KXKgYBPzmmouJmVCME/eP60INsi7SQSvrTD8yw59ef1p3VgsOwEkIBVh2Oaa7CPzAGySd3tT/4iR0AIpqcDn+FTn86TfkABwzsCcs45HpTnPlOASCBxmmqPkjyO+D+tA/1bf7+B9M0XAeGydvVU5BoMRWMOzDOc4phQHzTjtx2pwc5jGSQ3PPammuoehZgBCc45OeKs1Wt/wDVfif51ZrpjsjN7le7HMZ98VUJwSf7pGfz/wDr1cvD+6x3JwPaqciKsZZR8w5yTnP1qZUnJ3Q1Kwj9Zh2IzSuc5x1IB/Dmho0VCQOVGc+v1oKYj3biGC9an2D6MfMO4LAfTH05pjDcy+helEbbFbcS4GPb6URRqY1ZhknnB7UvYyYc6An52PqQo/D/ACaQ8IuOqtj9aIohht2W2kgA9qWKIEtu+bBwM0/YPqxc4ZAMhPQMCfpxSLwCW6ZBP0pVjBd1JO0cYz1z60gQl3Xe23AHvR7GSHzId3j/ABP+fzry5yX1TV2Yfev5h9QDt/pXp+wtMQ5yAOD0z7V5dF817fsOhv7n/wBHvXfltNxqtvt+qOLHSvTSXcp/D1ryHRFstRjijniCTxGI5WSGVd6OB1HO9SD0Kntg11FRWGiz6h4T8N6hpjxx6jBaLHsmJEc8eOY2IBI5AIbBwexBIpy6d4iuDtXT7WwXODLc3Al/75SP734stfLYvLqzrN01dM9/D4uCppTeqH0VU8RQ6h4WshqWp3VreaWjolzJFA0L24ZgokILsGQEjd0IGTzjFXDXn4jDVMO0qi3OulWhVV4iCuU1v/j+8W/9gWL+V1XViuU1v/j+8W/9gWL+V1XblH+8r0Zniv4ZsaJ/yOUv/YIh/wDRz1DaZ/4RBcdf7VP/AKcam0X/AJHKT/sEQ/8Ao56isQD4SQHvqp/9ONe5V/iP5HnPZ/M9Ol+5Jjqpz/WuO+K//IvQ/wDX9bH/AMeNdl5a+bIGGQpwAa4z4rLjw5bgH5Rf25/8ePH6VrRouNSLv1RyTleLPLfEHGgamfS2kP8A44a9J1VifGbDt/ZkZ/OWSvNPEp2+HNWI6i0lP/jhr0fUWLeNnH/UJhP5zS1jxJ9j0f5ovK/j/rsyzRRTJ5Y7eCWeeRYoYkLyO5wqqBkknsAOa+QPoRLieG2gea5ljhhQZZ5GCqPqTVGLXdMkkRFvoQznC7ztDewJwD+FZGg3SeI4ItcmhcW7s32GGZf9XGCQJSvZ2wTnqFIHrnblCzRtHMqyRsMMjjcGHoQetdXsIx0nuebUzC0rQV0YXjb7Xc3Wl2lnEjRQXEd3eO7YEaeYsaADuzFmx/uE9sHb0N9vizSPVzOg/GJj/wCy1mJDFYadqdjGrFprqyuIpHYsRGJVUxAn+FCuQP8AbNaGkf8AI0aHnPNw65B6fuJf8K+vyuioYGSi73PHxlb2uKjI9J42AHvn86Juj49AP1pscZZclz94kYpY03FjIMnOMdjXMqMup08yHOBkjsq/5/lSP8wTHG5s0bB5hTnaBng+v/6qQrmTbuO0DPvT9jLuHMgPPmn1+Wub8coYrG01dAT/AGbP5s2ByYWUpL+QIf8A4BXRsjBlQE7Cc5706SNQF2jgnaR1yDS9g5JpgqlndHMghgGUhlIyCDkEUuCRkDihvCItk8vS9WvbGxBG21RI5FjBP3Y2dSVX0HIHQYGBWX/wre1Enm3eua5dlWDKWujHIT7umDj2XaPUGvN/supfdHb9cjbY06Ko2JuLS9utJ1CUzXNrteOcgA3EDZ2OQON2QytjuucAMBV6vPqU3Tk4S3R1QmpxUkZHij/kG2//AF+2v/o9Kt+Hzt8Ys3ppsn/o1KqeKP8AkG2//X7a/wDo9KteH0D+MSMkf8S1+n/XVK2wivWgvX8jOu7U5fL8zsk+SIZ/hPP+fxoIO2RT1wD/AJ/KiNCzOZOQp246Z96URqZWGPlABx/n6V7qoya1PM50cF8WYWj0+DU0HEcLwye2SkkZP/bSNF/4HUyusqiRDlHG5T6g811+oafbajbTWN5EstpcRsksR6Mp4I9utef6NA2l+boVxI7z6ZtiRpDlpYP+WUhPfKjBP95Wrys1wzjBVF0O/A1VzODNKimzSJDGXldY0HVnIA/M0sbpJGrxsro3IZTkEexrwz0ha5/W/wDkYbD/AK85/wD0OGugrn9b/wCRhsP+vOf/ANDhrty//eI/P8mceYf7vL5fmY/ij/kGD6yf+iJa09e/4+fFn/YLT+VxWZ4p50wfWT/0RLWnr3/Hz4s/7BafyuK+ro7M8nC/AzrY+qfhWXP/AMknuf8Arxl/m1akfVPwrLuP+ST3P/XjL/NqjF/Y9ThwvUkm/wCWv0NZugqJfB98o6G1RD/4BxCtGf8A5a/Q1T8KKH8JyBf449p+ohRf6V6+JXvx+f6HPgvhl8v1PQrFxJpNnIvIkijI+m0VZBzcE9sbf61n6EN2iaUASENnCfp8i1edGUqqsdrHqeoNeG6MnqevzIXODn+6QD/n8RSOOJgemAadJGqoSvB459e1K8arGSq8qM59frT9g+4c4kh+8PbP4c05seZ78f1pjJtiLAtuC9c0bGVd28lwuPal7GQcyA/MV9CxNKTyx65JH44xQkS7QWXrz16UkaBlJYng4GD6d6fsGuoucd/y29gtR8tCh7qwNPRCwYsx4JHHGaSOMEvv+bBxSVBj5xSQDL9QTQP489Dgn6UixgyMvO0frR5ZMjruO0DHvR7GQc6HA52e5J/z+dNT/Vx+rHP9aNpMu1+QBnPr7UroA6hPlDdcdu9HsH1Yc6DOI3I9Mfj/AJNAH7xB/dXNDpt27SQGOCDzQUKkEMdpwrZ9PWh0ZbhzItQD90vvzVmosY4qWtkrKxBDcoXQAYyDkZ9ar+U0nyuNqnrz1q5J2plVcCs0cpBTAIPG7/61NKOF2FC3GMjvVuii4FQblAV1JYeg60sccqKq4BI754q1RRcRWCSR5ULvGev+NKIXjBK/MW5Ye/tVpBk1454g8VaysHinVxq+p2tvo2otaGx022s5fs8SAYlnWch3D9QEZThhgHBNFxnrAjdGLkZB6qOopu11ZnKkKfbmvG9P8d67aarrOo3N3qd/pmm6lqsd7BLp6x2sFtAZBAIpxEpeUusabd7k5OQOtdP8JPFep6jp+q2XiuS6k1ixEd0xk06S1doZIwcLEyKzBJFljBCndtHJJouB3yq7SB1X5cBcHjNeS2ByJXHO+6uH6+szn+ter6Rq9hq8Rl027iuFU4cIfmQ+jKeVPsQDXkWkMr6dA6fdfc4/4ExP9a7sBrN+hxY74F6noHgMPL4P0rapHlqy8+zsMfpW+UeUbFDKe5I6VjfDtifCNqCMbZbhfynkFdJXHJ2bOuOqRnahYR6pp11p99Cr2l1E0EyNyGRgQw/I15V4Ke5trO60PUZGkvtFmayd26yxr/qpPxTH4g17JI6xxtJIyoigszMcBQOpJ9K8hmkMusQeIURkj1W8eLYRgmBkAhYj1/chvYSmvLzSMZ0dd+h24KTjU02NyuT1v/j+8W/9gWL+V1XWVyetvGmo+KPOOI20q2jJ9N73Cf8As2fwrzMof+0r0Z6GL0pmzon/ACOUv/YIh/8ARz1FY/8AIpJgZ/4mx/8ATjU+kFD41n8vOz+yotueuPOkxUOn/wDIqR/9hb/3I171X+I/kee9n8z1NonDFwQWP3h/LFcX8WUceGbZmwM39uMf8CNd6eprhfjE6R+FLd5XVEF/b5ZjgD5vWuqm/fj6o4pLRnkPiw48J62fSxnP/kNq9BnkDePJl7jRLRuvrNP/AIV534pljm8Ga5JDIkkZ0+4wyMGB/dN3FdzDJ5nj+dh38PaefzluDXJxHtH0f5o1yz4/67G6KwfENoPEGqaV4WDERahJ5t6R/wA+sfzMvtvIC/TdW9WR4fuVstWg8R3OPImvJbSZz/yxgz5SN9A6ZPp5jHtXzmXwjKsnLZfn0PZxcmqbUepavoP7L1u602QbC0klxbZGBJEzFvl9dpYqR2wp7io4ZPMaZcYMUpjP/fKsD+IYGvSNW0ux1e2FvqVtHcRBtyhxyjdmUjlT7gg1ydr4W0lvE9/YXcMtxbLbwXMUU9xI6tnfG28Fvnx5afez1r2auAU5OSe54Ryk6Nd2X9pKP9CkuoLW2ftLtLu7r6rlVUHvtY9MGremts8RaEwBP+m4494pB/Wum+JISPT9FiVQq/bgFCjAAEEp/DpXLWjFNZ0ZgOl/EPzyP6172DpqnhJRXS/5HDXf7+Py/M9QUNGMOpAySMDPfpSokq5IUFWOQM4Iq3XP+KPEn9kLp1vp9oupapqdybSzt/OEaM6ozuXfB2qqoxJAJ7AE1x3O81/JdPn+8x+8B+mKbsfdvCHAGMd64CP4k3txLp9pp+maBfX95qDWCm118TWylYXlLNIkJYHCEbWjByfTmltPivbXMvhsJpMgh1JQ19N54K2G6YwRE8fOryggH5Rgbvai4WO+KO5DKpAXnnjNO8l5OG+VRyPXParjAAcUyi4WKzRSOpUgKP72aaySMu3aQ3r2+tW6KLgcb45i+zxWetIjB9Pci4wOts+BJ+CkJJ/wA+tIetdfcRR3FvLDcKrwyKUdW6FSMEH8K888LyNJ4c01mcyfuFAc9XUDCt+IAP415GaQWlReh3YOT1iR+KP+Qbb/APX7a/8Ao9KueHDjxl0J/wCJa/Qf9NUqn4o/5Btv/wBftr/6PSr/AIX/AOR0/wC4c/8A6NSuTBfx4fP8joxH8KXy/M7FI5FLMVJDc4zyKcIZM+Zkb+mO2PSrNI7BEZmOFAyTX0VzybFYxylt+MY42561la1oFprLwS3cEqzQZEc8MjRSoDjIDKckHAyDkHA4qDw7468P+Irm2g0y7uPNuoftFsLmynthcR4zuiMqKJBjn5c8c1o+J9bh8Paal3cQXNy8s8VtDb2wUyTSyMFVV3FVHJ6kgAA80n7yswWmqMyy8IaPDKJhYi7uF/5b35M7/QF87f8AgIArlfH1mvhW903XbG2jttJmnFnqkMKhUXzOIrjA4BV8KxHVX5+6K7Xwx4iXxDJfC30y/tobSZrdp7jytjyodsiLtdjlGBUkgKSPlLDmrniTSrfW9A1HS7xA8F3A8Lg+46/gcH8KzqUoVIOm1oVCcoS509TjDXP65/yMVh/15z/+hw03wtqm3QrODVJWOoxRqjIqM8kg2gq2xQW5BGeOufSo9SmefxDZlraeBBaT7TLtBb95F/CCSPxwfavn8Hh6lPELmWiv+T2PSxtaM8O7Pt+Zm+KP+QYMesn/AKIlrT8Q4jvPEaTOkJuNPjih81gnmMfPGFz1PI6eorO8RsUsopAWDRyM42sVyRDIcZBBxxzV7U4ktH8UxWyLEi6YrDYOSSJ8kt1JO0dT2r6SlseZhb8rsdTZXIuCNkNyirjDyxGMN9A2G/EgD0zVKf8A5JPc/wDXjL/Nq1Ihyn4VjXFxD/wqG6m8xfKFlKpbPGdzLj8+KnF7Q9TjwurlYsTf8tPoareB/n8J25H8QYH8OP6VamHMg+tVvh4Q/g7S2H8Ssf8Ax817OI+KPz/Q5cH8Mvl+p2vhNXbwtojhSdtjAD7/ALtelapR5CNqkbTnJGM+1Z/ggk+DdD3dfsUIP/fArbrybnqlbymkG1xtXvzyaDHKQUIGDxuqzRRcCoyPtKFSeMZHQ+9HzAbWUl8YwB1q3RRcCqkcqoq4GQMbs8UGIxDCgsvXjrmrVFFwKapImSyHaxzgckfWnIkgLMF4b+E8H61aoouBV2SKS+M54KjtSbXDs5QhD+f5VboouFioFdn3ovy4xg8ZpxhdsOQAy/dXP51ZoouFiq6O+0KhBU5+ajazkKFYc8kjGKtUUXAKlqKpaQDZO1Mp8namUAFFFFABRRRQA5OtZWpeF9A1PUI7/UtD0q8vo8bLi4tI5JFx0wxBIrUBwadv9qAKZ0fTGtJrU6dZm1mmNxLCYF2SSl95dlxgtu+bJ5zz1qZrS2+2fbPs8P2vy/J8/YPM2Zzt3dcZ5x0zU2/2pC2RjFAGVq2h6dqTie7th9qjHyXMTGKZB/syKQwHtnFeTaMZH020kaQGOSFXCNGAyEgHAZcAj6rn3Ney6g/l2F1JnG2J2z9FNeO6QpXSbFT1FvGD/wB8iu/ARvJvscWNlaKR6D8N2J8LgH+G7uh/5HeukuJoreB5riVIoUG55JGCqo9STwK5n4bEnQLhf7t9OB+L5/rXPySDxLetqd+BNYrIw0+1bmNEU4ExXozsQWBP3VKgYO4nllHmqNLuzqpv3F6E3jHxTourvY6NbatYyWl0xe7ZZ12PGuMRbs4O9iuRnlVcd6z76X+09dihi5tNMcvK3Z7gphUH+6rkn3ZR2NaOsXIttGv55Y1mjgt5JTE43KwVScEHjHFZ+gafFpWi2VnAFCxRjOBgFjyx/FiT+NeJnEfZcsr3buv8z08B711bYv1x/iSGRtS15tpEJ0jzd3YmNLhQPzmU/wDAa7CuZ1i6jni8VxAkyW+n+X7BfLkb/wBCLj/gFcWTwcsRfsmdWMfuJeZqaJ/yOUv/AGCIf/Rz0yzRk8KxBgQf7WB/D+0abp9wtp4nvLp/uwaJHKfoskjf0o02SWTwVpwuABNHdwQv/vJeKhP5qTXu1V+8v5o89vdep6frepW+j6Zc394W8mBclUGWck4VVHdiSAB3JFeefZptTuF1DxAqT3pO6OAnfDaDskY6Fh3fqxz0GFF74p6za2F1pqX8pW0tg99KqglpJARHCgA+8xZ2IA6sornfC3iK41/w3PqS6W9vdRyzwiyaZSxeJ2XaWxgElfoPU9aVWT2Rrg6cfiluUvG/hmPUbcLp4htJL9hYXTbcKyS/JvIHV1JGD3yQTjpJobiXxlPKv3T4e0wDP1mP/swqTRdZu9Z1IaZfWMNreW+p2kTfZ7k3EbciZgHKIdwVDkY4yOuar+E/m12eQjBGl2UB+qJyPzY1xY/meH16f5otKKxKcev/AATrKzdKKW15d6LeIr2115k9sHGVkVzmWIj1DMTjur/7JrSrK8Tjy9GmvE4nsf8ATIiOzR84/Fdyn2Y14VGVpW7ndVjdX7HZ+BLqU6fdabcyPLLps3kLI5y0kRUNGSe5CttJ7lCe9WNR/wBH8ZaNP0W5t7i0Puw2SL+iSfnVPwQpkvtfuh9xrpIE+iRLn/x5mH4Vd8WnyY9Kven2XUYGJ9pCYT+ktfWUZOVOLlvY8KokpNIx/iW3/IDTHW6kb8oX/wAa5EvML6w8hEVxdwbJZW+UOZAF+UZZhkjP3eO9dT8SSft+hp2Bnc/gqj/2auWmbZJZuOq3tqf/ACOlevQjfDy+f5HmVnauvl+Z6GfDj33Ov6ldagD1t4z9nt/psQ5Yezs1P1nwnpuqaZZ2kQl002EwuLKbT9sT2sgBXKDBXkMwIIIIJyDXQbeKaGIrzT0Dhpvhbol9eJda9Pd63P8AbRfTf2gkDpcOIDAoeNYlTaEIwAo5UEk85l1T4W+FdUbVHvdOiknvYkhhm8qMSaeiRhEW2bb+6C43DGfmJ7YA7XefajefagBqIY4ERnaRlABd8Zb3OABn6CilLE0lABRRRQByfji/kmEWg2bsk98jNcyqcGC26MR6MxOxf+BN/DVWONIo0jiRUjRQqqowFA4AHtioZvm8XeIHfmRWt41z2jEQYD6bnk/WrFeBj6rnV5eiPTwsFGF+5keKP+QbB/1+2v8A6PSr/hf/AJHQe+nSf+jU/wAaoeKP+QbB/wBftr/6PSr/AIX/AOR0X/sHS/8Ao2Oowf8AHp/P8i8R/Cl8vzO8pkyGSGRFxllIGafR3r6I8k8ktvh34j1PwfofhzX30iytNG097aKayuJLiS4la1ktgzbo49iBZWYqN2TgZwOYn+Gmta3qFvP4otPDskEQ0qL7Msr3KMlq03mE74lGWWYgDGMEgnufYt5o3mgDxLUfhrP4esIT4Ys7Ox1291i8gF1p1pxHYXLycSMFG0RRlGXPyho1UZzz03ivSLS0j0/QNNmvF3wrHFbLOVgsrWMBS+xcBieFUPu+Y5xhTXo+8+leZ6vqK2Wp+J9TmjaWWO4jtY41+8wWOPy4x6bnlb/vvNc+KqunTbjvsa0YKc7PYqqkVv4juLaxRYbZLKLzIolCxqxkfbwOM43Z9sVn65/yMNh/15z/APocNaek2b2sDtcyCW9nczXMo6M5x09FAAUD0Ud81ma5/wAjFYf9ec//AKHDXhYWfPi099/yPQxceXCyX9bmR4n/AOQaPrJ/6IlrS17/AI+fFn/YLT+VxWb4n/5Bo+sn/oiWtLXv+PnxZ/2C0/lcV9NR2PMwvws62L7yfhXBmHHwqutKbJV7qWbb/wBMyWuj+GQRXeRdY/wrmv7KuT4Nl1bcn2EaBPEVz83nb2w2PTYWFVWjzW9ThwvU1peXf8ap/DIh/Afh915D26vn6kmrjf6xvrVH4XDb8OvC47/2fAfzUH+teriPiXz/AEOXB7S+X6neeBG3eDtIPpbqPy4rdHJxWD4HcDwnZFiFVBIpJOAMSMP6VJF4l0+9uHtdHnW/ugrYMCtJCrAEgPKoKLyMYJzXkM9Y3NnvRs96+eLbxKUstElGsahdeJbqJ11WA69NFcWdx5MjOrWBUosKMoAYbDyvJzku0qfxJaeEtL1a8u/EWmeGby205dRurrUTdTncC0tzE2+RoYzlAeVIDE7VxmkB9C7PekYYrmPAU2gypqI8M67daxaLIm5pL+S+jibb0jmcsTnqRubB9OldTJ2oAZRRRQAUUUUAFFFFABRRRQAUUUUAFS1FUtADZO1Mp8namUAFFFFABRRRQAUUUUAFFFFADZUSWJ45FDI6lWB7g8EV5wfBet2ZW2sZbC6tUGyKa4leORVHQMoRgxAxyCM9cCvSaco7mtKdWdN3gyJ041FaSMTRdPg8MeG5FvbtSsYkubm5cbFycszY52qBwBk8AcnrXA+FD5GiLJdXISK1iW28uT92IEiXBMgP3XP3mz90FR2JPZzn/hJtYMI+bRNOm/entdXKH7nukZGT6uAP4GBwvFekWl743thhlj+zfar2IH93curBYC69CVw5z32qDkAYIN812N2jEzpb19VspobHSb67tLiJo/OOyFHVgRlfMZWI564wexpvh+5e70OwlmUpMYVWVT1VwMMPwYEV0sUyXEUc0MiyRSKHR1OQwPIIPcGub05fs9/q1njAiu2lQf7EoEn/AKEzj8K8zPKfNRjU7P8AM6ssrN1XB9UXndI0aSU4jQF3PooGSfyFcVKjpH4lMw2zSaJHNIPR3+1Ow/AsR+FdVqwEtoLY/wDL1Ituf91jl/8AyGHrA1wlr/xcx6nRYj+l1XDlHuzXnf8ABf8ABf3Hfitfl+pZK+b4ie3/AOfrT7S3P+61y2//AMcD1YW48jwW9yY3lMeptJ5ceNzY1AnAyQM/UipbCzZ/GGn3e792tgSV91JUH/yOfyquP+RFl/7CL/8ApwNexV/iW80cEtpMk1W60/xh4luY9U0NvsotERYdSihkV3jlfeQAzjjzE6461n6f4E07S7N7XR7q/wBNjeS5lb7G6RZaYEcgLg7M/Jx8uB1xWvbacb63mlgm+z3ltfzNDLt3DnAZWXIypHUZHQEEECrb2GpXS+VdXMFtCeHNoWMjD0DNjZ9QCfQg81dWjLn93YjCY+kqK9r8SMT4a2mkaH4ke3uPEbS2+nqYraG/aCItcPnzHQpGm8gHaWJYlmfoQc6EGiHQfENxbG4FwJ4pLlXC7QqPO2xOpztUKM98ZreitbaOySzSCIWiLsWEqCgX0wa52DTrPTvFc62Fuluj2EZMcfCA+a/Rei/gBmubMafLhZfL80GExPtcStP6sa1ZPioPLok1pCyrLeOlopZdwHmMFJIyM4UscZHStas27xP4g0q3xkQiW8b6qvlr+spP/Aa+dwVP2uIhHz/LU9qvLlptmp4c1u58NWxt9biglsWmkmk1C2BXy2kcuTJGckKN2NwZsAcgDJHWeMrdrvwnqqQcy/ZnkiI/vqNyn8wK5YjnBwc8YPfParQ19dA+Gmo6gIVuF0tZYY4mk2qwViqKWPQAFQT2ANfYSgo7HhzVtTV1/Ro/E2n6feWs/kzxjzoXIyrK68qw9DwcjoQDz0OLY+C72W9t21Ga3jtYZUmZIWZ2lKMGUZIG0ZAJ6k4xxVHX9b8Q+APCUlzq934ZaBYYbSxWOGW3SG5dljRXLysGiUEsWyhwp4HUaGmeM7nWvhHceJtMl07+07e0mkkwpmt/Ph3CQAK4JQlDtO7owPPdxqzjFwT0ZhKlCUlJrU7tjximVw/hDxBr9/4vOm6rPpUln/YlpqY+zWckUnmTM6ldzTONoMTHpn5gM/Llu7k7VmaDKKKKACiiigAooooA4rX4vs3jRZBwl/Y/+Pwv/PbMP++aWrfj2Mxw6TqCj/j1vURz/sSgxH/x50P4VUrwcxhy1b9z08JK8LdjI8Uf8g2D/r9tf/R6Vf8AC/8AyOi/9g6X/wBGx1Q8Uf8AINg/6/bX/wBHpV/wv/yOi/8AYOl/9Gx1ng/49P5/kXiP4U/l+Z3lFFKozX0R5IlFQpe2b6jJYJd27X0cYle2EimREJIDFc5AJBGfanPc2sd5FaSXMK3cyM8cLOA7quNzBepA3LkjpketAEleW+NI/svi/Yx/c3N1a3h/3tkkP6NHCfxrvdH8S6BrdzNbaLrml6jcwjdJFaXccroM4ywUkjnjmuS+Ltuy2thfxKTJGJIhj+8AJ0/8etwv/Aq58VDnpNGtGXLNMbXP63/yMNh/15z/APocNb8brKiyRnMbgMpHcHkVga3/AMjDYf8AXnP/AOhw187l/wDvEfn+TPTzD/d5fL8zH8T/APINH1k/9ES1p69/x8+LP+wWn8ris3xP/wAg0fWT/wBES1pa/wD8fPiv/sFp/K4r6ujseThfgZ1sXVPwqFf+SIXX/YOm/m1TRdY/wqKFd3wSu+MkaZcNj6bz/StanQ4cL1KkpwZD6Zqp4Qt5x4B0CC0nFtKLC2AkMYk2jy1zgE4zj1/I1PcSAW80meAjN+lWfDS7fDmkAcAWUOP+/a16VfdHNg9pfIueCvC+nXWgwSap5+qSLPOMXsm+METOMiIYjB467c13UaLFGqRoERRhVUYAHsK8r0ldQvbW4t7q6lttMhvLlYre0laN5szOS8jjDAZOAikDAySc4E02m6bp8TXEdxJpbL/y8xXjQkH3JO1vowIPoa+HxXEmFoYl4ZRlKSdnZde292e1GlJx5j1DJ9TRk+priPD3iu9uIGs2sptVv0yY57dBBHPFxiQ+ZtA5ODs3DIyOuBrfZ/El9n7ReWOkxH+C0Q3Ev/fyQBR/37Ne9CSnFSXUyNfVdRttJ0u81LUZTDZWcL3E8m0tsjRSzHABJwATgAmuP1f4i2zaVLc+F9PvNZu4J4Yp7V7W6geKOUMVmKiB5CmFOGVGB7GrniHwgb7wn4gsLS8ubjU9S024skuL+6d1DSRlRlR8qjJGdq/hUOn/AA/NrG9x/wAJJrqazL5Hm6hG1uJCkSOqxbfJ8sxjzHOChJJBJyBigMPUvifeWml6TqEWjWM1heW8k0+oLdXZs7YrLsCNKtmxU9SfMSMKVYHpz6ch3Ro3y/MoPytuH4HuK4y5+G9lLoyaRDreu22ltBJb3VtFPGUvFkdnkMm6MkM5d8shQkMR0xXabFjREQBUUYAHQCgAooooAKKKKACiiigAooooAKlqKpaAGydqZT5O1MoAKKByaXafSgBKKXafSjafSgBKKXafSjafSgBKKXafSjafSgAUZNYPiW9uZ7iLQ9IlMV/cpvmuF5NpBnBk/wB88qgPfJ5CmtDXtUTR9P8AOMbT3EjCK3t0OGnlb7qD+ZPQAEngGq/hzSpNPt5ZbyRZ9Tu3868nUcM+MBVz0RRhVHoMnkkkAu6fZW+m2MFnZRLDbQIEjQdgP5/XvXAeNZbW78Q5LSjTY1Sw1Ocf6rcW3xwsewJbDnoA6r/ESvX+Ib+dJYNL0ll/tS7BKuRuFtGOGmYe2cKP4mIHTJGV4u06DSfh3eabZqwgkRbV2c7mYTSKkjsT1Y72Yk9SSaL21E1dGEmo3+rkvo/2e108HCXk0ZkafHGYowQAnozHnsuME55gurLxPHJeXpulvrUxgmFY9rxNuA+XrlZH/wC+a6VUSJVjjVURRtRBwABgYA9BwKzdfspbyyR7Pb9utpRPb7zhWYAgoT2DKWXPbOe1cGJnPEQlB7P+kLDTVGpGZWkPm6xCmfltoWmP+852L/46sv51ga0M3vi3H/QFi/ldVcg1zTre4vHv7uG2uZZOIJXHmBEHlgBRnd86yH5c/eqsNIbXLu/vLiW+s4b6NbT7Op8tpbdd2N4IJQsXfoQwUgHB4HNl9GosSlbSKt83/wAFs9LFYmnTpc0nuzc0C6jk8Q3dtyZIbK357AZZj+e9fyrOH/Iiy/8AYRf/ANOBqLRP+JXqjamYr+7gu7cxbox5rKElby8rx95MfMPQZxxTLaW7k8OjS5tMu4Lt70zEttMSxm587JcHGdpwVHO7jkc16koSdS9uxxOvBwd33LcuupoNkWazu72a81Z7WGG18vczlSw5dlUDCHvU0PiwXNjcTWei6rPdWs3kXVl+5jmtztDZbfIqkEEEFWbOeKrajodzrNnbPYXsNndWOrNeo81uZ0YhWXaVDof485z2rI8R6G+k6JfXur6zaTtf3KG/+1aMbuC4ZtkcMaW6NuAUhdoDMSTk57dktzyaaXKjt9D1O31rRrLU7Lf9mu4Vnj3rtbawyMiqNz/yNsn/AGD0/wDRr1S8H6rpNp4VWFdVmnj0iER3c1/G8Ese1c7pEkAZRgHGR0HU08aja6hHZeJdLeS60y5tvLZ44m3BN25X2EbsZLA8Z5B6A1xY+EqmGlGKu/8Ago7MDJU8RGUtF/wDVrm3t/t+valc/abuFYRHZp5E7R52jexOOvMmP+A1ZuPEtiVaPTJE1K+xlLe3bccnoXI4ReuS3ocZPFGmWrWdkkUkglmJaSWQDAeRiWYgdhknHtivCy6jOEnUkrdj6HETjJKK1KeoXN3p9lIl8r6vp0mI8OVjmhckBGLjA27sfPgMn3uccd1oMCWdrJ4T8RQwzm5SVklYZj1BXy0oOf8AloCzbl4yPmUAZC8pfpFJYXSXOPIaJxJnpt2nP6Zru7HT113wXpUWqeYJ3tIJTKh2yxTBARIrdmB5z+fGRXvU5ua1PMrxUWrFfTfAHhvT9RsL+GyuJbqwObV7q+uLjyBtZdqCR2CqAxwoGBwcZAI0LnwzpNxY6zZvbSrb6xIZb1YrmWPzWKqpIKsCuVRQQuM85zk5j0PVLgXb6RrRRdViTekqrtS8iHHmoOxGQGX+En0Kk7201oYHP6J4Q0bRNWOpafFei8Nqllvm1C4nHkp9xNsjsvHJBxnLMf4jnoGbNLtNG00ANop200hU0AJRRRQAUUUUAZviXTzqvh/UbFDiSeBkjP8AdfHyn8Gwa5TS7xdR021vEGBPGsmP7pI5H1ByPwrva4vUPD+o6dfTz6HHBdWVy7TSWcknltFIxyxjbBBDHJKnGCSQecDhx2HlWinDdHThqqptqWzMjxR/yDYP+v21/wDR6Vf8L/8AI6r/ANg6X/0bHWdqOjeKL29tHl0m1FlC3mrCt8PMaUZAMhK4CjOQFLHOD2wep8JaDcadNc3+qSRPqNyqx7IcmOCNSSEUkAsckktgZ44AArkwuEqwrRlJWSv+JvWrwlTcU9zpKRw7RSLE4SQqQrFdwU9jjvS0oOOleyeeeQ+GfBvizwh4y1rWw1n4hkm0jLSrD9kl1C6EjsI2ZpnCHBUbtuwLtUAba6DUdNvW+LOga1beGJhElhcW19qEbWwyZDCYwxMgkdU8uQfdON3yg5OO+3H1o3H1oA8g+HvgrxF4fuPD9xqf2i52WVzZ7C8GdIaSTfvXbgSowVByXZTjqCcdT4otNfOiTJdtp2oW8DJc+aitbyr5bB/ufMr5CkHletdtuOOteSfETVr/AP4TCW2tdRu7a3tLeIbIJiil23MxYD73Gzrkfmaajz+6aUoOcrR3INDv7a00e2t7mV4Vt1EPmzJhMLwAZBlM4x/FUesMsmu6dJGyvE1nPtdTuU/PD0I4NZPw11C0MmoWVhqAu4hsljkWdZMYURsm5f7u1Pf5xWjrkFtaeIbC4WGCE3EM0LSKipvfMbAEjqcKxGfQ14MKcKWN5LWevpqv67ndied4Z31/4cyfGDyR6QphRHYuykO20AGKQE9DyBkgd/brWxrwzc+K/fS4/wCVxWXqU0d7PBawQSXyxTkXSxRSSKiGNwQzICVb5hgDJGQcVsaVoVjrltdXFxqV65nUW14BdowmiXP7th5atHjcwPyo/wAxyemPW+sRoRbnsefhU1Hbc6iIcp+FVfDutaRJ8PU0u8vBaySWs1uTPG8a5JdeGYBSOeoNY97P4c04eTceLp4Ao2iIagjOo9OAX/HOfeki8feGdLtobbTWvpYYVCRpBaSYAHT5nAB+uaxrZiml7OLfroLDYGcW76+mpnanqDf8K5u9QhwztpLSpjuxhyP1IrsdKjMOk2MX/PO2jT8kArx+/wDFcN3by6AmhX8ti0zuXmZEjNuWLquQWGckLt9BV7/hZutRQRwf2BBHLGgTdvknV8DGRtVRz6EivWlmFGTV5dEZUMtxMU/ce56RogIhvQT0vbj9ZCf61oFQSrFQWU5Ukcg+o9K8Uh8YeMLfz5kfTilzM87wJb5eAtj5UZn2sOMnPcnBIwKil8Y+K5+I7u/Vj/0wt4VH1Yqx/IGvy3MMmxFbG1K9KStKTad31fpoe5TwdZRSlE9w0kl/G+n7SS6WVy0h9ELRAZ+rDj/dNd1g18oafrfiG1M013qGrS3k+0TS2t2qghc7VUfIQo3H65JPWpZPEM7Em81jxBED1NxeXIQfUhto/OvrsqUcDhYYdvmave3m2/1IlltWb5m0vW/+R9VYPoaPm96+XZEd12y3V84/27yZv5tUX2OLGCZT9ZnP8zXf9cj2KWT1esl+J9UfN70nJ7Gvlf7FB/cJ/wCBH/GlFnCB8ocfSRh/Wj67HsP+xqn8y/E+p8H0NGD6GvlqOARnMc12h9VupR/JqnSa8jH7rVNXj/3dRnH/ALPR9cj2Ynk9XpJfj/kfTtFfNR1TWipVfEGtoCMcX0hP5kmqLPq7OWPivxTz1H9qPj8qpYyn5mbyiutrff8A8A+o8H0pcH0NfLiTayh/5GbXnHpJeMwpJG1KRSJNUmlz188yP+m8U/rdMX9lV+34n1E7Kgy7BR6scVl3niPQ7LIvNZ02AjtJdIp/U183eTIeZItJmfu0thvz+clWoL2/tx/o0Ojxn/Ys2T+T1P1uPT+vwKWVVev6f5nuM3xB8MpxFqRuj2Fpbyz5/FFI/Wuwr5lXWtYP3/7Mb6RSD/2evpqtaNX2lznxWFeH5b9RsnasfxZq/wDwj/hbWdZ8j7R/Z1lNd+Tv2eZ5aF9u7BxnGM4P0rYk7VmeIdKg13QNT0i7aVLa/tpbSVoiA4SRCpKkgjOCcZBrY4zjrD4r+HrvWYraG+0+a0XSX1O6uba8Wf7MVkiQRFEBJYmXjuSMAHNas3xK8MQIhlur5ZWkki+z/wBl3RnVo0V3DQ+XvXCOrZKgYOelR6/8O9F8QFF1JrqSNdMbSgm5dvlmSKQOQVOXDQoR/D1yDUXh/wCGWjaHLBLbTSmSHzwpjtbS2DCVFRtywQxg4CDBIzyckjAABKvxJ8P3dhJcaXeCUobVh9qguLdZI55liSRCYiXUsSAVBXOASoJYUvFHxL0+xsln0YzXSx6lbWlxM2n3LQeW1ykMvlyhQkjjc2AjMcjocEVbb4a6O1hYWhudQ8uzsbHT4z5iZMdpMs0ZPyfeLIA3QEZwB1pYfh5aQxRWq6zrB0qC9jv7fT2aAxQSJcLOoVvK8wruXGGc8MRwcEAFyH4geHJjZpFd3Lz3bzRxW4sLjzi0LIsqmLZvUqZFJBAODnoCRWPxO8JC2nuDqcogiVZA5srjEyNKsQaL5P3q73Rd0e4fMKt2HgnTbLxCusRzXb3IkvJNjspQm5MRkGNucDyVxz3Oc8YxYvhTpCwW0E2p6zcW1mkUNjDLLHts4kuIpxHHiMEgtBECXLNtXGR1oA09P+I/he/vo7SK+uYpnleD/SrC4t0WVFZ2jZ5I1VXCqzbWIOBnGCKuaN400LWRcGxvJFFvALpzc20tsDCc4lUyqu6P5T865HHWqt34C0i8ZvtL3ciNqkmrPGXUK0jwNAyHC52bHPGc579qreCfhvo3g77QNN/exzRCApLZ2iEIOxeKFHf33s2evXmgC9oMUusagPEF9G6RlDHp1u4wYoT1lYdnk4PPKrgcEtnX1zVItH083EiPNKzCOCCP788rfdRfc+vQDJOACasXM8Vpby3FzKkMESGSSRzhVUDJJPYAVgaHFNrF+uv6hE8abSunW0gw0MR6yMD0kcdjyq4XglsgF7w5pklik93qEiTateEPdSr90Y+7Gn+wgJA9eWPLGo/GUlkPDl9DqXmmC5Q26xwjMsjvwqxju5OMenU4AJrSv7y30+ynu72ZIbaFS8kjHhQKxNDsrnU9QXXdWheGQKVsLOTraxt1dx/z1Ydf7o+UfxFgDkLKX7BqTx+I3FtrcqhFaYhYnj6hYH6MM8sB8xbJIA2gX9Q1a106CSSS4g85UZ4ojIN0jKCQoHU9O1dvrJsYdJu59XWJrCCJppxLH5ihFBJJXBzgA8Yrz2417wW+jvPo1v8AZUjudPknii0lrSaWOW5RYiFkWMtGz4ywyMA9TxWLopu9yHHUyrC2vtG1IQa7ELWea3jjsz5gZWijB3KW6CXczOw54cYJ2nF+7vFt7O5njdGeKJ5FAYElgpI/XFd/4o0Cz8RaRLYaguUYh45AAWhkH3ZFz3B/A8g5BIryE2H2C+bTdQs7aHUoZow5iiAWWMEv5qf7DLEwx2OVPTntpyXLY469Jqop9Huch4h03S4/Eeuxajot1qM32C0t9PmgsnkbeiyKdk4GIznYSSy0yBrGDxNpD6xZ3Npqll5LXmqixnka9n8kIY0lVSoiycnLAEjgdWrp7270Sw1OxsLpbWO9vS3kJ5AJcjk8gYHXvjJ4FWNTlstH0281SS2TZaQPO5ijXeVVSxA6c4HrWvIl1OP6xJ9Nza8NaoIPPTU2Fv8AaZmnhMnyhQ3/ACzJ6BuAeeuSO1TeOdPn1jQlt9NlsjdR3dtdILiYxo3lTJIQWVWIyFIzg1mRulxbq+3KSKGww7Hnmqt1bWNvA8sllEyryRHbeY34KoJP4CnKCepEK7jpa5Hc+Dp/EGp3Gqa/qi6dcyGBUttLmSWILC0jJ5hmjxId0hPKADauOma3vh5pMvhrwhp2lX+oRXNzboVZ1ddo5zhcKvA9xmsn+z7L/nztf+/K/wCFJa6KmsanHpWmWtsk7qHnuPIQi1iPG88cscEKO5yeimpcIx1bNY151GoRibeoWt9rGtPceHoY7h7CMw3heTas+cMsKN08xclsngbtp++StCfUreHdFe/arCcgqUnt2SRT7AjDEe2QfevVdE0qz0TSrbTtNhWG0t12og/MknuSSSSeSSTV/JrinBTdz26M3SjynkmjaXd+KnFpNELewjKrqLN8rScA+VGh+YK6kEs2MI2Bls7fWgABgDAHYVzfiRW0i+j8RwKxjjQQ6ii8l7fJIkx3MZJb/dLjk4rpY9siB0YMrDIIOQR6inGKjsEpOW5ma7pMWr2qI0jwXML+bbXMWPMt5ACA659iQQeCCQcg1wXxYvPEV3Fo3hrw82oNrU0Ml9dzaTIkLxrGm1CDJIgCNM8eV3ElVYc816ls96cOBTJPBbPx7Outanr1obKyfULPRba6uL5SYNPYverK0oDLkK6lPvKMkZIFZ/h/4g6hoOi6gLbUNCVGutU1CO5uYJPL1Wb7bKPItlWXKswwQMyHDrw3Jr6KooA8B1Hx/deErXXJLN7a11C91q8lWC9t1dG2QQEpve4gVWywGAWY9lOK0bf4tatLecR6XcGXS/t9tpliq3FxI32Pz9jss++E7sjmArjaAxLDHs9zd29qYRc3EUJmkEUQkcL5jkEhVz1OAeB6GpXOBQB5t8IvGup+MBqf9pDTHjt1haOSylgJBcNuR447icqRtGCxXOT8o2mvRaKKACiiigCvf3trp1nLd6hdQWlpCu6SeeQRog9WY8AfWmalqNnpujXWrXlwqafbW73UsyguBEqliwCgk8AnjOe1ct8StC1bxOmjaTpwto7A3Yur6e6i86LbF80cbRCRGcNJtPBxhDnsD53rXhHxtL4Sm8P3djqepW9to9zpVl/Z+pLaRySgssM8ymZSyNEUXYxfBVsqQ2aAParzVrGzOmC5uAh1KYW9r8jHzJDG0gHA4+VGOTgceuK0Nh9q8Vm8J+K7vxDprXdpqrTWuqyTpfnU1+xw2ptZY41SAS8OrOoLCPd1IYgmlXTviLd6TYwS2msWzWek2dpd/wDE0iEt9LHMhuGidZTtd4w2JGKtzyVPNAHsS3Nu169mtxCbtI1maAOPMVGJCsV6gEqwB6EqfSpiCK8j1Dw/4pvLtY9Kh8SaZpEi6ajRXWtb7iMLfStdHzBO5yYWXkMSVwo5G0df4X0fWbPSdSsLnUL632ajM1lPNMLuX7MSCgLSFiRyR8x3AUAdZRWCNK1oHjxHKf8Aesoj/ICsvxDYa9HHDLPqVxf6XGSbu1sYfs9y6eqOpJOOcou1mHQ5G1gDZ1HxDZ2t21lbLLqGpgc2loA7r6FySFjHu5Ge2a8R8e3j3g8UXcqLFcusySJE24K0cfl48wgFsbOwXn+9XuugLpUOjwPoa2yaa6+YhtwAjercdT6k85614TBHqFyjXccNvJFcyPcIDMVcK7lxuyuN2GGecVcGr6nXg6TqSemxzPgqwurYNdos1mR5UltI8glkLeXtck5OY2G0BWPAHRcDHafbNV8QXUOizxacIJF8y6mRWZliHdVbIVi2ADlsfMR0qi5uo8mXTrsADrGFkH/jrE/pWPrHiDUdE8PatdaPa3iXt0ZcXpsZZY7WOCPowCnDFy+N2FGSxOBg5YmjRqWm0nJbHfNKnG2p61Y2ltp9nDaWMEdvawqEjijXaqj0Arzv4k6BpsviOzv57G1mlvLZ4ZWkiDFihXb1Ho5H0Uelbc+uw3nhS1uBrr6bcCOB7ho4Fa4y65CCJ1JDOfujYSewNctqd5q01x4YsNZkhTU2t53eS5GwbnkHlK2xSokMcZJUYGQcVxyT5WXGcFKN9tDh7ryFlli0VPsFujFPNgdgXI4O1c7QM8ZIOcdu5Z3N5BMi3epSy27sFMjwxloyeATgDK+vQjrzVSGNYI2t5b15HtiYpDZ2pkUEEjO8kg5xmiV9IudPultNQuby7MbKlusu2Qtg8bFAPvnpXnc0nU5d9bbD+uJap/jZfmbF9qNzaTPDbrBfvGSrlQYVUjqNxLAn6A4qO019JiyT2wt5kGWjNzEePUEkZH6+1TWmj2LwxC00e6uk2goxtJZAfQ5cY96uXNhqmnQxXVhorWlxHPEIJJRDEvmM4QAjdnncRjHeojKEpKLj+n6jeYyi78yt2vf9L/iZ9x4k0m1lEd3dG2kK7gssbcj1BAIP51Ys9Vtb5FaxMtwrfdKRkbh6jdit+Dw5r3zN5VmjucvLPeMzufVtqHJ/H6U4aLqmjurvPps0V4/kfZRavKhlYEo5ywA5GGIHQ55IFEHRnLlWnzX9fiT/AGs1u19z/wAzOWC/cAppV5g/3jGv83plxBqMdncSyabtWONmYSXEfIAJPQmteX4f/aZzLca/f27k5C6XGlmi+wC5yP8Aeya1rLwxoy2d3Z+Itb8QlVHmxSQ3K77pCwUwbQn3sso4xkNnIwadJU6s+SEl87ol5v6/gYlho+tRWFpELO0YpCiEvdkHIUDtGanfS9VRcvFp6D/aunx/6LrrPJ00ybz4Yjmizny7rWJ5JCPfIKA+2SPeu18N6b4IvNKk1GHQtLtFgJW4F1bRh4GAyQ5OR0IIOcEEEHBrvpQpVm1CSf8AXqZf2rJKyv8Ah/keJyrPF/rbzQk74OoEf+yU1PtEn+pk02f/AK4Tyy/+gxGvfLTxL4Rt3VLea0tkJwJPszRRf99lQv61vXmr6ZYuqXuo2ds7DcqyzqhI9Rk1vHDQfUh5rW6f1+B82fYNedh5Gh3M47mOG5/rBU66J4rYkR+EdUkx3VkXP/fwrX0wjJLGrxuHRhkMpyCKaRg1X1WmT/amI7/gj51g8K+LZV3P4Vv4fZri2J/SWmyeHPEsefM8NaoAO4Eb5/75c19GUUfVKY1m2IXb7j5qk0vWY8eZoGtDPpYyNj/vkGoHgvUJEml6smOu7Tpx/wCyV9OUuT6mp+pw7stZxW6pfj/mfLRn2g74LtAP79rKv81qM39sOsoH1BH86+qcn1NGT6ml9Tj3LWcVOsV+J8pNq2nrw17bj6yAV9Y1EeeoFS1tRoqlez3OPF4yWKtzK1hsnamU+TtTK2OMVPvCpKiooAloqKjNAEtFZniPWbTw74e1DWNRLC0sYHnl2jLEKM4A7k9BXL6b45uRrMlh4htNF0147R7yWGHWkuLm2RV3fvYCilflOcqXHv0JAOV8SeC9T8QfFDXbi20yxhTbpjw63c71ntvLZ2f7MQh3MQAG+dQMjOc4rm9N8A6pafCV7iLR9Ji1qZ4BGsWhNHfoft0bEzSby0ihV3EbV4AOeK7uy+KF1e+GYr6Lw+INVl1K109bC6vDGFFyEaGRnEbEArIpICnBDDnFLpvxG1jWNTXS9H8OWM2oxR3T3KS6qUiDQTLEyxOIW8zJcYJCdwcYoAl8FeHRLZ3Vn4gtLxdaivVuNUuXQmLVXGTG4k24aIcERDGzbtIx970J2VFZnYKoGSScAD1Neb23xi0Q3TRak1rpQ/sv7cn2+9jiZ5hNNDJbgHglXgIyCc56eujpN7cfEDSdKuJ7OSx0O5s7e9uYmbd9qaWNZBADgbol3DccDefl6bhQBfsFbxTfQ6lOpGh2ziSwhYf8fUg6XDD+6P8AlmP+B/3cdYnemDgYHanx96AM7xTp8ureGdX062ZFnvLOa3jaQkKGdCoJwCcZPpXl1x8Kr+LSJtLtri0u7W+h00XbahczSyRtbTxu0cbsGLQsokwhxtY8cN8vslfL819qy+DtZu9Zvb2Kx1DSNdijnn1Oe6jvplMqpEY5Pkt3RUYrszvAPOQRQB7t4G8Nf8IvDrVrElpDYXGpSXVnb2o2pBCyRjZtwAvzK5wOPmz3NUfGemz67rVvY2MywXNrZS3KyMuV3s6qit32sBKDjnuORXA634p8Szn/AIQlWafVZ/sUkc2hL9luFtGR5JtplmwGURBN+9c+YOAeDXg8W3GofYIPGOozaSLPTjbFJ9Vl0uGfU4pHSZZrqEkqdixuqgsCJMjd2NhNJqzOX1rwvqOvanql9JeyafqVsY4La0+RhDJERIBKShYZkOcoRuTackHFUrzwBdzWl1JCunQ6jdSakZplZsulwsojQttyQrOpIPAwSMmvVdM0ibX/AAJpHiLS47htXWBhJDcXPnveRB2whlKruYdUcgdcHhiaz7WeO6t0mgJZG9QQQRwQQeQQcgg8ggiuqDU15nk4iM6Dstuh55feG9W0vSxLamK51qO8RrW+RGaWTzAY2EwxgIiscEHbhV4XHNm58AoLTU4LVbUl7WCCykmJLRlFIdicHBYE8jJOTmu/IqG6n+zxqQjyyOwjiijGXlc8BFHqfyHJOACa05Uc6rTbstzitO8IXdp4m06bTYLGXWLnUb6Y7SQ0kMu8rvbbnYm5C2eBjjLEA/Q3hXQIPD2m/Z4nM1xI3m3Nyww08hHLH0HAAHYACqPgjw1/YtvJd35jl1i6A8905WJeoiT/AGRnr/Eck9gOnrknK702PYoUuRXluFFFFQbiEAgggEHsa8i8UeHdF0/xjpUet6Bfa3oUGj3MFuq6XJfiGRp42SNSiNsIQMqsSMAfe7169TlbA6UAeBQ3vxJ0VNG06FLy1tUtleDzIZboHM8hEVw0drO2Vi8pT88Xc7m5xunW/GJ1G6S4uPEML774XUUGirJDZxLu+zPbOYv3ztiPK7nzubITHHsO/wBqN/tQB43N4q8b6R4eTWtYhuG1KG+NndaN9lSOFzKgS3+zyYJk/emMkhzjfIDjaAOg+I2la5N8PtFskmbUdbi1HTWmuVtd6l0uIy8pjTb8gwWIBX5R1HWu9ura2uzAbq2hnMEgmiMqBvLkAIDrkcMATyOeTU+/2oA8G8RaT4jg8U6neam967f2tpkp1HR9HlO2NYJ1Zo4j524qWAJ+YAkZHavUvh3daxe+FYpvEAuPtRnnET3MAgnkgErCJ5YwFCOU2krgfQdK6ff7UjNkdKAG0UUUAFFFFAADil3H1pKO9AC7j60bj60uz3o2e9ACbj60Ek9aXZ70bPegBtFO2e9NoA43xZp8+j2Wq6nosixRXET/AGy0YgI7MMedH2WXkZ7P0ODhh5ze6jZ6RoUl9K5NnaxclVO75eNu04IbPG04IPBxXqPxJWZ/CU6QQyzBpoPMESlmEYlUscDkjA5xXll5NpOoQXFneS2rpcKUlilYKzjGOQcHOABnrwKD2MrulJprUr+H/EMWs3N7brZX1ncWewTR3SKpBcEgfKxzwAfxHvjovDSwz2eq6dcRpKouZDJFIoZXjlG4ZB6g5Zf+AmsDRPDmmaPNLc6dDKssyhZJHnklL47ksxyenPXAA6Cr09q8t7ZvaTy2t7JNFbLNERkq8iggggqwwScEHB6YqJx5lY9GtGXsuae61+Rq65pXh8WMj6ppFhcws0Y8prRJTK6grGqqR8zclVHvgVky/CnSrHRLzUPFYWPTWPnvomlgwRbyQI4jtbDEEqMqFy3J610eq3Wm+G9UKacZdb8QxcefeuDHZAj0QBVYj+FQGI6kDmtK9ur7xP8ADZb02ytfxyidoIAf3ohnwdgPPKoSBzzgZPWsdEnFatdDwMTN1UmlaP5nkMvhoW0NvFcaUjRW6BLe40iKFJ4h/dkLLmTsN3Q4ztBrUtE1AxmW1WLQtQsYJLmHUrhybi6QAKYCoLJHncOgOTghQQa6KCRJ4UlgcSROMq6nIYVl6kFudX0tRCZILO5LTSg/LDK0TiNT/tHJOO2FPdc+FQxdWU7y1snf5L8DhcLqzZz0kelXNw/9kaVZyAECW01272XURAwdpw3HoD+BA4FtGsrS2c2dw+sQGORJrNA4XRZDgLO0h3Dapz1zwcqMZrpruztbzH2y1guMdPNjD4/MVnMqR60ml2rRwWU1m0t3aRqFEqrIBECB/DlpMjvjHTILoYqLm5Siu+n9W1J5H00My61K8tr/AOz3viG2jui2ENnYme1k9MSDPX0JU+1W7yW+hkgbxDG2n3toyXNpaIjFtSBJjYovJyqsT5f3skE4FWBohgVotO1K+srVsj7MhSSIA9QodTtHsOKq2+n+RM2n2b3Caha+VcwazK3mTW0eGUQx54A3KxIxt2nGOhBQlh25SatZf8Dtv23C0lsWYdauJ4FuYdE1GS0bkSIY2OPXYGz+HWmC5g1K803VYFSTSrczRfa3+UJcMgwnPQhBJn0JA6njNn0m+N8bubSorrUjybxb9tkx9ZIpMhvcEH2NTalDeXN6b+80e1vUZCL7R7YtBbIwG2KRMH55doLZx90oAAQDRQo0ZczUtk99N9L7sfM1tqbdtq2m3cvlW2oWc0v9yOZWJ/DNVXC3PiaW2MpMMVtFPNb7fleXe/ls3qVG4gf7Snstc819p858nV76xudPYhTBDp+y+i+gbhiP90H0ya0blLi1isoPtsmlabOJZ9IuZ4/Mu79HKZjlZd20nClWKk425xgglDCu0pQl0t/w+1kHtLeZ05wcg854Oe9ZWj2kFrcajawxRiNJVdcDkK6A7SfQHOB2BAHAFReGnuZ7v+zobXVhfSvhF1iZI1OBzsfJ3DjOFBPtTbrUbbwtJPbeJZvI1M7p5xGjSq5wBlCgOFwFADYbA5Gc1isNWjTbUdH2/P8AruaLzO08BXbaZrsNjCStje718gfcjkVS4ZR2yFbIHU4PXOfTG5PArwC0smv47e91SWSWRl82OGORkihDL0AUjcdpwWbOecYHFTf2PpwIK2cSsOjKNpH4jmvr8FlteFFRqyVzB4iKdj3eivGrC/1fSmDaVqtwEX/l2vGa5hb2+Y71/wCAsPoelej+EfEcfiC0lLwm1vrZglzbFt2wkZDK3G5Dzg4HQggEECqtCdL4tjSFWM9jeooorE0CiiigAqWoqloAbJ2plPk7UygAooo7Z7UAFFYOp+MPD+myGK61a1NwOsELebL/AN8Jlv0rCu/iNByNM0fULn0kn226f+PHf/45UuSjuy405z+FXOy1WwtdW0q703UYVnsruJoJo2JAdGBBHHI4NcXffDO01KFYdX8Qa/qEUdvJaQrPLBmOGQp5ibliDNuCKpLljjOCCc1kXXjTxHckiBdL09T/AHUe4cfiSg/8dNcj4m8YzWAkOt+ItXkZIvOaK2BjATOMnyVXAJ4+ZqzdeGy1OhYKra8tPU9E1X4XeD3laY2Nvpuns1vJcWNvHDDaXBhkLoZIymD95lPqpx6VQ1uPwbHqFnPpXiv+wZbS0ksEt9Da3YeU7h2UJ5Um07lHK4IrzHxDPBHbXp0/TWu9RtymZL6B3XBdQSrykB2AJIAbk45rm7rxPeSIscWpXNqy2UzRRxWqoZLuJwAhQb85DKCFbB9ulT7e+yLeDUfil9x7Hp9z4O0ieaTSIdfnEumLpRVbZgpjDySF90oUly0rksSQfT1n0jx1a+H9J0fQNN0e8ZLW1S2thfXcKSSRxKq7js3ZOMZwB16CvFXtvFb397OGvItTfzxAkcbNCVaM+WC7SeWApK/wbsr3yc3/AOxftdxpN7Z6JqVytjMWmi1FyWYuhBZPOY/ddUJIwO655qHXl5GkcJDs/wCvkes6h8TdTt7iKKTTtKtFlV3Ekt27hQgy2fkXHFV7L4h6zqkcjadqWhOsbFHNtbtLtb0J83rXko8HiPw7ZwyS2VneKLpLlp5wWkWSKSNCWyc9UOD0HuK3NFl07TNSurqTV7B0mtbaJkifeQ8QcE8djuHvxUSqztozWGHpJ+9H8T0FvE3iV/vayqcf8srSMf8AoW6q7a14gcYfxFqH1WO3X/2lXPv4h0xVyJ5pOM/u7WVv5LVaTxZpqHAg1Z/9zTpj/Naz9pUfU6PYUF0R0j6hrD/e8Qav+EiL/JKb9r1Q9dd1g/8Ab0R/IVy58YWmcJpWvP7iyx/NhTT4wi/h0HX2/wC3eIfzko56nf8AEfsqP8v4GrrfiDxBpz2lnaa5fC2vd/mtJJvlQoAR5bkZUNnB+gxjnPPnz/OmlN/qHmTP5kjC7kG5sAZPPXAFR6vq76obe5i0zUYfsRYi3miQSXG8AHaQ5VdoGfmIznHFUTq1xjI0HV/xEA/9q0pTqq1pfiaUaOGaanDr1j5LyNPdc9tQ1H/wLk/xp0M17DeRXcGqahHcxKypIJySgbGcZyMnHXr+ZrKGrXH/AEAdXz9IP/jtOGqTc50XVh/wCI/ykqfaVv5n9/8AwTX2GDWqpr/wH/gHSx+JfEsfCeJNT/4F5TfzjqZ/HHii1jeZ/EM3lRqWYyW0DAADk8JmubsbyW+QvaaZqUka8F1iUgN3U/N94dCOoPBqPX4ryXRb+KHTtQ8+W3kSNRbMfmKkDoCBzRzVb2bYnTwji2oo6Pw98W/EuqRyPbXlo6xEKwuLEEnKhgcpIB0PTqO+K0rX4z6r9rktpE0SeSPO4ASw/d+9ySw4746d68u0bRLe3tHTV7cky+WwhNpIiRlU25BI+8ecnNZWuWfkWWrNBqNqxuYmj+zQlk8xpHHzspYgEAnJUDOSTWyqT5rX/A5HhqHIpOK+/wD4J7/B8ZJFi8y80S28sHDPBqIIB/4Ei/zrZtfi3pMn/H1perW/+0I45R/445P6V82TeHrq7uDfW8UMcRlDfY7WVCMCMIGyVKluvBGMHrU+naZNYXHk3lrqUgjSP7GYpiViULypKlRndnPHIwBnpT+sSXVCeApSfwtfP/gH1Fa/ErwnPgPqotieMXcEkGPxZQP1roNN1rStUGdN1Kyux/0wnV/5GvjPw9LfwWFkkWo3KW0Fk11dM8SnD5GYwSoxjD+/P0xPa6tizg+3aZDdGKO2a4mZ8urzH7qggkkZXuODV/WJLdXOd5fB2ak16q/5f5H2rzRXzJZXV/p4A03VNStAOixXb7R/wAkr+ldBZePvFlnj/iZW96o/hvLVST/wKMp/WnHF03voKeU147Wfz/zPe6K8lsPi1cpgaroO8d3sbkE/98yBf/QjXS6f8TvC91tW4vZdOc/w30LRAf8AA+U/8eraNWEtmcdTDVqfxxaO1oqvY3tpqEAmsLqC6hPSSCQOp/EVYrQwCiiigArlvirdXFj8M/FV1ZTy29zDplxJFNE5R42EbEMrDkEHuK6mgdaAPEL3xcfDpvb/AMA6hdeJtKh08PfCbUHv4LW4M0CIwmkkJzseZ2TzAMICSvWruj/EPxVrUNhFYv4dSaeW9H2vat1G8cEUTr8kF04RiZCpBlbgBu+K9nyPWjI9aAPEh8UddstDgvdZl0iE6hpNjqlrJBZMUgNxIV8uXzLhFIxj94ZI1BPOe+PpnxF1zWdV0zUrzV9L0y2ksNTtTA4YQ3k0NzEqiMpcbRKyY2lXk2/PguGBH0LketGR60AeN6f498RrBb3CLpX9l2z6PbSwyRTSTy/bFhDEStKcbTLkblYt3OeT6LdeJLOyuZYtQhvrVUYjzpLRzCw9RIoKgfUit/I9aioAp6bqlhqcfmabfWt2g6mCVXx9cGp7m3huYzHcwxzJ/dkQMPyNUdS0DSdTk8y/020nm7StEPMH0f7w/A1T/wCEda350vWdWs/RGn+0p+UwYj8CKAEufBnh2dmY6PaROerW6+S35pg15prx0tdUWPwvLebLdzvvGunkQOMjEIYnJGT8/Kg9MkZXc+IN1rtrBDp2o3An0+dS0lxa20kHmAcGJ2XzNvYn7oI4zjIrkIL2yfEVvcW+VGBGki5UemBXHiq8qatH7ztwsObd6du5LGsVpB8ihYo8uRnOe5JJ5JPUk8nvXR+HNItZ7VDf2kUssFvbQBnX5lPkrK2D1HzTN0NcxqSPJYSxKDunAgX3LkIP1YV6Tc2OoaZqF6ItOmvLKabzo5bZkLJlQCrKzKeCOCM8Y6Y54IRnKlJw3ujbEySlFM5668C6FPcSzxpqFpLK2+Q2uoTxh29WUPtJ9cjnvV86LImjPpUF5H/Zzf8ALCW0TCnOdwMewhgcHdnORnrU13rdjYQtNqpuNNhXrJe27xIPq5G39amsdW03UFVrDUbK6DcjyZ0fI/A1j7TEU97r1/4Jjy05HITaF4ns1JOpaJc2qZLTTQyQSKg7nDFCcd/lFW7zTDDpUL2Ol3z6pG5ma5aWKUXQZQCjFWBVcBduFwpA45bOb8Y9B17WdCnj0xhNZtAYmsQGVpJHIVZMrncFznaRjIyc4GGfEbVrSP4fatYxz3Vpe26CzUwGaJUm8sEASADcgDZJ6HGD6VVKSS0SfNo9CHShqRDWWDiOfSNZtJz/AA3Vm0SD6yn93j33VZmtoNLk/tN9Usbxb1FW7e2uFeO1dSfLX1CEMQWIHzDJxuAGB4h1fUR4sWLQ76+jsYI9PsrW6huR9kSSRmfdMpJ3BkKKCFPJAyMivWLuxs7wEXtnbXAIIImiV8j8RUclKnBpx+Lz26kKhfZnJSSJDH5suTGFLfJyWHovqTwB7kVWs4tStLi6ttZhSC9Li68pDnCSAYye+CrL7BQK0rfwpoNv4hUaRpVnp5toxNcyWkYiJY58pBtxjGDJxzlY+xq/rfh59VjizrWpwzw58mf91I8YOMjLISVOBkEkHA780lSpQpODb5pWe34f15E+xk9jJDEHcTjHcnGPxrC0O3ttR0md7lPtMNxLKipOn3YVlfy0APRQOR/vZ71tSeHL6xguLnVNRt9Zs4EaU2s0P2ZXCjOHMedw46Ywe4NbfjHQLiKzvtesWjhimtWnu7V2IMUnlY3xsB14XKnGSMgg5yUcFKdJ8kru627fgZyg46M5qLTYI9ONjE0yw9UYyszxnOQysTkFTgg54wKTw+//ABJ7OVBseaJJZCOruwBZm9SSSSTzzXQHwbrWrG4trjZpNo4dGmWQSzEHI+RR8q59Sc+2eRny6bq2nsLa60e6LIAivZRGaFwOAVI5UezAEe/WspYLERp2ae+39dybWMS3trzT721sNPt2vrW4Z1ghjIEsG1WcqNxAZMKcDII6c8Ylm1Wyt53gvZjZToAzRXaGB1BzgkOBwcHnpwa7vwP4cvl1Qavq0X2URRNFa2rMC4LY3SPgkA4AAUE4BOTk4G3qv+h+K9Iu/wDllepJp8voWwZYifpskH/A6+pwGLxFOjGNbV+e5jKhGTvseUJq1hK+y2uo7mXtHbZmcn2VMn9K734c6Nf291fatqNu9p9pijght5MeZsUs29wPukluF6gDnBOB3CgIMIAo9hilrorYqVVctrIdOioO4UUUVzGwUUUUAFS1FUtAHDfEzxrN4POmCC1tblrvzfkmmZG+XZ90KrFvvenpXJxfFHxPc4+y+E7bb/z0uLx4V/8AHo93/jtdZ8TSQdNI6/vf/ZK4UZJ45NcdWtKE2keph8JTq0lKRq3HjDxPeQqpk03TSR832WNrhs+zyYH/AI4axLyKXUc/2te3uo56rczkxn/tmuE/8dqnqeuaTpQzqWpWtsf7ryDd/wB8jn9Kzj4st52K6Zp9/et/eELIv8i35LWTnVmdKpYek7WV/vN+CGK3iEdvFHFGOiRqFH5CpFUnoD+Fc8sniu/B+y6RfQr6Q6bKzf8AfcoC/wDjtSf8Id4rvgPP0bV7kHtc3USL/wB8eYB+lR7KXZmvt6f8yXzX6XNG71Owsm23d9bRP/caQbj/AMBHP6VzOuDRdWuvPMOpzs0X2eUQR+Uk0W7dsYybeM91weTzXQ2nw78UoAtvo1lbKeu67RP/AEANV5Php4rcc/2PEf8Aau5G/lFVKlUW0SXXw7Vp1PuTOWbUHfTxZR6Tbm12bCl7cGbcPRhg7vxY1V23H2i2mie0tGtkeOEWtttCI+CygMxHO0du1d7H8LPEDff1LSYx7JI/+FTxfCbVSB52v2AP+xYOf5y0/Y1uwfWsGt239/8AwDgHa7kx52pX7+wm8sf+OBarvY20hzLEZjnOZnaT/wBCJr04fCO5ON3iQD122A/rIanHwjT+PxDd/wDALaMfzzR9Xrdx/X8Gvs/h/meXR28Ef+rhiT/dQD+VTZIGATivUF+EVnkFvEGrfRUgH/tOp1+EulY+bV9Zb/gUI/8AaVL6pUe7RX9rYeOyf3L/ADPJyaM165/wqbQ8fNf6yf8At4UfyQU5PhP4fU/Nc6u/1vD/AEFH1OfdCecUez/D/M8hzRn3r2MfCvw33/tNs/8AT9J/Q08fC3wuOsN+frfzf/FU/qcu6F/bFP8Alf4HjGaXPvXs/wDwq3wp3tL0/wDcRuB/7PR/wq3wn/z5Xv8A4Mrn/wCOUfU5dxf2xT/lZ4xn3oz716hqHg/wLpt81nqVlf2q7Fkjne9utkuc5AYOeRjkHHUGoT4b+Gvaecf9xC7/APiqPqcu4f2zT/lZxnhGQPorFDnF1cqfqJnBrZya6VtJ+HaFRaXcUCbEO2xvZVQjAwxCNjcRjk8nqc1G+meBQpI1W/GB0S9uGJ9gOc1o8K76M5Y5jC2sWc+HYdCaRzvGJAGHowzXZ2HgTSr7T7e5L65aNMgfypbs70zzhgc4PqKl/wCFcaePu6rrI/7bof5oaX1WXcr+0ab3TPOptJ02fHnadZOR3MC5/lVZvDulkfu4JYOc/ubiRP0DY/SvSm+HNvt+TXdXU+pFu3/tKoj8OWA+TxFfk/8ATS3gP8kFH1ep3BY2h2f3I8zl8NxsrCLUL1QeqyiOVcenK5/Wsu68HyuSyyWM5MyTndG8JZ0xsJILDjaO3avXH+Hd5/yz8QD/AIHYqf5OKib4f6qp/d63YsP9uwcfylpewqeRX16k+r/r7zyySz1OI/vNOZ1/vW8yOPyJU/pVSW7igOLoS2p9LiJov1YAfrXrDeBfECj5b/SJD7wyx/8AszVG3g3xOvC/2PIncC6lXP4eWah4aXb8TaOZQX2vvX+VjzGN0lQPE6uh/iUgj8xTq7W8+HeqTMXl8PaU8h/5aW975b/99BFP61l3Hw+8QxAm00/UUx0Q3NvcL/486t/49UvDTNo5nS6v+vnY5dbSGOfz4FMFx/z2gYxP/wB9Lg/rW7ZeKvFFhHts9fuWHZbxFuAPxYbv/Hqr3XhjxdZqS/hu7ugP+eBQN/3zvI/8eqjLDqFvCZdQ0XWLBBwTc2ThR9WUFf1pctantcp1MFiPitfz0/E6S3+JfjW2P+kDRL5PVLZ4m/IyEfrWpbfFzUU4vdPs4/UyLNGv/fSCRR+JrgYLmC5GbeaOUDrsYNj8qmBx0NUsVUWjIllVCWsdP6/rqep6f8UHvFzFpVrdDv8AYtSSQ/kyritSP4i2gOLnR9XhPchIpR/465P6V4lPa29wwaeCKRh0ZkBI+h606IT2+Psl9ewAdFExdf8Avl9w/KrWLZhLKY9Pz/4H6nu8XxB8OMB5t1c2x6YuLKaP9SmP1q5D408MzNhPEGlbsZw10in8iRXhEOratCR++tLgf9NYSjfmpx/47VkeIZiMXWlO3vBOr/o22tFijnlljXdfK/5HvsOt6TNjydUsJM9Ntwhz+tWReWrfdurc/SRf8a+eTquhyc3No0RyBmaxJH5hSP1p6T+GJidr6KSOzLEpH4EA1X1l/wApk8Bb7Z9Bm8tQObmAf9tB/jVeXWdLi4l1OxT/AHrhB/WvEYtO0mQZis9NceqRRn+QqwumWqkFLC3U+qwKP6UvrXkNZc39o9Ym8YeGoSPN8QaSpzjH2yMnP51Uk8feGUOF1RZv+uEMkv8A6CprzpISn3Iyv0XFOKSHqGP4Gk8W+iLWWrrL8DuJviNpK5+zWer3H+7ZmP8A9GFaxtV8ZxaipVvCcNwP+ojNEB+SiSuccqgJkZUx/eIFUp9X0yDPnalZJjqDOufyzU/WZvZFrAUY/Ey4JWS/iu7LR/D2nTRNujMVu8uw9iAWRcj121YudS1q8GLvXtRZf7kDJbr/AOQ1Df8Aj1Yb+ItMXPlSzTkf88LeR/124/WoH8Qsf+PbTLhv9qeRIx+hY/pWbq1Ort+BvDDUfsxv97NNbC1E3nPCJpv+es5Mr/8AfTkn9akntLe6x9otoZvTzIw38656TV9Vl+6bK1HokbSt+ZIH/jtU5ftNxn7Xf3swPVRL5a/km39c1m5dWzpjRla0Y2XyOjn+waUgL3p00dgl40H5AMM/lUP/AAl1zAMafqWrXfpugRk/76lVSfwJrn4LW3tzuggijY9WVQGP1PU1Nmoc091f1H9RjL4rfJfr/wAA1x4u1e5W4i1PSdDu7OYDfFIrBpMY+/1XsOx6V0Vj4/EsgS80eZByWeCdZAAO+CFP5ZOTXAT3UEDBZpo42b7qswBP0HU1uaLpGr6hDIdI024nuBtLK4EOwH7hPmbcDILcZ+6nXNEKKqv4dDDE4fD0Yb2fqdPo/jDRrWGRL6W5hvZZWluXNs7IZDwQGUEbVAVAT2UVu2niXQ7xgttrFg7nohnVW/I4Nc3pvwr1y5wdS1Cw09P7kCtcOPxO1R+RrqbH4T+G41H9qC71c9xeTfuz9Y0CqfxBrR4F1HzS0PPqzw8FanJv5f8ADfkM19kuNM+xxury37paxqpBL72AbA74XcT6AE10vjs/8UrqCDA80JCP+ByKv9ataVoGj6QVbStJ0+yZU8sG2t0jIX0yB0qr4zG7SII+P3t/ZJz/ANfMZP6A124bDqhFq97nBUnzu5vEHJ4owfSiSNZ7d4nLhXUqSjlGAPowIIPuDkV4xE914e8Va8dMvNRuZINesdLtY9S1W8uYYop7aFnyjSkMd0jMC2cZ47Y6CD2fB9KxvF9pPc+H7k2cbSXlvturdF6tJEwdVH1K7fxrzyT4j65aa3NYXE2iT3cNzPaSabHbSJdBYoGcXh/etiFmUEKRwHA3k1nWHxY1mfTvOW78OXkMkFjLNqdtDJ9l0p55CrpcfvW3FAM/eTr82BzQB7XGd8auFZQwBAYYIz2Ip2D6V40fiP4nvIZBpUvh+QW2n6lfm9NpM8N6trJGqtCBKNqv5hGdzjKkgkdZJ/iN4isZmtNUm0C23/2fKdTe3lW2sormO4Y+aply2GgCBt6AmQZx0IB7Dg+lGD6V86/EP4i6jrPw91exvbvRNOjudHuJUlkhkP8AamJ5ocWoMi7QUjSTneQJV4wM11eufEiaaW68PzPpq6lJqeo6fNajd50dpHbTSRS7d2QW2x/MRggnA9AD16ivD/CnijXIp9B0LRmsIXulsrXz7xJrhUX+zDOSIxKoBymMLtBzzk816h4B1q58Q+ENN1O+jhjup0YSrDkJuVipKgkkA7c4JOM9TQB0FS1FUtAHM+MvDtzr72Qt79LKOHf5h8jzHbO3G3LADoeoPas+z+Heixgf2g97qbdxdTkIf+2abUP4g12knamVPJG97al+0ny8t9Cpp2m2OmQCHTrK2tIh/BBEqD9BVzJ9aSiqIDvRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTkAOc02nx96AF2j0o2j0paKADAFc3ZeNdBvtXTTbW6uHnklkgjk+xziCSRM70Scp5bMNrZAY/dPoa6SvKf+EH8StfzLZT2WgW8rXJmn03UrmRJvNRwCLN1EUTbnVy6sTleOvAB3V7d6Z4YFjDHaGJdT1DyVFuigefLvdnbkdSrEnk5NL4S8QReJ9KXUrSyvLaylY/Z5Lnyx9oj7SIFdiFPbcFb2ryzwn8JNT0yW0+2jTxFHd20txElxG8VwkaTKxMSWkIDnzByxcsOC3Az6J8L/Cy+DfA2k6MYLKO7ggQXT2ibUmm2gNJnALE4HJGTgUAdTtHpRtHpS0UAJtHpTXGDxT6Y/WgBtFFFABRRRQAUUUUAFH40UUAY2seF9C1k7tU0ixuZP8Ano8I3j6MOR+dcrqHwn0SXJ0671LTz2Cz+cn5Shj+RFeh0VMoqW6LhUnT1g2jxi/+Fmu24J0/UtOvlHRZke3Y/iN4/QVzt74X8TWGftegXjKP47UrcL+AQ7v/AB2vomisZYWm+ljthmeIhu7+p8tTXcVvL5V2WtZc42XKGFvycA1MrBlDKQV7EcivpyeGK4jMc8aSxnqrqGB/A1zd94B8K3pLS6FYxuer26eQ35pg1i8F2Z1wzl/bh9zPCB7UjgONrgMvo3Ir166+E+hSEm1u9WtPZLnzQP8Av4GrJuPhFKM/Y/EUg9BcWavj/vhkrN4Oa2OmOb0Humjy97CykYNJZ2zEdCYlyP0pBp9mPu28a/7o2/yr0Kb4Va8n+p1bS5ef44ZI/wCTNUD/AAx8TL92XRnHr9olX9PLNT7Csv8Ahyvr2Dlu/wAP+AcJ/Z9p/wA8f/H2/wAaP7PtO9ujD/a+b+ddx/wrTxV6aP8A+Bcn/wAap6/DLxQT80mjKP8Ar5lP/tKj2Nb+mP65gu6+5/5HCLp1irbhZWu718pc/wAqsRokX+rRU/3QBXcR/CvxA5/e6lpMY/2Y5X/+Jq9D8I7s5+1eIkAP/PCxwR+LOf5U/q1V7/mL+0sLD4fwR52T70ds9q9YtvhLpC4N5qer3XqPNSIf+OID+tbNn8OfCdqQx0aC5Yc7rxmuDn/toSKpYOXVmU84pr4Yt/h/meCi9t3m8mGVZpj0jh/eP/3yuT+lbdh4c8Rajj7FoGobD/y0uFW3X/yIQ35A19BQ2FvbWb2+nxR2KlSqm2jRNnHUDGMj3BFeW22u6/ovirVLefWNT11INZt9JtrS4+yQI3nWazb5Hjtw3DMfukcY4bGDrHBwW7OSeb1X8KS/Ep6d8LdfucHUL/TrBT1WFXuX/M7AD+ddNp/wo0OEA6lc6jqLdxJP5Kf98xhePqTUT/Eq7t52a80O1SzW8n0wvHqBaX7VFE0jgRmIfu8owD53YwxQA1Vg+Kd+Z9Osrjw7ax6lqkNpPYRpqReIrcF9omk8kGMjYeAr56DNbxowjsjiqYyvU+KT/L8jsk03w/4P0q6vrTTbSygt4zJI0EKh2AHTPVieg55JqbwrYT2emNNfjGpXshu7vnOJGA+QH0RQqD2WuA1L4oXUthdmPwvZXZ060u7+/jl1HCR/ZJtriJhE3mHcoZSQnTnBFaafEq4s55R4h0W3sLa3ntku7mK+MyQRXEbGKQ5iX+NQjDtuBBatTmPRaK8zT4oXjQNdP4dihtLaK0nvRNqASaNblyIvLj8vDtt2kgsnJKjcRTdS+It8gv7e80ptKuLe5tkii89xcyRvexQF8SW3lFCJASUd+GxlWOVAPTqwvFfznRYuvmanBx/u7n/9krn/AAt49vNa1jTLa80WGytdTS8a0mjvTM5NtIEbenlqFznIwze+K6HxD82seGU/6f3f/vm2m/xFAHQKflFLketRUUAF1BFd2s1vcKHhmQxuuSMqRgjI9qZp9pb6dYW1lZp5dtbRLDEm4naigADJ5PAHWn0UAS5HrRketRUUAS5HrQSMdaiooAKKKKACpaiqWgBsnamU+TtTKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArgvi141n8HWNibGe1hu7tpBGLq3R432Lnbve4gVTyMfMSecKcV3tKDigDxfSPixqmoahpqyz6BbR32nRXUVsCssgka084+cwuA8CBs/MYWXaASwLDEen/FbVLq0thcat4dsg80kc+qT2ubG3ZYg6xh47t0kZyTg+YpG0gpkgV7bvNG80AeP2XxI1PUw6ahdaL4ff+zobiOwvkkFzqDSQl2MDebGVAPyjCswIOccVnJ8V9Qh1zwzpFnJYv9rGn29xDPDmSNriJDvV3uvNkALqc+Uw6gvnmvcd5o3mgD560P4ga3pmgaJJJqVjrmoRWF+Z1DTiS0eOW2U/aVEzByokZyWUMFXC7cknrNM8eeIdX1W00rSb7w7d+ffzWqaxDaSvazolsJsxoJuSGJQ4kI46g5Fes7zRvNAHA/8ACaahN8HbbxXEul2upTW0UpF3MI7ZGZ1VuXdB0JKqXXJwNwzmvPNf8eaxq2hS3lhqsNs8UFnPLexxSxRqo1MRSYRLl4ygUfNIrsHUMN20jb9A7zRvNAHjuifE7Wr7x7baKTolxZtcpAXjkhha5iMQb7TDuui7KxIKqsTjb/y0JFexP1o3mkJzQAlFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFVv7J05p2uGsLQztMtw0hhUsZVXYshOM7goChuoHHSrNFAGVeeFtEu7y7vW0uxTUrqFoJL+O3QXBRl2keZjPSqmjeBPDGk+H/7GttC0xrB440nR7SI/aSgwGlAUB275I6mugooAoR+HtFitPssWkaclt9naz8lbZAnkN96LbjGw916H0qt4g8K6XrmnXFlcQrDDdND9p8hEVriOJgyxOSpynG0jrgkAjNbFA60AUb7w/o1/qVrqF9pOn3OoWuBb3M1sjyw4ORscjK888Gq9r4S8N2j3LWvh/SIGuXWScx2UamVlcOrNhfmIYBgT0Iz1rbooAz4tJ063e2a30+0ia2EghMcKqYg5y+3A+XcQCcde9U9TtZ5vEWhypGxgt/PeRx0UlAqg/XcfyrgfiL4/wBQ0Px1aQWL3I0bSkil1cR2DzI6zOFw8oQiLy48y8sucgZPSpvFPjnxBN4X13UvD1hYW9pY3/2GO6nvj5zSJdJC+YfJZVU/NglicYOBmgD1DB9KMH0rzT/hO9bg8S3GjLpEFzqsuppYLDJqW22hP2Bblisgtw5Xg/eUnJJGBhR2vgzXP+Ek8M2GrG2Nq1yhLQl9+xgxVgGwMjIODgZ9BQBrYPpSYqWmv0oAZRRRQAUUUUAFFFFABUtRVLQA2TtTKlIB60m0elAEdFSbR6UbR6UAR0VJtHpRtHpQBHRUm0elG0elAEdFSbR6UbR6UAR0VJtHpRtHpQBHRUm0elG0elAEdFSbR6UbR6UAR0VJtHpRtHpQBHRUm0elG0elAEdFSbR6UbR6UAR0VJtHpRtHpQBHRUm0elG0elAEdFSbR6UbR6UAR0VJtHpRtHpQBHRUm0elG0elAEdFSbR6UbR6UAR0VJtHpRtHpQBHRUm0elG0elAEdFSbR6UbR6UAR0VJtHpRtHpQBHRUm0elG0elAEdFSbR6UbR6UAR0VJtHpRtHpQBHRUm0elG0elAEdFSbR6UbR6UAR0VJtHpRtHpQBHRUm0elG0elAEdVNV1Sw0i0N1q19a2NqCFM1zMsSAnoNzECr+0elcj8StG1LWdM0qLRFg+1Qara3JedN6Rqj5Lsm9CwHXaGBPagDWXxV4ea3t5117STBcrugkF5HtlG8JlTnDDeyrx3YDqayda+JHhPSbP7TJrmnXES3sNjKbe7ifyJJH2gyfMNoX5mbPIVWOOKzfDvw3TTNbTVL3URd3Tw36z7LbygZbqWN2eP5iYwoQqBkn5id3XOSnwovfs2nI/iC2M+kQWttpjppuxUSCeOZfOUS/vSTEoJUoOWIAyaAOul13wWHv7Z9S8PNJe25u7uDz4S1zCYgTI65y6mID5jkbQO1eeaN4n8J61p0Grnwd4ZluNTlsbU+RNbXEn2e6mWBVnwm9XXB3RlSnyhQ5IYL0zfDq9l1B3udbtmspb/APtWWKPT9spujD5Z2yGQ4jzyF2lgPl3kVDF8LfLTRVGsn/iXWWkWeRa/6z7BOZd33+N+cY529fm6UAbOk3/w9tlmm0i68KRLprCSV7WS3X7K23yQzFT8h2/u8nHHy9OKv6D4n8HzPa6ZoGuaBI0m77PaWV3CS2MltiKee5OB61wkPwfv5ri8m1nxXJqUtxaLaNJNbzOWAuIptzCSd1GfLK7UCL82ccYPR3Pw8huLy8na+C/addXWm2wYYAWwg8oNu9i27/aIx3oA3l8Y+GHiupV8R6M0Vo4juHF9ERCxO0K53fKSeAD3rPuPiH4WXWNF05NZsJm1ZJXtbiK6iaFyjImzdu5ZmfCgA5KsO1cfovwa/s9LKKfWUuo7KS08h5Irl38mC4jm8phJcvGA3lgfJGgGcgY+Wugt/ANzZeJ7fWtP1aBJUvb24kimsy6vFcmEugxIuGHkjD8jk5U0AdzRUm0elG0elAEdFSbR6UbR6UAR0VJtHpRtHpQBHUtJtHpS0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of two types of multiprotein complexes in the red cell membrane. LEFT: Protein complex attached to spectrin near the center of the tetramer (dimer-dimer interaction site). Tetrameric band 3 is bound to ankyrin, which is bound to spectrin. The membrane skeletal protein 4.2 has binding sites for band 3 and for ankyrin. Transmembrane glycoproteins GPA, Rh, and RhAG bind to band 3, and CD47 and LW associate with Rh/RhAG. The two cytoplasmic domains of band 3 contain binding sites for soluble proteins, the short C-terminal domain for CAII, the large N-terminal domain for deoxyhemoglobin and for glycolytic enzymes, aldolase, phosphofructokinase (PFK), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). RIGHT: Protein complex at membrane skeletal junctions. The junctions contain the ternary complex of spectrin, F-actin, and 4.1R, as well as the actin-binding proteins tropomyosin, tropomodulin, adducin, and dematin. 4.1R enters into an additional ternary interaction with the transmembrane protein GPC and p55 and is taken also to bind to band 3, in the form of a dimer, which also carries GPA. Rh, Kell, and XK also have binding sites on 4.1R. Note, however, that the copy numbers of all transmembrane proteins except GPA and GPC are low and therefore will not be present on all complexes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Salomao, M, Zhang, X, Yang, Y, et al. Protein 4.1R-dependent multiprotein complex; new insights into the structural organization of the red blood cell membrane. Proc Natl Acad Sci USA 2008; 105:8026. Copyright &copy; 2008 National Academy of Sciences, USA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_7_9334=[""].join("\n");
var outline_f9_7_9334=null;
var title_f9_7_9335="Clinical evaluation of musculoskeletal chest pain";
var content_f9_7_9335=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical evaluation of musculoskeletal chest pain",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/7/9335/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/7/9335/contributors\">",
"     Christopher M Wise, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/7/9335/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/7/9335/contributors\">",
"     Don L Goldenberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/7/9335/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/7/9335/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/7/9335/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest pain is one of the more common symptoms requiring medical attention in the outpatient setting. Cardiac and pulmonary problems are usually the focus of the initial diagnostic evaluation. After these areas are excluded, other conditions affecting the structures in and around the thoracic cage enter into the differential diagnosis, including diseases of the esophagus, upper abdomen, head, neck, and chest wall [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9335/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the clinical evaluation of chest pain of musculoskeletal origin (",
"    <a class=\"graphic graphic_table graphicRef79217 \" href=\"UTD.htm?41/37/42587\">",
"     table 1",
"    </a>",
"    ). The major causes of chest pain are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2201?source=see_link\">",
"     \"Major causes of musculoskeletal chest pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15240?source=see_link\">",
"     \"Chest pain of esophageal origin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15144?source=see_link\">",
"     \"Pathophysiology and clinical presentation of ischemic chest pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of musculoskeletal chest pain is also presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5592?source=see_link\">",
"     \"Treatment of musculoskeletal chest pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Demographic features, characteristics of the chest pain, and associated symptoms may favor the diagnosis of musculoskeletal chest pain or may suggest other causes of chest discomfort (",
"    <a class=\"graphic graphic_table graphicRef55901 \" href=\"UTD.htm?40/49/41755\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9335/abstract/2\">",
"     2",
"    </a>",
"    ]. As an example, a history of repetitive or unaccustomed activity involving the upper trunk or arms is common in the patient with musculoskeletal pain [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9335/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Demographic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of chest pain should be undertaken in the context of the patient&rsquo;s age, sex, family history, other coronary risk factors, and additional elements of",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    general health. In middle-aged or older patients or in those with other risk factors for coronary artery disease, a cardiac source should always be considered first, since patients with a known cardiac source of chest pain may also have chest wall tenderness that reproduces their pain [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9335/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15144?source=see_link\">",
"     \"Pathophysiology and clinical presentation of ischemic chest pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of musculoskeletal chest pain occurs more frequently among women than men. One study examined the incidence of musculoskeletal chest pain in 122 consecutive patients presenting with chest pain [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9335/abstract/4\">",
"     4",
"    </a>",
"    ]. Of 36 patients diagnosed with costochondritis, 69 percent were women. By comparison, women represented only 31 percent of those presenting with chest pain but without a subsequent diagnosis of costochondritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Characteristics of the chest pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Musculoskeletal chest pain is often insidious and persistent, lasting for hours to days [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9335/abstract/3\">",
"     3",
"    </a>",
"    ]. It is frequently sharp and localized to a specific area (such as the xiphoid, lower rib tips, or midsternum), but it may be diffuse and poorly localized. Most chest wall pain is positional and is exacerbated by deep breathing, turning, or arm movement. These associations, however, are also noted in a variety of visceral processes, particularly those involving the pleura and pericardium.",
"   </p>",
"   <p>",
"    Certain characteristics of the chest pain or associated symptoms may suggest a non-musculoskeletal origin (",
"    <a class=\"graphic graphic_table graphicRef77753 \" href=\"UTD.htm?42/29/43483\">",
"     table 3",
"    </a>",
"    ). These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Exertional pain",
"     </li>",
"     <li>",
"      Radiation to the neck or arms",
"     </li>",
"     <li>",
"      Numbness",
"     </li>",
"     <li>",
"      Fever",
"     </li>",
"     <li>",
"      Chills",
"     </li>",
"     <li>",
"      Cough",
"     </li>",
"     <li>",
"      Dyspnea",
"     </li>",
"     <li>",
"      Pain localized to atypical areas such as the axilla or midthoracic spine",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other musculoskeletal symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of musculoskeletal symptoms in areas other than the chest may alert the clinician to a possible musculoskeletal cause. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain in the neck, thoracic spine, or even the shoulder may cause pain referred to the chest wall.",
"     </li>",
"     <li>",
"      A history of chronic low back pain (particularly in a younger patient with morning stiffness) may suggest ankylosing spondylitis or another spondyloarthropathy which frequently involves the chest wall. A history of ocular inflammation (uveitis, conjunctivitis), psoriasis, or other skin lesions may also be a clue to the presence of a spondyloarthropathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13640?source=see_link\">",
"       \"Diagnosis and differential diagnosis of ankylosing spondylitis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic widespread musculoskeletal pain associated with sleep disturbance and fatigue is suggestive of fibromyalgia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=see_link\">",
"       \"Clinical manifestations and diagnosis of fibromyalgia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with rheumatoid arthritis may have involvement of the sternoclavicular joints. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=see_link\">",
"       \"Diagnosis and differential diagnosis of rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general physical examination should be directed toward detecting abnormalities of the heart, lungs, and abdomen that might cause chest pain. In addition, careful attention to the skin may reveal lesions (sometimes not mentioned by the patient) associated with specific musculoskeletal chest wall syndromes, such as psoriasis, palmoplantar pustulosis, acne, hidradenitis suppurativa, or dissecting cellulitis of the scalp. Symptoms of conjunctivitis or uveitis are usually obvious to the patient and are confirmed by examination, but a brief ocular examination should be performed in patients with symptoms of photophobia or redness (",
"    <a class=\"graphic graphic_table graphicRef59998 \" href=\"UTD.htm?14/60/15308\">",
"     table 4",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Musculoskeletal examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general musculoskeletal examination should begin with an assessment for mobility of the cervical spine and shoulders. The lumbar spine should then be examined for range of motion, particularly any deficit in forward flexion that might suggest ankylosing spondylitis or one of the spondyloarthropathies (",
"    <a class=\"graphic graphic_figure graphicRef58884 \" href=\"UTD.htm?6/39/6768\">",
"     figure 1",
"    </a>",
"    ). Discomfort in the posterior pelvic girdle from sacroiliitis should also be sought by compression of the anterior iliac crests or by external rotation of the hip.",
"   </p>",
"   <p>",
"    In the thoracic spine, tenderness or pain on motion is very suggestive of a musculoskeletal cause of chest pain [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9335/abstract/7\">",
"     7",
"    </a>",
"    ]. Movement of the articulations of the ribs with the thoracic vertebrae (the costovertebral joints) should be assessed by measurement of chest expansion. Chest expansion is measured at the level of the fourth intercostal space or just below the breasts in females. The patient is instructed to exert a maximal forced expiration followed by a maximal inspiration. The expansion is usually 5 cm or more; an expansion less than 2.5 cm is abnormal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13640?source=see_link\">",
"     \"Diagnosis and differential diagnosis of ankylosing spondylitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An evaluation for &ldquo;tender points&rdquo; characteristic of fibromyalgia should be undertaken in patients with suspected musculoskeletal chest pain, particularly in those with a history of widespread musculoskeletal pain and a generally normal musculoskeletal examination. These tender areas are often found in places unsuspected by the patient and include points in the upper and mid cervical spine, trapezius, upper scapular borders, lateral elbows, lateral gluteal, lateral trochanteric areas of the hips, and medial knees, in addition to the anterior third and fourth costochondral junctions (",
"    <a class=\"graphic graphic_figure graphicRef77950 \" href=\"UTD.htm?28/31/29170\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=see_link\">",
"     \"Clinical manifestations and diagnosis of fibromyalgia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Ribs and chest wall examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important diagnostic feature in musculoskeletal chest wall syndromes is chest wall tenderness that consistently reproduces the patient's pain [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9335/abstract/3,5,6,8\">",
"     3,5,6,8",
"    </a>",
"    ]. This finding is generally considered diagnostic for a chest wall syndrome. Many chest wall syndromes are defined on the basis of the location of areas of tenderness.",
"   </p>",
"   <p>",
"    Examination of the ribs and chest wall begins with an assessment for areas of localized swelling, such as the sternoclavicular joints and upper costochondral junctions. The articulations at either end of the clavicle (acromioclavicular and sternoclavicular joints) should then be palpated. Along the course of the sternum in the midline, tenderness may be found beside the sternalis muscle, the manubriosternal and xiphisternal joints, or the xiphoid process. In addition, tenderness should be sought at the costochondral junctions along both sides of the sternum and over the lower rib tips laterally. In the posterior thorax, costovertebral joint dysfunction may be assessed by palpation over the areas just lateral to the vertebral bodies or over the affected rib.",
"   </p>",
"   <p>",
"    In addition to direct palpation, various maneuvers have been utilized to reproduce chest wall pain. These include the &ldquo;crowing rooster&rdquo; maneuver, horizontal arm flexion, and the &ldquo;hooking&rdquo; maneuver [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9335/abstract/6,8\">",
"     6,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The &ldquo;crowing rooster&rdquo; maneuver is done with the clinician standing behind the patient and exerting traction on the upper arms by pulling them backward and slightly superiorly (",
"      <a class=\"graphic graphic_figure graphicRef80833 \" href=\"UTD.htm?0/61/977\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In horizontal arm flexion, the arm is flexed across the anterior chest, and steady, prolonged traction is applied in a horizontal direction (",
"      <a class=\"graphic graphic_figure graphicRef71579 \" href=\"UTD.htm?34/48/35586\">",
"       figure 4",
"      </a>",
"      ). Both horizontal arm flexion and the &ldquo;crowing rooster&rdquo; maneuver may be done at the same time as neck extension or rotation.",
"     </li>",
"     <li>",
"      The &ldquo;hooking&rdquo; maneuver is done by hooking the fingers under the anterior costal margins and by pulling the rib cage anteriorly (",
"      <a class=\"graphic graphic_figure graphicRef82160 \" href=\"UTD.htm?32/49/33555\">",
"       figure 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/7/9335/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As with palpation, findings with all three of these maneuvers should be considered diagnostic only if the patient&rsquo;s presenting pain is reproduced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LABORATORY STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory and radiographic studies have three major purposes in the evaluation of a patient with suspected musculoskeletal chest wall pain (",
"    <a class=\"graphic graphic_table graphicRef60641 \" href=\"UTD.htm?32/61/33755\">",
"     table 5",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To evaluate the patient&rsquo;s general health and to exclude cardiac, pulmonary, and abdominal sources of pain",
"     </li>",
"     <li>",
"      To determine whether a suspected chest wall syndrome might be associated with a specific rheumatic disease",
"     </li>",
"     <li>",
"      To directly assess an anatomic area of the chest wall or surrounding structures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the young, healthy patient with pain of relatively short duration and with a normal general physical examination, the likelihood of an underlying visceral or systemic illness is low; laboratory and radiographic evaluation is, therefore, unlikely to be fruitful in this setting. By comparison, in older patients or in those with persistent pain, fever, cough, weight loss, abdominal symptoms, or chronic medical illnesses, visceral processes should be excluded before chest wall syndromes are considered.",
"   </p>",
"   <p>",
"    The evaluation in such patients should consist of a complete blood count, routine chemistries (including serum creatinine concentration), urinalysis, a chest radiograph, and an electrocardiogram. A more complete evaluation for coronary disease is often indicated in patients with risk factors for coronary disease, even if the chest pain is atypical. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15144?source=see_link\">",
"     \"Pathophysiology and clinical presentation of ischemic chest pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most rheumatic diseases in which the chest wall is involved, the diagnosis is based upon the pattern of joint involvement outside the chest, extraarticular features, and laboratory abnormalities (",
"    <a class=\"graphic graphic_table graphicRef60641 \" href=\"UTD.htm?32/61/33755\">",
"     table 5",
"    </a>",
"    ). As an example, the erythrocyte sedimentation rate (ESR) is a relatively nonspecific test for inflammatory disease which is elevated in a majority of patients with septic arthritis, active rheumatoid arthritis, ankylosing spondylitis, and other spondyloarthropathies. An elevated ESR is not as predictable in psoriatic arthritis or sternocostoclavicular hyperostosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with unexplained arthritis of the sternoclavicular joint, an evaluation for rheumatoid factor is indicated, since some patients with rheumatoid arthritis present with an atypical, monoarticular pattern of arthritis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link\">",
"       \"Clinical features of rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with pain or stiffness in the lower or upper back, with evidence of sacroiliac tenderness, or with limited lumbar flexion or chest expansion on examination, radiographs of the sacroiliac joints are the initial step in evaluation for ankylosing spondylitis or another of the spondyloarthropathies. In most cases, irregularity, narrowing, or sclerosis will suggest sacroiliac inflammation. When sacroiliac films are equivocal, checking for the HLA-B27 antigen may be useful in increasing or decreasing the likelihood of diagnosing these conditions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13640?source=see_link\">",
"       \"Diagnosis and differential diagnosis of ankylosing spondylitis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with obvious swelling and erythema of an isolated joint (usually the sternoclavicular joint), aspiration and synovial fluid analysis should be attempted. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/14/28904?source=see_link\">",
"       \"Evaluation of the adult with monoarticular pain\"",
"      </a>",
"      .) In this uncommon situation, an infectious process should be the initial concern, and cultures should be the first studies obtained, with a cell count done on any remaining fluid. In patients with negative cultures and a strong suspicion for an infectious process, a repeat aspiration and cultures for atypical organisms, such as mycobacteria and fungi, should be obtained. Direct biopsy of areas of persistent swelling and tenderness may be necessary to definitively diagnose atypical infections or primary or metastatic neoplasms of the chest wall. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20360?source=see_link\">",
"       \"Synovial fluid analysis and the diagnosis of septic arthritis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Radiographic studies of the chest wall",
"    </span>",
"    &nbsp;&mdash;&nbsp;The radiologic evaluation of the anterior chest wall in patients with different musculoskeletal disorders presents difficulties due to the anatomic complexity of the region complexity and the variability of the radiographic findings. The integrated use of plain radiography, computerized tomography (CT), magnetic resonance imaging (MRI), and nuclear scintigraphy may be needed to fully define abnormalities and to allow for clinical correlation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9335/abstract/10\">",
"     10",
"    </a>",
"    ]. In particular, imaging of the sternoclavicular joint may reveal findings characteristic of a number of different conditions that may be associated with musculoskeletal chest pain [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9335/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain radiographs &mdash; Plain radiographs of the ribs can detect localized tumors (primary or metastatic) or fractures; however, subsequent films may be needed in up to one-half of patients with fractures to confirm a diagnosis.",
"     </li>",
"     <li>",
"      Tomography &mdash; Visualization of the sternoclavicular and manubriosternal joints may require tomographic views since assessment may be difficult with plain radiographs. These areas may show erosive or sclerotic lesions in rheumatoid arthritis or ankylosing spondylitis and more periosteal reactions in sternocostoclavicular hyperostosis (SCCH). Bony bridging and ankylosis may be present in patients with chronic ankylosing spondylitis or SCCH.",
"     </li>",
"     <li>",
"      Scintigraphy &mdash; Nuclear scintigraphy may show increased uptake in involved areas in inflammatory syndromes, after trauma, or with tumors; these studies are usually normal with the common localized chest wall syndromes when not associated with a more generalized arthropathy. As a result, a positive bone scan in the rib cage area increases the possibility of ankylosing spondylitis, SCCH, rheumatoid arthritis, or infection (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef54771 \" href=\"UTD.htm?42/13/43230\">",
"       image 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/7/9335/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. In addition, bone infarcts of the ribs may be seen in patients with chest pain in sickle cell crisis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/7/9335/abstract/14\">",
"       14",
"      </a>",
"      ]. Knowledge and experience in interpreting scintigraphy is essential in differentiating abnormal tracer uptake from variable areas of uptake seen in this area in asymptomatic healthy people [",
"      <a class=\"abstract\" href=\"UTD.htm?9/7/9335/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Computerized tomography and magnetic resonance imaging &mdash; CT is extremely useful in further characterizing lesions of the sternoclavicular joint or sternum and may be needed when a pulmonary or pleural-based lesion is suspected on clinical grounds. The multidetector CT scan (MDCT), using pulmonary embolism, aortic dissection, or coronary artery protocols, may be very useful in imaging of the musculoskeletal structures of the chest wall [",
"      <a class=\"abstract\" href=\"UTD.htm?9/7/9335/abstract/16\">",
"       16",
"      </a>",
"      ]. Important normal variants of the sternum seen on CT need to be differentiated from findings of pathologic significance [",
"      <a class=\"abstract\" href=\"UTD.htm?9/7/9335/abstract/17\">",
"       17",
"      </a>",
"      ]. Identification of an associated soft tissue mass is important in distinguishing destructive lesions due to infection or neoplasm from normal areas of cortical irregularity. The lesions of sternocostoclavicular hyperostosis (SCCH) are seen earliest in the periosteal and ligamentous structures, with relative sparing of the sternoclavicular joint [",
"      <a class=\"abstract\" href=\"UTD.htm?9/7/9335/abstract/18-20\">",
"       18-20",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Although several descriptions of magnetic resonance imaging (MRI) studies of the chest wall have been reported, the role of this technique has not been fully defined in this setting [",
"      <a class=\"abstract\" href=\"UTD.htm?9/7/9335/abstract/21\">",
"       21",
"      </a>",
"      ]. MRI findings described in a series of patients with Tietze&rsquo;s syndrome include enlargement and thickening of cartilage at the site of complaint, focal or widespread increased signal intensities of affected cartilage on both T2 and STIR weighted images, bone marrow oedema in the subcondral bone, and gadolinium uptake in cartilage and subcondral bone marrow. It is unclear whether these findings might be more characteristic of the closely-related SCCH [",
"      <a class=\"abstract\" href=\"UTD.htm?9/7/9335/abstract/22\">",
"       22",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Erosive changes of the corners of vertebral bodies appear to be a consistent finding in patients with SCCH with vertebral involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?9/7/9335/abstract/23\">",
"       23",
"      </a>",
"      ]. Chest CT or MRI should be considered in patients with sternoclavicular joint infections to better define the extent of soft tissue involvement in nearby structures [",
"      <a class=\"abstract\" href=\"UTD.htm?9/7/9335/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of laboratory tests in a patient with an apparent musculoskeletal chest wall syndrome is directed by the history and physical exam. Healthy patients with tender areas, but without swelling or other musculoskeletal or systemic findings, can be managed without any further laboratory studies.",
"   </p>",
"   <p>",
"    In patients with a suspected systemic process, a complete set of blood studies and chest film is indicated. Scintigraphy may be most useful in patients with diffuse pain and tenderness in whom ankylosing spondylitis or SCCH is suspected or when an area of localized tenderness is found without swelling. Areas of localized swelling in the area of the sternoclavicular joint should be aspirated, and cell counts and cultures should be obtained. Other areas of localized swelling are best visualized by computed tomography, with special attention to soft tissue and bony structures. One of these advanced imaging studies is also recommended if there is proven sternoclavicular joint infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1480153\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The evaluation of patients with an apparent musculoskeletal chest wall pain syndrome is directed by the history and physical exam (",
"      <a class=\"graphic graphic_table graphicRef55901 \" href=\"UTD.htm?40/49/41755\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef77753 \" href=\"UTD.htm?42/29/43483\">",
"       table 3",
"      </a>",
"      ). Demographic features, characteristics of the chest pain, and associated symptoms may favor the diagnosis of musculoskeletal chest pain or may suggest other causes of chest discomfort. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The general physical examination should be directed toward detecting abnormalities of the heart, lungs, and abdomen that might cause chest pain; cutaneous lesions that may be associated with specific musculoskeletal chest wall syndromes; and ocular disease (",
"      <a class=\"graphic graphic_table graphicRef59998 \" href=\"UTD.htm?14/60/15308\">",
"       table 4",
"      </a>",
"      ). The musculoskeletal examination should focus on the neck, shoulders, back, and chest, and an examination for evidence of fibromyalgia should be performed. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Physical examination'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Musculoskeletal examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most important diagnostic feature in musculoskeletal chest wall syndromes is chest wall tenderness that consistently reproduces the patient&rsquo;s pain. This finding is generally considered diagnostic for a chest wall syndrome, many of which are defined based upon the location of areas of tenderness. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Ribs and chest wall examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major purposes of laboratory and radiographic studies in the evaluation of a patient with suspected musculoskeletal chest wall pain are to evaluate the patient&rsquo;s general health and to exclude cardiac, pulmonary, and abdominal sources of pain; to determine whether a suspected chest wall syndrome might be associated with a specific rheumatic disease; and to directly assess an anatomic area of the chest wall or surrounding structures. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Laboratory studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most rheumatic diseases in which the chest wall is involved, the diagnosis is based upon the pattern of joint involvement outside the chest, extraarticular features, and laboratory abnormalities (",
"      <a class=\"graphic graphic_table graphicRef60641 \" href=\"UTD.htm?32/61/33755\">",
"       table 5",
"      </a>",
"      ). Healthy young patients with tender areas, but without swelling or other musculoskeletal or systemic findings, can usually be managed without any other further laboratory studies. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Laboratory studies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnostic approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Older patients or those with persistent pain, fever, cough, weight loss, abdominal symptoms, or chronic medical illnesses should have a complete blood count, routine chemistries, urinalysis, a chest radiograph, and an electrocardiogram. A more complete evaluation for coronary disease is often indicated in patients with risk factors for coronary disease, even if the chest pain is atypical. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Laboratory studies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnostic approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The integrated use of different imaging studies may be needed to fully define abnormalities and to allow for clinical correlation, because of the anatomic complexity of the region and the variability of the imaging findings. In particular, imaging of the sternoclavicular joint may reveal findings characteristic of a number of different conditions that may be associated with musculoskeletal chest pain. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Radiographic studies of the chest wall'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnostic approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9335/abstract/1\">",
"      Stochkendahl MJ, Christensen HW. Chest pain in focal musculoskeletal disorders. Med Clin North Am 2010; 94:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9335/abstract/2\">",
"      Yelland M, Cayley WE Jr, Vach W. An algorithm for the diagnosis and management of chest pain in primary care. Med Clin North Am 2010; 94:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9335/abstract/3\">",
"      Fam AG, Smythe HA. Musculoskeletal chest wall pain. CMAJ 1985; 133:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9335/abstract/4\">",
"      Disla E, Rhim HR, Reddy A, et al. Costochondritis. A prospective analysis in an emergency department setting. Arch Intern Med 1994; 154:2466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9335/abstract/5\">",
"      Wolf E, Stern S. Costosternal syndrome: its frequency and importance in differential diagnosis of coronary heart disease. Arch Intern Med 1976; 136:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9335/abstract/6\">",
"      Levine PR, Mascette AM. Musculoskeletal chest pain in patients with \"angina\": a prospective study. South Med J 1989; 82:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9335/abstract/7\">",
"      Yelland MJ. Back, chest and abdominal pain. How good are spinal signs at identifying musculoskeletal causes of back, chest or abdominal pain? Aust Fam Physician 2001; 30:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9335/abstract/8\">",
"      Epstein SE, Gerber LH, Borer JS. Chest wall syndrome. A common cause of unexplained cardiac pain. JAMA 1979; 241:2793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9335/abstract/9\">",
"      Heinz GJ, Zavala DC. Slipping rib syndrome. JAMA 1977; 237:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9335/abstract/10\">",
"      Guglielmi G, Cascavilla A, Scalzo G, et al. Imaging of sternocostoclavicular joint in spondyloarthropaties and other rheumatic conditions. Clin Exp Rheumatol 2009; 27:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9335/abstract/11\">",
"      Hiramuro-Shoji F, Wirth MA, Rockwood CA Jr. Atraumatic conditions of the sternoclavicular joint. J Shoulder Elbow Surg 2003; 12:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9335/abstract/12\">",
"      Kahn MF, Chamot AM. SAPHO syndrome. Rheum Dis Clin North Am 1992; 18:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9335/abstract/13\">",
"      Massie JD, Sebes JI, Cowles SJ. Bone scintigraphy and costochondritis. J Thorac Imaging 1993; 8:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9335/abstract/14\">",
"      Rucknagel DL, Kalinyak KA, Gelfand MJ. Rib infarcts and acute chest syndrome in sickle cell diseases. Lancet 1991; 337:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9335/abstract/15\">",
"      Kakhki VD, Zakavi SR. Age-related normal variants of sternal uptake on bone scintigraphy. Clin Nucl Med 2006; 31:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9335/abstract/16\">",
"      Hillen TJ, Wessell DE. Multidetector CT scan in the evaluation of chest pain of nontraumatic musculoskeletal origin. Radiol Clin North Am 2010; 48:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9335/abstract/17\">",
"      Hatfield MK, Gross BH, Glazer GM, Martel W. Computed tomography of the sternum and its articulations. Skeletal Radiol 1984; 11:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9335/abstract/18\">",
"      Chigira M, Shimizu T. Computed tomographic appearances of sternocostoclavicular hyperostosis. Skeletal Radiol 1989; 18:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9335/abstract/19\">",
"      Earwaker JW, Cotten A. SAPHO: syndrome or concept? Imaging findings. Skeletal Radiol 2003; 32:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9335/abstract/20\">",
"      Sall&eacute;s M, Oliv&eacute; A, Perez-Andres R, et al. The SAPHO syndrome: a clinical and imaging study. Clin Rheumatol 2011; 30:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9335/abstract/21\">",
"      White CS. Magnetic resonance imaging of the chest. Respir Care 2001; 46:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9335/abstract/22\">",
"      Volterrani L, Mazzei MA, Giordano N, et al. Magnetic resonance imaging in Tietze's syndrome. Clin Exp Rheumatol 2008; 26:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9335/abstract/23\">",
"      Laredo JD, Vuillemin-Bodaghi V, Boutry N, et al. SAPHO syndrome: MR appearance of vertebral involvement. Radiology 2007; 242:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9335/abstract/24\">",
"      Ross JJ, Shamsuddin H. Sternoclavicular septic arthritis: review of 180 cases. Medicine (Baltimore) 2004; 83:139.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5631 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-655E7897C0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_7_9335=[""].join("\n");
var outline_f9_7_9335=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1480153\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Demographic features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Characteristics of the chest pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other musculoskeletal symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Musculoskeletal examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Ribs and chest wall examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LABORATORY STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Radiographic studies of the chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1480153\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5631\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5631|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/13/43230\" title=\"diagnostic image 1\">",
"      Anterior chest pain bone scan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5631|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/39/6768\" title=\"figure 1\">",
"      Low back flexion test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/31/29170\" title=\"figure 2\">",
"      Tender points in fibromyalgia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/61/977\" title=\"figure 3\">",
"      Crowing rooster maneuver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/48/35586\" title=\"figure 4\">",
"      Horizontal arm traction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/49/33555\" title=\"figure 5\">",
"      Hooking maneuver",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5631|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/37/42587\" title=\"table 1\">",
"      Isolated chest pain syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/49/41755\" title=\"table 2\">",
"      History in musculoskeletal CP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/29/43483\" title=\"table 3\">",
"      Characteristics of major noncardiac causes of chest pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/60/15308\" title=\"table 4\">",
"      Exam in musculoskeletal CP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/61/33755\" title=\"table 5\">",
"      Lab studies musculoskeletal CP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15240?source=related_link\">",
"      Chest pain of esophageal origin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromyalgia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13640?source=related_link\">",
"      Diagnosis and differential diagnosis of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=related_link\">",
"      Diagnosis and differential diagnosis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/14/28904?source=related_link\">",
"      Evaluation of the adult with monoarticular pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2201?source=related_link\">",
"      Major causes of musculoskeletal chest pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15144?source=related_link\">",
"      Pathophysiology and clinical presentation of ischemic chest pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20360?source=related_link\">",
"      Synovial fluid analysis and the diagnosis of septic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5592?source=related_link\">",
"      Treatment of musculoskeletal chest pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_7_9336="Musculoskeletal manifestations of Lyme disease";
var content_f9_7_9336=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Musculoskeletal manifestations of Lyme disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/7/9336/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/7/9336/contributors\">",
"     Robert T Schoen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/7/9336/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/7/9336/contributors\">",
"     Allen C Steere, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/7/9336/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/7/9336/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/7/9336/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lyme disease was first recognized in the United States in the 1970s, presenting as oligoarthritis during an outbreak in children in Lyme, Connecticut [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/1\">",
"     1",
"    </a>",
"    ]. Lyme disease is now the most common vector-borne illness in North America and Europe. Arthritis is the most common manifestation of late Lyme disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/2\">",
"     2",
"    </a>",
"    ]. Because antibiotic treatment of early infection is usually curative, arthritic complications have become less common [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and therapy of the musculoskeletal manifestations of Lyme disease will be reviewed here. General issues related to the clinical manifestations, diagnosis, and treatment of Lyme disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link\">",
"     \"Clinical manifestations of Lyme disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7225?source=see_link\">",
"     \"Lyme disease: Clinical manifestations in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=see_link\">",
"     \"Diagnosis of Lyme disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=see_link\">",
"     \"Treatment of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL STAGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of Lyme disease can generally be divided into three phases: early localized, early disseminated, and late disease (",
"    <a class=\"graphic graphic_table graphicRef72018 \" href=\"UTD.htm?39/7/40060\">",
"     table 1",
"    </a>",
"    ). However, the clinical features of each stage can overlap and some patients present in a later stage of Lyme disease without a history of prior signs or symptoms suggestive of earlier disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations of Lyme disease in adults\", section on 'Clinical stages'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lyme arthritis is a late finding of Lyme disease, whereas migratory or transient arthralgias can occur during the early localized or early disseminated stages, as discussed below. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical features'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SEASONALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early Lyme disease occurs primarily during the late spring and early summer when nymphal Ixodes ticks are active (",
"    <a class=\"graphic graphic_figure graphicRef70029 \" href=\"UTD.htm?31/13/31965\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef82209 \" href=\"UTD.htm?31/44/32453\">",
"     figure 2",
"    </a>",
"    ). In contrast, Lyme arthritis may begin in any season, weeks to months after initial infection. Affected individuals are typically active outdoors in locations endemic for Lyme disease (",
"    <a class=\"graphic graphic_figure graphicRef80168 \" href=\"UTD.htm?10/32/10757\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41431?source=see_link\">",
"     \"Epidemiology of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Antecedent erythema migrans",
"    </span>",
"    &nbsp;&mdash;&nbsp;A characteristic rash, erythema migrans (EM), usually develops at the site of the tick bite (",
"    <a class=\"graphic graphic_picture graphicRef81270 graphicRef57414 graphicRef67424 graphicRef75337 \" href=\"UTD.htm?22/37/23130\">",
"     picture 1A-D",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. EM may be the only disease manifestation of early localized infection, but migratory arthralgias and myalgias may also be evident.",
"   </p>",
"   <p>",
"    Within several days to weeks, B. burgdorferi may disseminate to multiple sites (early disseminated disease), including the skin, heart, nervous system, or joints [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/6\">",
"     6",
"    </a>",
"    ]. Appropriate antibiotic therapy is almost always curative for both early localized and early disseminated stages of Lyme disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lyme arthritis occurs as a late manifestation of Lyme disease. These patients may have a history of antecedent erythema migrans (EM), but such a history occurs less frequently now than in the past because recognition of EM leads to curative treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations of Lyme disease in adults\", section on 'Erythema migrans'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7225?source=see_link&amp;anchor=H4#H4\">",
"     \"Lyme disease: Clinical manifestations in children\", section on 'Erythema migrans'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasionally, signs and symptoms of early disease, including EM, may not occur or be recognized, however. In the United States, up to 60 percent of individuals with untreated early Lyme disease will subsequently develop Lyme arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Arthralgias",
"    </span>",
"    &nbsp;&mdash;&nbsp;During early disseminated infection, patients may experience migratory pain in joints, bursae, tendons, muscle or bone, in one or a few locations at a time. Some patients develop only migratory arthralgias without arthritis. Arthralgia symptoms may be intermittent or migratory. Once diagnosed, arthralgias respond promptly to antibiotic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Lyme arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of the articular manifestations of Lyme disease was described in the late 1970s, before the cause of Lyme disease and the role of antibiotics in its treatment were known. A cohort of 55 patients was followed prospectively from the onset of disease with erythema migrans (EM) through later manifestations of the illness [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following findings were observed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lyme arthritis is characterized by intermittent or persistent arthritis. Monoarthritis of the knee is most common, but Lyme arthritis may also cause an asymmetric oligoarthritis, usually including the knee.",
"     </li>",
"     <li>",
"      The most commonly involved joints, after the knee, are the shoulder, ankle, elbow, temporomandibular joint, and wrist, although any joint can be affected and occasionally, there is periarticular involvement, leading to bursitis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tendinitis. Almost always, fewer than five joints are affected. Large joints are most commonly involved.",
"     </li>",
"     <li>",
"      Attacks of joint swelling tend to begin abruptly and last from several weeks to months. In 10 percent of untreated patients with Lyme arthritis, joint swelling lasts for more than a year.",
"     </li>",
"     <li>",
"      Large joint effusions are common in the knees and elsewhere and often recur after aspiration. Popliteal cysts occur and can rupture if not aspirated.",
"     </li>",
"     <li>",
"      Lyme arthritis is not particularly painful, except when there is pressure from a tensely swollen joint. Affected joints are usually very swollen and warm.",
"     </li>",
"     <li>",
"      For most patients, there is little joint dysfunction after resolution of arthritis. However, chronic, unremitting arthritis sometimes causes erosion of cartilage and bone and permanent joint damage.",
"     </li>",
"     <li>",
"      Some patients with Lyme arthritis have accompanying fatigue. In this study, 10 of 28 patients with intermittent arthritis and 4 of 6 patients with chronic arthritis had fatigue. However, systemic symptoms are usually minor, if present at all, in patients with Lyme arthritis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this study, 60 percent of individuals with untreated early Lyme disease developed Lyme arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/8\">",
"     8",
"    </a>",
"    ]. Although less common as a result of early detection and treatment of Lyme disease, Lyme arthritis is still the second most frequent manifestation of Lyme disease. Among more than 150,000 reports of Lyme disease made to the US Centers for Disease Control and Prevention between 1992 and 2006, 32 percent had arthritis characterized by brief attacks of joint swelling (",
"    <a class=\"graphic graphic_figure graphicRef60753 \" href=\"UTD.htm?20/14/20718\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lyme arthritis is an infectious arthritis with an inflammatory synovial response. However, it may be confused with a mechanical injury when it presents as an acute monoarticular knee effusion in an active individual.",
"   </p>",
"   <p>",
"    Unlike other forms of infectious arthritis, Lyme arthritis is only occasionally associated with fever or constitutional symptoms, and is less painful. Lyme arthritis may resemble spondyloarthropathy or pauciarticular juvenile rheumatoid arthritis when it is oligoarticular. It is not usually mistaken for adult onset rheumatoid arthritis, however, since it is not polyarticular or symmetrical. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=see_link\">",
"     \"Septic arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/14/28904?source=see_link\">",
"     \"Evaluation of the adult with monoarticular pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9114?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24056?source=see_link\">",
"     \"Pauciarticular onset juvenile idiopathic arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link\">",
"     \"Clinical features of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fibromyalgia symptoms are sometimes incorrectly attributed to Lyme arthritis. Lyme disease can cause migratory arthralgias; however, such symptoms are usually not chronic or associated with tender points, in contrast to fibromyalgia. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Distinction from fibromyalgia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LABORATORY TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lyme disease serologies are used to establish the diagnosis of Lyme arthritis in patients with potential exposure to Ixodes ticks and signs and symptoms of Lyme arthritis. Synovial fluid testing can establish the presence of an inflammatory arthritis, characterized by mean synovial white blood cells counts of 10,000 to 25,000",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Serologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serological responsiveness to B. burgdorferi is the primary laboratory test for diagnosing Lyme arthritis. The immune response can take several weeks to develop, so some patients with early Lyme disease will be seronegative for B. burgdorferi-specific antibodies at the onset of illness [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/11\">",
"     11",
"    </a>",
"    ]. In contrast, all patients with Lyme arthritis will have positive serologies for B. burgdorferi since Lyme arthritis is a late manifestation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Criteria have been developed for establishing the diagnosis of Lyme disease using enzyme-linked immunosorbent assay (ELISA) screening, followed by Western blot testing for B. burgdorferi. According to validated standards determined by the United States Centers for Disease Control and",
"    <span class=\"nowrap\">",
"     Prevention/Association",
"    </span>",
"    of State and Territorial Public Health Laboratory Directors, the criteria for Western blot immunoglobulin (IgG reactivity) require the presence of at least five of ten specific bands (",
"    <a class=\"graphic graphic_table graphicRef50882 \" href=\"UTD.htm?8/63/9211\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. These criteria were developed to maximize sensitivity and specificity during all stages of Lyme disease. Patients with Lyme arthritis usually far exceed the Western blot IgG reactivity criteria and often have IgM reactivity as well [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/12\">",
"     12",
"    </a>",
"    ]. The use of serologic testing for the diagnosis of Lyme disease is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=see_link\">",
"     \"Diagnosis of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most Lyme arthritis patients remain seropositive for years after successful antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Such seroreactivity, in the absence of other evidence for ongoing infection, is NOT an indication for retreatment. In fact, the robust immune response observed in patients with Lyme arthritis seems to confer protective immunity to reinfection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Analysis of synovial fluid by ELISA or Western blot will also demonstrate B. burgdorferi reactivity, but such testing is unnecessary, since it is neither more sensitive nor more specific than serum analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Culture and PCR",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are only isolated reports of successful cultivation of B. burgdorferi from synovial fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. However, in clinical practice, it has been difficult to culture B. burgdorferi, except from erythema migrans (EM) skin biopsy specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/20\">",
"     20",
"    </a>",
"    ]. In contrast, B. burgdorferi DNA is detectable in synovial fluid by polymerase chain reaction (PCR) in most untreated Lyme arthritis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/21\">",
"     21",
"    </a>",
"    ]. Synovial fluid PCR testing usually becomes negative after treatment, but in one patient with antibiotic-refractory Lyme arthritis, it remained positive for 11 months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/22\">",
"     22",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    PCR was used to detect B. burgdorferi DNA in skin samples from 90 patients with EM, in synovial fluid from 63 patients with Lyme arthritis, and in synovial tissue from 9 patients with Lyme arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/22\">",
"     22",
"    </a>",
"    ]. The skin lesions from most patients with EM were positive, as were the synovial fluid samples from patients with Lyme arthritis. Although it took longer for the PCR results from patients with antibiotic-refractory Lyme arthritis (defined as arthritis lasting more than three months in spite of antibiotic therapy) to become negative than those from patients with antibiotic-responsive arthritis (arthritis lasting less than three months), positive PCR results from patients who had been treated for Lyme arthritis did not correlate with relapse or with subsequent duration of arthritis. In addition, PCR tests performed on synovectomy tissue were negative. B. burgdorferi messenger RNA, a marker of spirochetal viability, was detected in 8 of 10 skin samples from patients with EM, but in none of 11 synovial fluid samples, even when obtained prior to initiating antibiotics. This study suggests that the skin lesions of patients with EM contained viable B. burgdorferi organisms, whereas those detected in the synovial fluid of patients with Lyme arthritis were moribund or dead.",
"    <br/>",
"   </p>",
"   <p>",
"    PCR testing of synovial fluid has not been validated for widespread clinical use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF LYME ARTHRITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of the natural history of Lyme arthritis demonstrate eventual resolution, even in the absence of antibiotic therapy, in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/8\">",
"     8",
"    </a>",
"    ]. However, in untreated patients, Lyme arthritis can last for years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/8\">",
"     8",
"    </a>",
"    ]. We recommend antibiotic treatment to accelerate resolution of arthritis and to prevent arthritis recurrence and other damage [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/23\">",
"     23",
"    </a>",
"    ]. Not all patients respond to antibiotic therapy immediately. Clinical response may require several months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Clinical trials of antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of Lyme arthritis is based upon small randomized controlled trials. The efficacy of antimicrobial therapy was demonstrated in a randomized trial in which 40 patients were assigned to 2.4 million units of intramuscular benzathine penicillin weekly for three weeks or to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/25\">",
"     25",
"    </a>",
"    ]. Seven of the penicillin-treated patients (35 percent) had complete resolution of arthritis soon after the injections and remained well at a mean follow-up of 33 months. In contrast, all 20 placebo-treated patients continued to have attacks of arthritis during the trial.",
"   </p>",
"   <p>",
"    A later randomized trial addressed the comparative efficacy of 30 days of therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    or with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    in 38 patients with Lyme arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/23\">",
"     23",
"    </a>",
"    ]. The arthritis resolved in 90 percent of patients within one to three months after study entry. However, neurologic manifestations were later recognized in five patients, four of whom had received the amoxicillin regimen.",
"   </p>",
"   <p>",
"    The latter findings emphasize the importance of looking for neurologic disease in patients with Lyme arthritis, since these two late complications can occur simultaneously. Late neurologic manifestations require intravenous therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of Lyme disease\", section on 'Early disseminated disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of Lyme disease\", section on 'Late disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Antibiotic regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations are intended for patients with objective findings of Lyme arthritis (eg, joint swelling, warmth), and not simply arthralgias. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Lyme arthritis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Without neurologic involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;For Lyme arthritis in the absence of neurologic disease, the recommended initial regimen is oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg twice per day) or oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    (500 mg three times per day) for 28 days (",
"    <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/7\">",
"     7",
"    </a>",
"    ]. The Infectious Diseases Society of America has suggested",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    as an alternative agent in those with contraindications to doxycycline and amoxicillin, but its efficacy for this indication has not been proven in clinical trials.",
"   </p>",
"   <p>",
"    Approximately 90 percent of patients with arthritis respond to a single course of oral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/23\">",
"     23",
"    </a>",
"    ]. In patients whose arthritis has improved but not completely resolved after one month of oral therapy, a second 28 day course of the same antibiotic is suggested. In contrast, patients who have had little or no improvement after the initial 28 day course should be treated with intravenous therapy, usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (2 g once daily for 14 to 28 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/7,26\">",
"     7,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the unusual situation that a person has had previous attacks of well-characterized Lyme arthritis and has not previously received antibiotic therapy, it is reasonable to treat with a 28 day course of appropriate oral antibiotics to prevent subsequent attacks of arthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     With neurologic involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with both Lyme arthritis and neurologic manifestations should be treated according to the recommendations for neurologic disease, which are discussed separately (",
"    <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=see_link&amp;anchor=H22#H22\">",
"     \"Treatment of Lyme disease\", section on 'Late neurologic findings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Adjunctive therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjunctive measures, including nonsteroidal antiinflammatory drugs and physical therapy may be beneficial. Joint aspiration is indicated for diagnosis. Reaspiration may be required to treat intensely swollen joints and prevent popliteal cyst rupture. Intraarticular glucocorticoid injection is not recommended, as there is some evidence that this may delay the resolution of Lyme arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Antibiotic-refractory Lyme arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In rare cases, the arthritis persists after two to three months of oral and intravenous antibiotic therapy, an entity that is called antibiotic-refractory Lyme arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/17\">",
"     17",
"    </a>",
"    ]. Persistence of synovitis in patients who are antibiotic refractory may result from infection-induced autoimmunity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    retained spirochetal antigens rather than ongoing infection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients with antibiotic-refractory Lyme arthritis have been successfully treated with synovectomy or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    , modalities that have been used in rheumatoid arthritis and other chronic inflammatory arthropathies. In a series of 20 such patients treated with arthroscopic synovectomy, 16 (80 percent) had resolution of joint inflammation during or soon after the first months following surgery and remained well at three to eight year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28565?source=see_link\">",
"     \"Synovectomy for inflammatory arthritis of the knee\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Activity restrictions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Lyme arthritis should reduce high levels of activity and high impact on affected joints. A period of rest and possibly physical therapy when the joint or joints are swollen may reduce the magnitude of swelling and hasten recovery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35896?source=see_link\">",
"     \"Overview of joint protection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     POST-LYME DISEASE SYNDROME (CHRONIC LYME DISEASE) AND FIBROMYALGIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with Lyme disease, whether early or late stage, do not develop chronic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/31\">",
"     31",
"    </a>",
"    ]. Lyme disease is sometimes misdiagnosed, however, in patients with fibromyalgia, based on nonspecific symptoms such as widespread musculoskeletal pain and fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. Such patients are often mistreated with antibiotic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Distinction from fibromyalgia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with noninflammatory musculoskeletal pain, cognitive complaints, fatigue,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    irritability may have fibromyalgia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/36\">",
"     36",
"    </a>",
"    ]. Fibromyalgia is a chronic disorder characterized by pain in muscles and associated fibrous tissue and occurs in 2 percent of the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/37\">",
"     37",
"    </a>",
"    ]. Physical examination reveals multiple \"trigger points\" near joints.",
"   </p>",
"   <p>",
"    In contrast to Lyme disease, fibromyalgia is not an inflammatory or infectious disorder. Thus, an important distinction between these two clinical entities is the presence of objective evidence of inflammation or organ system dysfunction in patients with late Lyme disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=see_link\">",
"     \"Clinical manifestations and diagnosis of fibromyalgia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Post-Lyme disease syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In untreated patients, objective manifestations of late Lyme disease, such as monoarticular or oligoarticular arthritis, may persist for several years. In contrast, there is no evidence that persistent subjective symptoms after antibiotic treatment, so called post-Lyme disease syndrome or \"chronic Lyme disease,\" is due to active infection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9336/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lyme disease is not a diagnosis of exclusion to explain puzzling complaints, particularly when they are not accompanied by objective markers of organ damage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inflammation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical manifestations of Lyme disease in adults\", section on 'Post-Lyme disease syndrome and chronic Lyme disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/40/30338?source=see_link\">",
"       \"Patient information: Lyme disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/17/32022?source=see_link\">",
"       \"Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/41/5778?source=see_link\">",
"       \"Patient information: Lyme disease treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/0/27649?source=see_link\">",
"       \"Patient information: Lyme disease prevention (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lyme arthritis, a late manifestation of Lyme disease, occurs primarily in individuals who live in or travel to Lyme disease endemic areas. It may begin in any season, weeks to months after initial infection. Many, but not all, patients will describe an antecedent history of erythema migrans or other early disease manifestations. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical stages'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lyme arthritis is characterized by intermittent or persistent arthritis in a few large joints, especially the knee. The most commonly involved joints, after the knee, are the shoulder, ankle, elbow, temporomandibular joint, and wrist. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Lyme arthritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Migratory arthralgias may occur during early localized or early disseminated Lyme disease, and should be distinguished from frank arthritis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Arthralgias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serological responsiveness to B. burgdorferi is the primary laboratory test for Lyme arthritis. All patients with Lyme arthritis will have positive IgG serologies for B. burgdorferi. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Serologies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that the initial treatment of Lyme arthritis in patients without evidence of neurologic disease be oral therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      &nbsp;(",
"      <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"       table 3",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The typical course is 28 days. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Antibiotic regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients whose arthritis has improved but not completely resolved after one month of oral therapy, we suggest a second 28 day course of the same antibiotic (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, in patients who have had little or no improvement after the initial 28 day course, we suggest treatment with intravenous therapy (usually",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      for 14 to 28 days) (",
"      <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"       table 3",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Lyme arthritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of Lyme arthritis in patients who also have neurologic involvement is discussed separately. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'With neurologic involvement'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/1\">",
"      Steere AC, Malawista SE, Snydman DR, et al. Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three connecticut communities. Arthritis Rheum 1977; 20:7.",
"     </a>",
"    </li>",
"    <li>",
"     Dennis DT, Hayes EB. Epidemiology of Lyme Borreliosis. In: Lyme borreliosis: biology, epidemiology and control, Kahl O, Gray JS, Lane RS, Stanek G (Eds), CABI Publishing, Oxford 2002. p.251.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/3\">",
"      Steere AC. Lyme disease. N Engl J Med 1989; 321:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/4\">",
"      Steere AC, Bartenhagen NH, Craft JE, et al. The early clinical manifestations of Lyme disease. Ann Intern Med 1983; 99:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/5\">",
"      Smith RP, Schoen RT, Rahn DW, et al. Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. Ann Intern Med 2002; 136:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/6\">",
"      Wormser GP, McKenna D, Carlin J, et al. Brief communication: hematogenous dissemination in early Lyme disease. Ann Intern Med 2005; 142:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/7\">",
"      Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/8\">",
"      Steere AC, Schoen RT, Taylor E. The clinical evolution of Lyme arthritis. Ann Intern Med 1987; 107:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/9\">",
"      Bacon RM, Kugeler KJ, Mead PS, Centers for Disease Control and Prevention (CDC). Surveillance for Lyme disease--United States, 1992-2006. MMWR Surveill Summ 2008; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/10\">",
"      Puius YA, Kalish RA. Lyme arthritis: pathogenesis, clinical presentation, and management. Infect Dis Clin North Am 2008; 22:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/11\">",
"      Shrestha M, Grodzicki RL, Steere AC. Diagnosing early Lyme disease. Am J Med 1985; 78:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/12\">",
"      Craft JE, Grodzicki RL, Steere AC. Antibody response in Lyme disease: evaluation of diagnostic tests. J Infect Dis 1984; 149:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/13\">",
"      Dressler F, Whalen JA, Reinhardt BN, Steere AC. Western blotting in the serodiagnosis of Lyme disease. J Infect Dis 1993; 167:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/14\">",
"      Centers for Disease Control and Prevention (CDC). Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep 1995; 44:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/15\">",
"      Kalish RA, McHugh G, Granquist J, et al. Persistence of immunoglobulin M or immunoglobulin G antibody responses to Borrelia burgdorferi 10-20 years after active Lyme disease. Clin Infect Dis 2001; 33:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/16\">",
"      Kannian P, McHugh G, Johnson BJ, et al. Antibody responses to Borrelia burgdorferi in patients with antibiotic-refractory, antibiotic-responsive, or non-antibiotic-treated Lyme arthritis. Arthritis Rheum 2007; 56:4216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/17\">",
"      Steere AC, Angelis SM. Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. Arthritis Rheum 2006; 54:3079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/18\">",
"      Snydman DR, Schenkein DP, Berardi VP, et al. Borrelia burgdorferi in joint fluid in chronic Lyme arthritis. Ann Intern Med 1986; 104:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/19\">",
"      Schmidli J, Hunziker T, Moesli P, Schaad UB. Cultivation of Borrelia burgdorferi from joint fluid three months after treatment of facial palsy due to Lyme borreliosis. J Infect Dis 1988; 158:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/20\">",
"      Berger BW, Kaplan MH, Rothenberg IR, Barbour AG. Isolation and characterization of the Lyme disease spirochete from the skin of patients with erythema chronicum migrans. J Am Acad Dermatol 1985; 13:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/21\">",
"      Nocton JJ, Dressler F, Rutledge BJ, et al. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. N Engl J Med 1994; 330:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/22\">",
"      Li X, McHugh GA, Damle N, et al. Burden and viability of Borrelia burgdorferi in skin and joints of patients with erythema migrans or lyme arthritis. Arthritis Rheum 2011; 63:2238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/23\">",
"      Steere AC, Levin RE, Molloy PJ, et al. Treatment of Lyme arthritis. Arthritis Rheum 1994; 37:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/24\">",
"      Dattwyler RJ, Wormser GP, Rush TJ, et al. A comparison of two treatment regimens of ceftriaxone in late Lyme disease. Wien Klin Wochenschr 2005; 117:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/25\">",
"      Steere AC, Green J, Schoen RT, et al. Successful parenteral penicillin therapy of established Lyme arthritis. N Engl J Med 1985; 312:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/26\">",
"      Dattwyler RJ, Halperin JJ, Volkman DJ, Luft BJ. Treatment of late Lyme borreliosis--randomised comparison of ceftriaxone and penicillin. Lancet 1988; 1:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/27\">",
"      Steere AC. Reinfection versus relapse in Lyme disease. N Engl J Med 2012; 367:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/28\">",
"      Drouin EE, Seward RJ, Strle K, et al. A novel human autoantigen, endothelial cell growth factor, is a target of T and B cell responses in patients with Lyme disease. Arthritis Rheum 2013; 65:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/29\">",
"      Bockenstedt LK, Gonzalez DG, Haberman AM, Belperron AA. Spirochete antigens persist near cartilage after murine Lyme borreliosis therapy. J Clin Invest 2012; 122:2652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/30\">",
"      Schoen RT, Aversa JM, Rahn DW, Steere AC. Treatment of refractory chronic Lyme arthritis with arthroscopic synovectomy. Arthritis Rheum 1991; 34:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/31\">",
"      Feder HM Jr, Johnson BJ, O'Connell S, et al. A critical appraisal of \"chronic Lyme disease\". N Engl J Med 2007; 357:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/32\">",
"      Sigal LH. Summary of the first 100 patients seen at a Lyme disease referral center. Am J Med 1990; 88:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/33\">",
"      Steere AC, Taylor E, McHugh GL, Logigian EL. The overdiagnosis of Lyme disease. JAMA 1993; 269:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/34\">",
"      Feder HM Jr, Hunt MS. Pitfalls in the diagnosis and treatment of Lyme disease in children. JAMA 1995; 274:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/35\">",
"      Reid MC, Schoen RT, Evans J, et al. The consequences of overdiagnosis and overtreatment of Lyme disease: an observational study. Ann Intern Med 1998; 128:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/36\">",
"      Hsu VM, Patella SJ, Sigal LH. \"Chronic Lyme disease\" as the incorrect diagnosis in patients with fibromyalgia. Arthritis Rheum 1993; 36:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9336/abstract/37\">",
"      Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995; 38:19.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7894 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.243-7F1A92C927-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_7_9336=[""].join("\n");
var outline_f9_7_9336=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL STAGES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SEASONALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Antecedent erythema migrans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Arthralgias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Lyme arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LABORATORY TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Serologies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Culture and PCR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MANAGEMENT OF LYME ARTHRITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Clinical trials of antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Antibiotic regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Without neurologic involvement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - With neurologic involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Adjunctive therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Antibiotic-refractory Lyme arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Activity restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      POST-LYME DISEASE SYNDROME (CHRONIC LYME DISEASE) AND FIBROMYALGIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Distinction from fibromyalgia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Post-Lyme disease syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7894\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7894|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/13/31965\" title=\"figure 1\">",
"      Lyme seasonality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/44/32453\" title=\"figure 2\">",
"      Ixodes scapularis life cycle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/32/10757\" title=\"figure 3\">",
"      Lyme disease map US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/14/20718\" title=\"figure 4\">",
"      Lyme sxs frequency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7894|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/10/10400\" title=\"picture 1A\">",
"      Erythema migrans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/35/575\" title=\"picture 1B\">",
"      Erythema migrans uniform",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/20/35140\" title=\"picture 1C\">",
"      EM vesicular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/16/26883\" title=\"picture 1D\">",
"      Erythema migrans multiple",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7894|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/7/40060\" title=\"table 1\">",
"      Signs of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/63/9211\" title=\"table 2\">",
"      Western blot diagnosis of Lyme",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/35/22078\" title=\"table 3\">",
"      Treatment of Lyme disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromyalgia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=related_link\">",
"      Clinical manifestations of Lyme disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9114?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=related_link\">",
"      Diagnosis of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41431?source=related_link\">",
"      Epidemiology of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/14/28904?source=related_link\">",
"      Evaluation of the adult with monoarticular pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7225?source=related_link\">",
"      Lyme disease: Clinical manifestations in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35896?source=related_link\">",
"      Overview of joint protection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/40/30338?source=related_link\">",
"      Patient information: Lyme disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/0/27649?source=related_link\">",
"      Patient information: Lyme disease prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/17/32022?source=related_link\">",
"      Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/41/5778?source=related_link\">",
"      Patient information: Lyme disease treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24056?source=related_link\">",
"      Pauciarticular onset juvenile idiopathic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=related_link\">",
"      Septic arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28565?source=related_link\">",
"      Synovectomy for inflammatory arthritis of the knee",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=related_link\">",
"      Treatment of Lyme disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_7_9337="Pelvic organ prolapse in women: Choosing a primary surgical procedure";
var content_f9_7_9337=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pelvic organ prolapse in women: Choosing a primary surgical procedure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/7/9337/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/7/9337/contributors\">",
"     J Eric Jelovsek, MD, MMEd, FACOG, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/7/9337/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/7/9337/contributors\">",
"     Linda Brubaker, MD, FACS, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/7/9337/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/7/9337/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/7/9337/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2327162\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic organ prolapse (POP) affects millions of women; approximately 200,000 inpatient surgical procedures for prolapse are performed annually in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Eleven to 19 percent of women will undergo surgery for prolapse or incontinence by age 80 to 85 years, and 30 percent of these women will require an additional prolapse repair procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with symptomatic POP experience daily discomfort, as well as interference with sexual function and exercise. Reconstructive surgery for women with prolapse consists of some combination of resuspension of the vaginal apex and anterior and posterior vaginal walls. The choice of a primary surgical procedure for women with POP depends upon a variety of considerations, including the anatomic site of prolapse, presence of urinary or fecal incontinence, health status, and patient preferences.",
"   </p>",
"   <p>",
"    The process of choosing a surgical procedure for women with POP who have not had a prior prolapse repair will be reviewed here. Evaluation of women with POP, conservative management, and specific repair procedures are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40473?source=see_link\">",
"     \"An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17530?source=see_link\">",
"     \"Vaginal pessary treatment of prolapse and incontinence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35914?source=see_link\">",
"     \"Pelvic organ prolapse in women: Surgical repair of apical prolapse (uterine or vaginal vault prolapse)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7306?source=see_link\">",
"     \"Pelvic organ prolapse in women: Surgical repair of anterior vaginal wall prolapse\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44424?source=see_link\">",
"     \"Surgical management of posterior vaginal defects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43607?source=see_link\">",
"     \"Pelvic organ prolapse in women: Obliterative procedures (colpocleisis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2327205\">",
"    <span class=\"h1\">",
"     CANDIDATES FOR SURGICAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candidates for surgical repair of POP are women with symptomatic prolapse who have failed or declined conservative management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10284328\">",
"    <span class=\"h2\">",
"     Women with symptomatic prolapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reconstructive surgery for POP should be performed only in women who have symptomatic prolapse, with few exceptions. Surgical correction of asymptomatic POP or non-bothersome POP is of uncertain benefit and adds perioperative risks.",
"   </p>",
"   <p>",
"    POP symptoms include pelvic pressure, sensation of a vaginal bulge, urinary retention,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    difficult defecation; some women need to reduce the prolapse using a finger in the vagina (also referred to as splinting) to urinate or defecate. Prolapsed vaginal tissue may protrude, leading to chronic discharge and bleeding from ulceration. Such symptoms may interfere with daily activities, sexual function, or exercise. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40473?source=see_link&amp;anchor=H21524755#H21524755\">",
"     \"An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many women have asymptomatic POP; approximately 40 percent of women are found to have stage II or greater prolapse upon routine pelvic examination [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. There is no indication for repair of asymptomatic POP as an isolated procedure.",
"   </p>",
"   <p>",
"    When women undergo other pelvic procedures (eg, vaginal hysterectomy, stress urinary incontinence [SUI] surgery), some surgeons repair asymptomatic prolapse to prevent the need for subsequent surgery. This practice is based upon the assumption that prolapse will progress. This approach remains unproven and may increase surgical morbidity. Interestingly, the natural history of prolapse does not follow a progressive course in all women. Data suggest that the course is progressive until menopause, after which the degree of prolapse may follow a course of alternating progression and regression [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. On the other hand, in addition to premenopausal status, risk factors for the progression of POP include obesity and hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40473?source=see_link&amp;anchor=H21524727#H21524727\">",
"     \"An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the paucity of data regarding repair of asymptomatic POP, for most women with asymptomatic prolapse who are undergoing other pelvic floor procedures (eg, SUI surgery), we suggest not performing prolapse repair. Prolapse repair for asymptomatic women at the time of other pelvic surgery is a reasonable option in women with risk factors for prolapse progression (eg, concomitant hysterectomy, premenopausal status, obesity).",
"   </p>",
"   <p>",
"    Combined surgical treatment of POP and SUI is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1546?source=see_link&amp;anchor=H16#H16\">",
"     \"Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment\", section on 'SUI with asymptomatic POP'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10284335\">",
"    <span class=\"h2\">",
"     Women who decline or fail conservative therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;First line management of POP is conservative therapy. The mainstay of",
"    <strong>",
"    </strong>",
"    nonsurgical treatment for POP is the vaginal pessary. Pessaries are silicone devices that are inserted into the vagina and support the pelvic organs. Pelvic floor muscle exercise is another conservative treatment option. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40473?source=see_link&amp;anchor=H8624710#H8624710\">",
"     \"An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women\", section on 'Conservative management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prolapse is typically a chronic problem, and many women ultimately prefer surgery to conservative therapy since successful surgery does not require ongoing maintenance. In the patients who can be fit with a pessary, approximately 40 percent of women discontinue pessary use within one to two years of use. It is difficult to estimate how many women who choose to have a pessary go on to have surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17530?source=see_link&amp;anchor=H32#H32\">",
"     \"Vaginal pessary treatment of prolapse and incontinence\", section on 'Treatment of prolapse trials'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10284349\">",
"    <span class=\"h2\">",
"     Women finished with childbearing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic support may be disrupted during pregnancy, and particularly following a vaginal birth. Most surgeons recommend delaying surgical management of POP until childbearing is complete. Small case studies have reported successful pregnancy after uterine-sparing surgery, but no study has specifically investigated the risk of developing recurrent POP after delivery. Seven pregnancies have been reported with one following vaginal and cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3439983\">",
"    <span class=\"h2\">",
"     Young or elderly women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients at a young age are at higher risk of prolapse recurrence and a lower overall risk from surgery compared to older women (",
"    <a class=\"graphic graphic_table graphicRef79651 \" href=\"UTD.htm?27/56/28556\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Thus, younger patients are best treated with procedures with better efficacy (eg, abdominal sacral colpopexy rather than vaginal sacrospinous ligament suspension).",
"   </p>",
"   <p>",
"    POP repair can be safely performed in many elderly women. In a cohort of 267 patients who were &gt; or = 75 years old, 26 percent of the patients had a significant perioperative complication at the time of surgery for POP. The most common perioperative complication was blood transfusion or significant blood loss, pulmonary edema, and postoperative congestive heart failure; however, the overall perioperative morbidity rate in elderly women who undergo urogynecologic surgery is low. Independent risk factors that were predictive of a patient having a perioperative complication were the length of surgery, coronary artery disease, and peripheral vascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10284356\">",
"    <span class=\"h2\">",
"     Obese women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although obesity is a risk factor for new onset and recurrent POP [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], obese women appear to have no difference in outcome of surgical correction of apical prolapse compared with non-obese women [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/18\">",
"     18",
"    </a>",
"    ]. Many surgeons feel that obese patients are good candidates for the most durable repair, abdominal sacrocolpopexy. Unfortunately, the open abdominal approach in the obese patient increases the risk usually in the form of wound complications [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2327248\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH TO CHOICE OF PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of a primary procedure for POP includes a variety of factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reconstructive or obliterative &ndash; Most women with symptomatic POP are treated with a reconstructive procedure. Obliterative procedures (eg, colpocleisis) are reserved for women who cannot tolerate more extensive surgery or who are not planning future vaginal intercourse.",
"     </li>",
"     <li>",
"      Concomitant hysterectomy &ndash; When apical prolapse is repaired, the decision must be made whether to perform a hysterectomy as a part of the procedure.",
"     </li>",
"     <li>",
"      Surgical route for repair of multiple sites of prolapse &ndash; Reconstructive surgery for POP often involves repair of multiple anatomic sites of prolapse (apical, anterior, posterior). The choice of surgical route depends upon the optimal approach for the combination of prolapse sites.",
"     </li>",
"     <li>",
"      Concomitant anti-incontinence surgery &ndash; Symptomatic POP often coexists with SUI and, in some women, anal incontinence. POP repair must be coordinated with treatment of incontinence.",
"     </li>",
"     <li>",
"      Use of surgical mesh &ndash; Surgical mesh is used in abdominal POP repair. Use in transvaginal procedures has increased, but questions have arisen about the safety of this approach.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A summary of all major decisions involved in choosing a primary surgical procedure to repair POP is presented in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef56020 \" href=\"UTD.htm?15/46/16111\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2327263\">",
"    <span class=\"h1\">",
"     RECONSTRUCTIVE VERSUS OBLITERATIVE PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of a reconstructive or obliterative procedure depends upon the medical status and sexual function of the patient.",
"   </p>",
"   <p>",
"    Reconstructive surgery surgically corrects the prolapsed vagina and aims to restore normal anatomy, while obliterative surgery corrects prolapse by removing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    closing off all or a portion of the vaginal canal (ie, colpocleisis or colpectomy) to reduce the viscera back into the pelvis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/20\">",
"     20",
"    </a>",
"    ]. Another difference between the two types of procedures is that reconstructive surgery can be performed using a vaginal or abdominal approach, while all obliterative surgeries are performed using the vaginal approach.",
"   </p>",
"   <p>",
"    Most women with symptomatic POP are treated with a reconstructive procedure. Obliterative procedures are reserved for women who cannot tolerate more extensive surgery or who are not planning future vaginal intercourse. The advantages of obliterative procedures in this population are that such procedures typically have a short operative duration, low risk of perioperative morbidity, and an extremely low risk of prolapse recurrence. The obvious disadvantages are the elimination of the potential for vaginal intercourse, as well as the inability to evaluate the cervix or uterus via a vaginal route (eg, cervical cytology or endometrial biopsy).",
"   </p>",
"   <p>",
"    Colpocleisis is highly effective with low morbidity for correcting apical prolapse in such women. Colpocleisis does not appear to alter body image and regret after the procedure is uncommon (less than 10 percent). Therefore, an obliterative operation is an option for women who are not candidates for more extensive surgery or are willing to accept the loss of vaginal intercourse.",
"   </p>",
"   <p>",
"    Obliterative procedures for POP are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43607?source=see_link\">",
"     \"Pelvic organ prolapse in women: Obliterative procedures (colpocleisis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2327312\">",
"    <span class=\"h1\">",
"     CONCOMITANT HYSTERECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hysterectomy is often performed at the time of POP repair. This practice is dependent upon the surgical technique used for pelvic reconstruction and other potential benefits. On the other hand, there is concern that concomitant hysterectomy may increase the risk of some perioperative complications (eg, mesh erosion) and, additionally, an increasing number of women wish to conserve their uterus as an important component of their body image.",
"   </p>",
"   <p>",
"    During POP repair, surgeons have generally performed hysterectomy rather than uterine-sparing procedures based upon several assertions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Apical prolapse is often present in women with symptomatic prolapse, and the most commonly performed techniques for apical prolapse repair require hysterectomy. In abdominal sacral colpopexy and transvaginal sacrospinous ligament suspension, hysterectomy is required because the apex is elevated by affixing the vaginal cuff to a support structure (eg, the sacrospinous ligament or the anterior longitudinal ligament of the sacrum).",
"     </li>",
"     <li>",
"      The common wisdom has been that retaining the uterus increases the risk of recurrent prolapse, although there are no data to support this. The role of hysterectomy at the time of surgery for POP is currently debatable and there are no data supporting hysterectomy at the time of surgery for POP. There are three underpowered studies that describe uterine preservation at the time of surgery for POP and uterine preservation did not affect the risk of POP recurrence [",
"      <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/21-23\">",
"       21-23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hysterectomy eliminates current or future cervical or intrauterine pathology. However, such benefits are less relevant with current advances in minimally invasive treatment of abnormal uterine bleeding and in cervical cancer screening. Uterine cancer typically presents at an early stage with uterine bleeding, and thus, preventive measures are not routinely recommended for average risk women.",
"      <br/>",
"      <br/>",
"      In a retrospective analysis of pathology findings at reconstructive pelvic surgery with hysterectomy, over a 3.5-year period, 17 of 644 patients (2.6 percent) had unanticipated premalignant or malignant uterine pathology. Two (0.3 percent) had endometrial carcinoma. All cases of unanticipated disease were identified in postmenopausal women [",
"      <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Potential disadvantages of hysterectomy and the associated pelvic floor dissection are an increased risk of pelvic neuropathy and disruption of natural support structures such as the uterosacral cardinal ligament complex [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Uterine sparing procedures correct apical prolapse by attaching the lower uterus or cervix to a support structure. These techniques are not widely used, since they have not been well evaluated and most surgeons have not been trained to perform them. &nbsp;",
"   </p>",
"   <p>",
"    Advantages of uterine sparing techniques are a shorter operative duration and less blood loss; however, their efficacy is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/21,22,26-29\">",
"     21,22,26-29",
"    </a>",
"    ]. Two randomized trials in women with stage II or higher POP that compared transvaginal sacrospinous hysteropexy with vaginal hysterectomy (with uterosacral or sacrospinous ligament suspension of the vaginal vault) yielded consistent results: the rate of prolapse recurrence after 9 to 12 months was higher in women who underwent hysteropexy in both trials, but reached statistical significance in one trial (27 versus 3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/28\">",
"     28",
"    </a>",
"    ]) and not the other (25 versus 13 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/27\">",
"     27",
"    </a>",
"    ]). Operative duration (59 versus 120 minutes in one trial [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/27\">",
"     27",
"    </a>",
"    ]) and blood loss (20 versus 120 mL in one trial [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/27\">",
"     27",
"    </a>",
"    ]) were decreased for sacrospinous hysteropexy compared with vaginal hysterectomy; complication rates were similar for the two groups. Further study is needed to evaluate the efficacy of uterine sparing techniques.",
"   </p>",
"   <p>",
"    A proposed advantage of uterine sparing surgery is a decreased impact on sexual function; however, this benefit is uncertain. The only study of this issue found no difference in effect on sexual function in women who underwent sacrospinous hysteropexy compared with vaginal hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/30\">",
"     30",
"    </a>",
"    ]. Also, studies of hysterectomy for POP and other indications have generally found no impact on sexual function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12602?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of hysterectomy\", section on 'Psychosexual issues'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Uterine-sparing techniques offer the potential for preserving fertility. There are few data, however, regarding the risk of intrapartum complication and postpartum recurrence of prolapse following these procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/22,31\">",
"     22,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While uterine sparing techniques offer benefits of decreased operative duration and blood loss, their efficacy remains unproven. Given the current data, for women undergoing apical prolapse repair, we suggest performing concomitant hysterectomy rather than uterine preservation. A uterine sparing procedure performed by a surgeon familiar with the necessary techniques is a reasonable alternative for women who strongly prefer to preserve their uterus and are aware of the potential risk of recurrent prolapse and the uncertainty regarding obstetric outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2327483\">",
"    <span class=\"h1\">",
"     CONCOMITANT REPAIR OF APICAL AND ANTERIOR OR POSTERIOR PROLAPSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reconstructive surgery for POP often involves repair of multiple anatomic sites of prolapse (apical, anterior,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    posterior). Repair of each prolapse site and how to best perform a combined reconstruction must be considered when choosing an overall surgical approach. The common teaching is that all procedures should be performed using one route (vaginal or abdominal), since it is generally preferred to avoid both abdominal and vaginal incisions. In some instances, however, surgeons may combine the two surgical approaches.",
"   </p>",
"   <p>",
"    Choice of surgical route is mainly of concern in women who require repair of apical prolapse, since isolated repair of anterior or posterior vaginal wall prolapse is typically performed transvaginally (posterior prolapse can also be repaired endoanally). Repair of apical prolapse abdominally with sacral colpopexy results in a lower rate of recurrence, while transvaginal repair (eg, sacrospinous ligament fixation, uterosacral ligament fixation) has a shorter recovery and less morbidity. The choice of surgical technique for specific anatomic sites of prolapse is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44424?source=see_link&amp;anchor=H7#H7\">",
"     \"Surgical management of posterior vaginal defects\", section on 'Surgical approaches'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35914?source=see_link&amp;anchor=H21188326#H21188326\">",
"     \"Pelvic organ prolapse in women: Surgical repair of apical prolapse (uterine or vaginal vault prolapse)\", section on 'Vaginal versus abdominal approach'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7306?source=see_link\">",
"     \"Pelvic organ prolapse in women: Surgical repair of anterior vaginal wall prolapse\"",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Patients with apical prolapse have a high rate of anterior prolapse and a lower rate of posterior prolapse [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/32\">",
"     32",
"    </a>",
"    ]. It is controversial whether repair of apical prolapse is sufficient to support the anterior and posterior vaginal walls or if additional procedures are required to address anterior",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    posterior prolapse. If the vaginal muscularis is well suspended at the apex, many anterior defects (55 percent in one study) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/33\">",
"     33",
"    </a>",
"    ] and some posterior defects will resolve. On the other hand, correction of anterior or posterior prolapse does",
"    <strong>",
"     not",
"    </strong>",
"    repair apical descent. The approach to concomitant repair of multiple sites of prolapse varies by surgical route and by site of prolapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H680302\">",
"    <span class=\"h2\">",
"     Abdominal route",
"    </span>",
"    &nbsp;&mdash;&nbsp;The abdominal route has been used for the repair of both anterior and posterior prolapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42450377\">",
"    <span class=\"h3\">",
"     Anterior prolapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among women undergoing sacral colpopexy who also have symptomatic anterior prolapse, anterior vaginal wall support can be achieved transabdominally either by sacral colpopexy alone or by a combined procedure with paravaginal repair. Data are limited on the efficacy and comparative efficacy of these procedures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review of 62 studies of sacral colpopexy found few data regarding the efficacy of sacral colpopexy alone for anterior prolapse [",
"      <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A literature review of five observational studies reported that combined sacral colpopexy and paravaginal repair successfully treated anterior prolapse in 76 to 97 percent of women [",
"      <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The only comparative study was a retrospective cohort study of 170 women in which a conclusion could not be reached since only six patients required reoperation for anterior prolapse recurrence [",
"      <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unfortunately, inter- and intra-examiner reliability of the clinical examination for central, superior, and right and left paravaginal defects is poor [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/37\">",
"     37",
"    </a>",
"    ]. Since it is difficult for examiners to agree on whether a paravaginal defect is present, in our practice, we do not routinely perform paravaginal defect repairs for anterior wall support and feel that a good apical suspension obviates the need for a separate repair of the anterior wall. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/46/8937?source=see_link&amp;anchor=H7#H7\">",
"     \"Pelvic organ prolapse in women: Diagnostic evaluation\", section on 'Inspection for paravaginal defects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42450384\">",
"    <span class=\"h3\">",
"     Posterior prolapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repair of posterior vaginal wall prolapse at the time of abdominal surgery can be performed in one of three ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Modifying the sacral colpopexy to extend the posterior mesh down the rectovaginal septum. Some data suggest that extending the mesh to the perineal body using a combined abdominal and vaginal approach (sometimes referred to as sacrocolpoperineopexy) increases the risk of mesh erosion [",
"      <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Posterior colporrhaphy, which is a vaginal procedure. &nbsp;",
"     </li>",
"     <li>",
"      Endoanal or endorectal posterior repair; however, the transvaginal approach appears to be superior to these approaches. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44424?source=see_link&amp;anchor=H21#H21\">",
"       \"Surgical management of posterior vaginal defects\", section on 'Vaginal versus transanal approach'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the Colpopexy and Urinary Reduction Efforts (CARE) trial, which evaluated the role of Burch colposuspension in women undergoing sacral colpopexy, 87 of 298 women (29 percent) underwent posterior vaginal wall repair in which colporrhaphy, perineorrhaphy, or sacrocolpoperineopexy was used according to surgeon discretion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/39\">",
"     39",
"    </a>",
"    ]. Women who did or did not undergo posterior repair had a similar rate of improvement in bowel symptoms, including obstructive symptoms (constipation, incomplete emptying and of pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    irritation with defecation); posterior anatomic outcomes were also similar for the two groups.",
"   </p>",
"   <p>",
"    Observational studies of sacral colpopexy with posterior mesh extension, but without posterior colporrhaphy, have had widely variable results. In two prospective studies, the rate of recurrence of posterior prolapse varied from 8 percent at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/40\">",
"     40",
"    </a>",
"    ] to 57 percent at two years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decision to perform a posterior colporrhaphy is dependent upon whether the patient has patient&rsquo;s posterior prolapse-related",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    defecatory symptoms and the degree of prolapse of the posterior wall. In our practice, in patients with posterior wall prolapse, we extend the mesh down the posterior vaginal wall to the lower half of the vagina. When symptoms are bothersome",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the prolapse of the posterior wall extends to or beyond the hymen, we generally perform a posterior colporrhaphy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H680377\">",
"    <span class=\"h2\">",
"     Vaginal route",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women undergoing a transvaginal apical suspension, the optimal management of separately addressing anterior and posterior wall prolapse is unclear. Many surgeons perform a simultaneous anterior or posterior colporrhaphy, while others think that an effective vaginal apical suspension obviates for a separate anterior or posterior procedure.",
"   </p>",
"   <p>",
"    High rates of anterior wall prolapse have been reported for sacrospinous ligament suspension or uterosacral ligament suspension in combination with anterior colporrhaphy (29 percent), and even higher for anterior colporrhaphy alone (30 to 40 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/42\">",
"     42",
"    </a>",
"    ]. However, most of these studies used a definition of failure defined as recurrence of stage II or higher; new evidence suggests that this definition is too strict and has been based on expert opinion only and not data. Current evidence supports a definition of success as a patient&rsquo;s perception of bother, which typically corresponds to prolapse beyond the hymen [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/43\">",
"     43",
"    </a>",
"    ]. Using this definition, most studies investigating the efficacy of anterior colporrhaphy show high success rates and low reoperation rates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35914?source=see_link&amp;anchor=H8286313#H8286313\">",
"     \"Pelvic organ prolapse in women: Surgical repair of apical prolapse (uterine or vaginal vault prolapse)\", section on 'Outcome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35914?source=see_link&amp;anchor=H8286377#H8286377\">",
"     \"Pelvic organ prolapse in women: Surgical repair of apical prolapse (uterine or vaginal vault prolapse)\", section on 'Outcome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7306?source=see_link\">",
"     \"Pelvic organ prolapse in women: Surgical repair of anterior vaginal wall prolapse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In our practice, when apical prolapse, as well as stage II anterior or posterior vaginal wall prolapse, are present during the preoperative examination, we perform an anterior or posterior colporrhaphy in addition to a transvaginal apical suspension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H679419\">",
"    <span class=\"h1\">",
"     CONCOMITANT INCONTINENCE SURGERY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H685054\">",
"    <span class=\"h2\">",
"     Urinary incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic POP often coexists with SUI. Women with symptoms of both POP and SUI are treated with a combined prolapse repair and continence procedure.",
"   </p>",
"   <p>",
"    Another important patient population consists of women with stage II or higher apical prolapse who remain continent despite loss of anterior vaginal and",
"    <span class=\"nowrap\">",
"     bladder/urethral",
"    </span>",
"    support. Unfortunately, 13 to 65 percent of continent women develop symptoms of SUI after surgical correction of prolapse. This likely occurs because the prolapse kinks and obstructs the urethra; this obstruction is alleviated when the prolapse is repaired. This is referred to as \"occult\" or \"potential\" stress incontinence.",
"   </p>",
"   <p>",
"    All women with apical prolapse should have a preoperative evaluation for occult SUI with clinical or urodynamic urinary stress testing with and without reduction of prolapse. However, preoperative prolapse reduction testing does not accurately predict postoperative stress incontinence (approximately 40 percent of women with negative testing will develop postoperative stress incontinence).",
"   </p>",
"   <p>",
"    For women with stage II or greater POP who are undergoing abdominal sacrocolpopexy, regardless of the results of preoperative testing for occult SUI, high quality data support a concomitant Burch colposuspension rather than sacrocolpopexy alone. Similarly, for women with stage II or greater POP who are undergoing vaginal vault suspension, regardless of the results of preoperative testing for occult SUI, a concomitant midurethral sling rather than vaginal vault suspension alone significantly decreases the risk of postoperative SUI, but is accompanied by an increase in postoperative complications [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/44\">",
"     44",
"    </a>",
"    ]. Concomitant surgery for POP and SUI is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1546?source=see_link&amp;anchor=H15#H15\">",
"     \"Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment\", section on 'POP with no symptoms of SUI'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H685101\">",
"    <span class=\"h2\">",
"     Anal incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repair of POP may improve symptoms in women who have bothersome symptoms of both POP and anal incontinence. When POP is the patient's primary complaint, some surgeons choose to repair POP prior to recommending surgery for anal incontinence.",
"   </p>",
"   <p>",
"    Data are mixed regarding the impact of POP repair, specifically rectocele repair, on anal incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. A prospective study of 101 women undergoing rectocele repair reported that 63 percent who had anal incontinence preoperatively reported resolution or improvement in these symptoms at one year after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/45\">",
"     45",
"    </a>",
"    ]. In contrast, in a retrospective series of 231 women who underwent posterior colporrhaphy, the prevalence of fecal incontinence increased postoperatively from 4 to 11 percent, and 19 percent of patients developed incontinence of flatus [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9337/abstract/46\">",
"     46",
"    </a>",
"    ]. Further study is needed to evaluate this issue.",
"   </p>",
"   <p>",
"    Anal incontinence is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22458?source=see_link\">",
"     \"Fecal incontinence in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2328056\">",
"    <span class=\"h1\">",
"     MESH AUGMENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical mesh use is standard in abdominal sacral colpopexy. The use of surgical mesh for transvaginal POP repair has been introduced with the goal of reducing the risk of recurrent prolapse, but this approach is controversial. At present, potentially higher success rates resulting from the use of some mesh products for the anterior, and possibly the apex, of the vagina are accompanied by a higher complication rate than traditional vaginal surgery.",
"   </p>",
"   <p>",
"    Use of surgical mesh in pelvic reconstructive surgery is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/62/26602?source=see_link\">",
"     \"Overview of transvaginal placement of reconstructive materials (surgical mesh or biografts) for treatment of pelvic organ prolapse or stress urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/62/44001?source=see_link\">",
"       \"Patient information: Pelvic organ prolapse (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2328294\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical candidates for pelvic organ prolapse (POP) repair are women with symptomatic prolapse who decline or fail conservative therapy (eg, vaginal pessaries). (See",
"      <a class=\"local\" href=\"#H2327205\">",
"       'Candidates for surgical treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no indication for repair of asymptomatic POP as an isolated procedure. We also suggest NOT performing prolapse repair for most asymptomatic women who are undergoing other pelvic floor procedures (eg, stress urinary incontinence [SUI] surgery) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Prolapse repair at the time of other pelvic surgery is a reasonable option in women with risk factors for developing prolapse progression (eg, concomitant hysterectomy, premenopausal status, obesity). &nbsp;",
"     </li>",
"     <li>",
"      Women who are elderly, unable to tolerate extensive surgery, and do not plan future vaginal intercourse are candidates for obliterative POP surgery. (See",
"      <a class=\"local\" href=\"#H2327263\">",
"       'Reconstructive versus obliterative procedures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women undergoing apical prolapse repair, we suggest performing concomitant hysterectomy rather than uterine preservation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). A uterine sparing procedure performed by a surgeon familiar with the necessary techniques is a reasonable alternative for women who strongly prefer to preserve their uterus and are aware of the potential risk of recurrent prolapse and the uncertainty regarding obstetric outcomes. (See",
"      <a class=\"local\" href=\"#H2327312\">",
"       'Concomitant hysterectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who are undergoing an",
"      <strong>",
"       abdominal",
"      </strong>",
"      apical suspension procedure who require repair of anterior",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      posterior vaginal wall prolapse (see",
"      <a class=\"local\" href=\"#H680302\">",
"       'Abdominal route'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For women with anterior vaginal wall prolapse, we suggest apical suspension alone rather than combined with abdominal paravaginal repair (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For most women with posterior vaginal wall prolapse, we suggest extending the vaginal mesh from the apical suspension down the posterior vaginal wall to the lower half of the vagina (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). When symptoms are bothersome",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the prolapse of the posterior wall extends to or beyond the hymen, we suggest performing a posterior colporrhaphy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women who are undergoing a",
"      <strong>",
"       transvaginal",
"      </strong>",
"      apical suspension procedure who require repair of anterior",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      posterior vaginal wall prolapse, we suggest concomitant anterior",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      posterior colporrhaphy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H680377\">",
"       'Vaginal route'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      POP often coexists with SUI. Some women with advanced POP remain continent despite loss of anterior vaginal and",
"      <span class=\"nowrap\">",
"       bladder/urethral",
"      </span>",
"      support. These women may develop symptoms of SUI after surgical correction of the prolapse. (See",
"      <a class=\"local\" href=\"#H685054\">",
"       'Urinary incontinence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All women planning repair of apical prolapse should have a preoperative evaluation for SUI with clinical or urodynamic urinary stress testing with and without reduction of prolapse. However, preoperative prolapse reduction testing does not accurately predict postoperative stress incontinence (approximately 40 percent of women with negative testing will develop postoperative SUI). This testing may impact surgical decision making, particularly for women undergoing transvaginal apical prolapse repair. (See",
"      <a class=\"local\" href=\"#H685054\">",
"       'Urinary incontinence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with symptomatic apical POP and no SUI symptoms may have occult SUI and may benefit from a prophylactic continence procedure at the time of POP repair. (See",
"      <a class=\"local\" href=\"#H685054\">",
"       'Urinary incontinence'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1546?source=see_link&amp;anchor=H15#H15\">",
"       \"Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment\", section on 'POP with no symptoms of SUI'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Use of surgical mesh for transvaginal POP repair has potentially higher anatomic success rates than repair without mesh, but also appears to result in similar subjective success rates and a higher complication rate than traditional vaginal surgery. (See",
"      <a class=\"local\" href=\"#H2328056\">",
"       'Mesh augmentation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/1\">",
"      Jones KA, Shepherd JP, Oliphant SS, et al. Trends in inpatient prolapse procedures in the United States, 1979-2006. Am J Obstet Gynecol 2010; 202:501.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/2\">",
"      Boyles SH, Weber AM, Meyn L. Procedures for pelvic organ prolapse in the United States, 1979-1997. Am J Obstet Gynecol 2003; 188:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/3\">",
"      Olsen AL, Smith VJ, Bergstrom JO, et al. Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence. Obstet Gynecol 1997; 89:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/4\">",
"      Asante A, Whiteman MK, Kulkarni A, et al. Elective oophorectomy in the United States: trends and in-hospital complications, 1998-2006. Obstet Gynecol 2010; 116:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/5\">",
"      Ellerkmann RM, Cundiff GW, Melick CF, et al. Correlation of symptoms with location and severity of pelvic organ prolapse. Am J Obstet Gynecol 2001; 185:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/6\">",
"      Gutman RE, Ford DE, Quiroz LH, et al. Is there a pelvic organ prolapse threshold that predicts pelvic floor symptoms? Am J Obstet Gynecol 2008; 199:683.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/7\">",
"      Swift S, Woodman P, O'Boyle A, et al. Pelvic Organ Support Study (POSST): the distribution, clinical definition, and epidemiologic condition of pelvic organ support defects. Am J Obstet Gynecol 2005; 192:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/8\">",
"      Mouritsen L, Larsen JP. Symptoms, bother and POPQ in women referred with pelvic organ prolapse. Int Urogynecol J Pelvic Floor Dysfunct 2003; 14:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/9\">",
"      Bradley CS, Zimmerman MB, Qi Y, Nygaard IE. Natural history of pelvic organ prolapse in postmenopausal women. Obstet Gynecol 2007; 109:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/10\">",
"      Handa VL, Garrett E, Hendrix S, et al. Progression and remission of pelvic organ prolapse: a longitudinal study of menopausal women. Am J Obstet Gynecol 2004; 190:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/11\">",
"      Dietz HP. Prolapse worsens with age, doesn't it? Aust N Z J Obstet Gynaecol 2008; 48:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/12\">",
"      Kudish BI, Iglesia CB, Sokol RJ, et al. Effect of weight change on natural history of pelvic organ prolapse. Obstet Gynecol 2009; 113:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/13\">",
"      D&auml;llenbach P, Kaelin-Gambirasio I, Dubuisson JB, Boulvain M. Risk factors for pelvic organ prolapse repair after hysterectomy. Obstet Gynecol 2007; 110:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/14\">",
"      Diez-Itza I, Aizpitarte I, Becerro A. Risk factors for the recurrence of pelvic organ prolapse after vaginal surgery: a review at 5 years after surgery. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/15\">",
"      Nieminen K, Huhtala H, Heinonen PK. Anatomic and functional assessment and risk factors of recurrent prolapse after vaginal sacrospinous fixation. Acta Obstet Gynecol Scand 2003; 82:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/16\">",
"      Whiteside JL, Weber AM, Meyn LA, Walters MD. Risk factors for prolapse recurrence after vaginal repair. Am J Obstet Gynecol 2004; 191:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/17\">",
"      Stepp KJ, Barber MD, Yoo EH, et al. Incidence of perioperative complications of urogynecologic surgery in elderly women. Am J Obstet Gynecol 2005; 192:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/18\">",
"      Bradley CS, Kenton KS, Richter HE, et al. Obesity and outcomes after sacrocolpopexy. Am J Obstet Gynecol 2008; 199:690.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/19\">",
"      Diwadkar GB, Barber MD, Feiner B, et al. Complication and reoperation rates after apical vaginal prolapse surgical repair: a systematic review. Obstet Gynecol 2009; 113:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/20\">",
"      Denehy TR, Choe JY, Gregori CA, Breen JL. Modified Le Fort partial colpocleisis with Kelly urethral plication and posterior colpoperineoplasty in the medically compromised elderly: a comparison with vaginal hysterectomy, anterior colporrhaphy, and posterior colpoperineoplasty. Am J Obstet Gynecol 1995; 173:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/21\">",
"      Hefni M, El-Toukhy T, Bhaumik J, Katsimanis E. Sacrospinous cervicocolpopexy with uterine conservation for uterovaginal prolapse in elderly women: an evolving concept. Am J Obstet Gynecol 2003; 188:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/22\">",
"      Maher CF, Cary MP, Slack MC, et al. Uterine preservation or hysterectomy at sacrospinous colpopexy for uterovaginal prolapse? Int Urogynecol J Pelvic Floor Dysfunct 2001; 12:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/23\">",
"      van Brummen HJ, van de Pol G, Aalders CI, et al. Sacrospinous hysteropexy compared to vaginal hysterectomy as primary surgical treatment for a descensus uteri: effects on urinary symptoms. Int Urogynecol J Pelvic Floor Dysfunct 2003; 14:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/24\">",
"      Frick AC, Walters MD, Larkin KS, Barber MD. Risk of unanticipated abnormal gynecologic pathology at the time of hysterectomy for uterovaginal prolapse. Am J Obstet Gynecol 2010; 202:507.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/25\">",
"      Nesbitt RE Jr. Uterine preservation in the surgical management of genuine stress urinary incontinence associated with uterovaginal prolapse. Surg Gynecol Obstet 1989; 168:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/26\">",
"      Diwan A, Rardin CR, Kohli N. Uterine preservation during surgery for uterovaginal prolapse: a review. Int Urogynecol J Pelvic Floor Dysfunct 2004; 15:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/27\">",
"      Carram&atilde;o S, Auge AP, Pacetta AM, et al. [A randomized comparison of two vaginal procedures for the treatment of uterine prolapse using polypropylene mesh: hysteropexy versus hysterectomy]. Rev Col Bras Cir 2009; 36:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/28\">",
"      Dietz V, van der Vaart CH, van der Graaf Y, et al. One-year follow-up after sacrospinous hysteropexy and vaginal hysterectomy for uterine descent: a randomized study. Int Urogynecol J 2010; 21:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/29\">",
"      Roovers JP, van der Vaart CH, van der Bom JG, et al. A randomised controlled trial comparing abdominal and vaginal prolapse surgery: effects on urogenital function. BJOG 2004; 111:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/30\">",
"      Jeng CJ, Yang YC, Tzeng CR, et al. Sexual functioning after vaginal hysterectomy or transvaginal sacrospinous uterine suspension for uterine prolapse: a comparison. J Reprod Med 2005; 50:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/31\">",
"      Kovac SR, Cruikshank SH. Successful pregnancies and vaginal deliveries after sacrospinous uterosacral fixation in five of nineteen patients. Am J Obstet Gynecol 1993; 168:1778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/32\">",
"      Rooney K, Kenton K, Mueller ER, et al. Advanced anterior vaginal wall prolapse is highly correlated with apical prolapse. Am J Obstet Gynecol 2006; 195:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/33\">",
"      Lowder JL, Park AJ, Ellison R, et al. The role of apical vaginal support in the appearance of anterior and posterior vaginal prolapse. Obstet Gynecol 2008; 111:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/34\">",
"      Nygaard IE, McCreery R, Brubaker L, et al. Abdominal sacrocolpopexy: a comprehensive review. Obstet Gynecol 2004; 104:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/35\">",
"      Maher C, Baessler K. Surgical management of anterior vaginal wall prolapse: an evidencebased literature review. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/36\">",
"      Shippey SH, Quiroz LH, Sanses TV, et al. Anatomic outcomes of abdominal sacrocolpopexy with or without paravaginal repair. Int Urogynecol J 2010; 21:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/37\">",
"      Whiteside JL, Barber MD, Paraiso MF, et al. Clinical evaluation of anterior vaginal wall support defects: interexaminer and intraexaminer reliability. Am J Obstet Gynecol 2004; 191:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/38\">",
"      Visco AG, Weidner AC, Barber MD, et al. Vaginal mesh erosion after abdominal sacral colpopexy. Am J Obstet Gynecol 2001; 184:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/39\">",
"      Bradley CS, Nygaard IE, Brown MB, et al. Bowel symptoms in women 1 year after sacrocolpopexy. Am J Obstet Gynecol 2007; 197:642.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/40\">",
"      Guiahi M, Kenton K, Brubaker L. Sacrocolpopexy without concomitant posterior repair improves posterior compartment defects. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/41\">",
"      Baessler K, Schuessler B. Abdominal sacrocolpopexy and anatomy and function of the posterior compartment. Obstet Gynecol 2001; 97:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/42\">",
"      Weber AM, Walters MD, Piedmonte MR, Ballard LA. Anterior colporrhaphy: a randomized trial of three surgical techniques. Am J Obstet Gynecol 2001; 185:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/43\">",
"      Barber MD, Brubaker L, Nygaard I, et al. Defining success after surgery for pelvic organ prolapse. Obstet Gynecol 2009; 114:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/44\">",
"      Wei JT, Nygaard I, Richter HE, et al. A midurethral sling to reduce incontinence after vaginal prolapse repair. N Engl J Med 2012; 366:2358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/45\">",
"      Gustilo-Ashby AM, Paraiso MF, Jelovsek JE, et al. Bowel symptoms 1 year after surgery for prolapse: further analysis of a randomized trial of rectocele repair. Am J Obstet Gynecol 2007; 197:76.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/46\">",
"      Kahn MA, Stanton SL. Posterior colporrhaphy: its effects on bowel and sexual function. Br J Obstet Gynaecol 1997; 104:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/47\">",
"      Hefni M, El-Toukhy T, Bhaumik J. Vaginal sacrospinous colpopexy and perineorrhaphy for faecal incontinence: preliminary report. Eur J Obstet Gynecol Reprod Biol 2003; 110:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9337/abstract/48\">",
"      Heriot AG, Skull A, Kumar D. Functional and physiological outcome following transanal repair of rectocele. Br J Surg 2004; 91:1340.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14212 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-B1A854215F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_7_9337=[""].join("\n");
var outline_f9_7_9337=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2328294\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2327162\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2327205\">",
"      CANDIDATES FOR SURGICAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10284328\">",
"      Women with symptomatic prolapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10284335\">",
"      Women who decline or fail conservative therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10284349\">",
"      Women finished with childbearing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3439983\">",
"      Young or elderly women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10284356\">",
"      Obese women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2327248\">",
"      GENERAL APPROACH TO CHOICE OF PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2327263\">",
"      RECONSTRUCTIVE VERSUS OBLITERATIVE PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2327312\">",
"      CONCOMITANT HYSTERECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2327483\">",
"      CONCOMITANT REPAIR OF APICAL AND ANTERIOR OR POSTERIOR PROLAPSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H680302\">",
"      Abdominal route",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42450377\">",
"      - Anterior prolapse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42450384\">",
"      - Posterior prolapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H680377\">",
"      Vaginal route",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H679419\">",
"      CONCOMITANT INCONTINENCE SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H685054\">",
"      Urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H685101\">",
"      Anal incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2328056\">",
"      MESH AUGMENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2328294\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/14212\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/14212|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?15/46/16111\" title=\"algorithm 1\">",
"      Choosing a primary procedure for pelvic organ prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/14212|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/56/28556\" title=\"table 1\">",
"      POP recurrence risk",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40473?source=related_link\">",
"      An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22458?source=related_link\">",
"      Fecal incontinence in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12602?source=related_link\">",
"      Overview of hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/62/26602?source=related_link\">",
"      Overview of transvaginal placement of reconstructive materials (surgical mesh or biografts) for treatment of pelvic organ prolapse or stress urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/62/44001?source=related_link\">",
"      Patient information: Pelvic organ prolapse (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1546?source=related_link\">",
"      Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/46/8937?source=related_link\">",
"      Pelvic organ prolapse in women: Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43607?source=related_link\">",
"      Pelvic organ prolapse in women: Obliterative procedures (colpocleisis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7306?source=related_link\">",
"      Pelvic organ prolapse in women: Surgical repair of anterior vaginal wall prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35914?source=related_link\">",
"      Pelvic organ prolapse in women: Surgical repair of apical prolapse (uterine or vaginal vault prolapse)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44424?source=related_link\">",
"      Surgical management of posterior vaginal defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17530?source=related_link\">",
"      Vaginal pessary treatment of prolapse and incontinence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_7_9338="Pharmacology of echinocandins";
var content_f9_7_9338=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacology of echinocandins",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/7/9338/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/7/9338/contributors\">",
"     Russell E Lewis, PharmD, FCCP, BCPS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/7/9338/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/7/9338/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/7/9338/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/7/9338/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/7/9338/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1239292403\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of echinocandins, the first class of antifungals to target the fungal cell wall, was a milestone achievement in antifungal chemotherapy. Echinocandins were discovered as fermentation metabolites with antifungal activity during screening programs for new antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/1\">",
"     1",
"    </a>",
"    ]. The candidate molecules were subsequently modified to improve solubility, antifungal spectrum of activity, and pharmacokinetic characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/2\">",
"     2",
"    </a>",
"    ]. Three semi-synthetic echinocandin derivatives have been developed for clinical use:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    All three echinocandins are structurally similar cyclic hexapeptide antibiotics with modified N-linked acyl lipid side chains (",
"    <a class=\"graphic graphic_figure graphicRef70049 \" href=\"UTD.htm?24/59/25524\">",
"     figure 1",
"    </a>",
"    ), which play a role in anchoring the hexapeptide nucleus to the fungal cell membrane where the drug interacts with the target enzyme complex involved in cell wall synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/3\">",
"     3",
"    </a>",
"    ]. Like other large lipopeptide antibiotics, these drugs have limited oral bioavailability and must be administered by intravenous infusion. Experience with this antifungal class suggests this it is among the best tolerated and safest class of antifungals available.",
"   </p>",
"   <p>",
"    The pharmacology of echinocandin antifungals will be reviewed here. Indications for the clinical use of echinocandins, antifungal susceptibility testing, and the pharmacology of other systemic antifungal agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , the azoles, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    , are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=see_link\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link\">",
"     \"Treatment and prevention of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/21/29018?source=see_link\">",
"     \"Antifungal susceptibility testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=see_link\">",
"     \"Pharmacology of amphotericin B\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link\">",
"     \"Pharmacology of azoles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43190?source=see_link\">",
"     \"Pharmacology of flucytosine (5-FC)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239292410\">",
"    <span class=\"h1\">",
"     OVERVIEW OF CLINICAL USES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echinocandins are widely used for the treatment of invasive candidiasis, especially in critically ill and neutropenic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/4\">",
"     4",
"    </a>",
"    ], and less commonly in salvage regimens for invasive aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/5\">",
"     5",
"    </a>",
"    ]. They are also used for empiric antifungal therapy in patients with neutropenic fever. The major advantages of echinocandins relative to other antifungal agents are their fungicidal activity against Candida spp, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    -resistant C. glabrata and C. krusei, combined with their relatively low potential for renal or hepatic toxicity or serious drug-drug interactions. Specific recommendations regarding the use of these agents are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=see_link\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link\">",
"     \"Treatment and prevention of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link&amp;anchor=H154974350#H154974350\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\", section on 'Addition of an antifungal agent'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All three echinocandins have been approved by the United States Food and Drug Administration (FDA) for the treatment of esophageal candidiasis and invasive candidiasis in adults, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    has been approved for these indications in children over three months of age. Caspofungin has also been FDA-approved as an empiric antifungal agent for febrile neutropenia and for salvage therapy of invasive aspergillosis in patients who have failed or are intolerant of other antifungal agents in adults and children over three months of age.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     Micafungin",
"    </a>",
"    has also been FDA-approved as a prophylactic agent for the prevention of Candida infections in adults undergoing hematopoietic cell transplantation.",
"   </p>",
"   <p>",
"    Because all three echinocandins share a similar spectrum of activity and mechanism of action, most experts consider these drugs to be interchangeable, particularly for the treatment of invasive candidiasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\", section on 'Echinocandins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the three echinocandins differ in terms of their dosing, pathways of metabolic elimination, and drug interaction profile. Therefore, these unique characteristics should be considered when selecting an echinocandin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239299741\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of action of the echinocandins exploits a biochemical pathway unique to fungi, which is different from the mechanisms of other antifungal drugs. Echinocandins target fungal cell glucan synthesis by competitively inhibiting the beta-1,3-D-glucan synthase enzyme complex in susceptible fungi (",
"    <a class=\"graphic graphic_figure graphicRef67408 \" href=\"UTD.htm?36/25/37269\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/6\">",
"     6",
"    </a>",
"    ]. This enzyme complex is composed of at least two components: catalytic subunits called Fks1p and Fks2p, and a GTP-binding protein, Rho1, which regulate the activity of glucan synthesis. Beta-glucans, when cross-linked to chitin and mannoproteins, provide structural integrity to cell walls of various pathogenic fungi and molds including Candida spp, Aspergillus spp, and Pneumocystis jirovecii. &nbsp;",
"   </p>",
"   <p>",
"    Beta-glucans account for approximately 30 to 60 percent of the cell wall mass in yeasts such as Candida species [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Beta-glucan depletion causes loss of resistance to osmotic forces and cell lysis among Candida spp, thereby having a fungicidal effect. In filamentous fungi, such as Aspergillus fumigatus, the bulk of beta-glucan synthesis is concentrated at the apical tips and branching points of hyphae [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Among filamentous fungi, echinocandin-induced beta-glucan depletion causes impeded growth at the tips and branching points of hyphae, resulting in dysmorphic hyphae; this growth inhibition has a fungistatic effect [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/12\">",
"     12",
"    </a>",
"    ].",
"    <strong>",
"     &nbsp;",
"    </strong>",
"   </p>",
"   <p>",
"    Beta-glucans and the intracellular beta-glucan synthase complex blocked by echinocandins are not present in human cells. For this reason, the echinocandins cause less toxicity than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    formulations or the triazoles, and are implicated in fewer drug-drug interactions. In addition, the mechanism of action of the echinocandins appears to complement the antifungal effects of the other antifungal drug classes, offering the potential for combination therapy.",
"    <strong>",
"    </strong>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment and prevention of invasive aspergillosis\", section on 'Combination therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Echinocandins",
"    <strong>",
"    </strong>",
"    may also amplify host immune responses by unmasking beta-glucan epitopes, which are highly antigenic, thereby",
"    <strong>",
"    </strong>",
"    accelerating host cellular recognition and inflammatory responses",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/13-17\">",
"     13-17",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    However, the evidence supporting such immunomodulatory effects is limited to in vitro studies and murine models.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239292431\">",
"    <span class=\"h1\">",
"     MICROBIOLOGIC ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the widespread distribution of beta-glucans in the fungal cell wall and the high degree of homology of FKS genes among diverse fungal genera, echinocandins would be predicted to exhibit activity against a wide spectrum of fungal pathogens. However, the echinocandins are primarily effective against Candida and Aspergillus species, with relatively weak activity against other molds and yeasts, including Cryptococcus neoformans [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/3\">",
"     3",
"    </a>",
"    ]. Differences in fungal cell wall construction may influence echinocandin penetration or render some fungal species less susceptible to the effects of beta-glucan synthesis inhibition [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239292438\">",
"    <span class=\"h2\">",
"     Candida species",
"    </span>",
"    &nbsp;&mdash;&nbsp;All three of the echinocandins exhibit excellent potency against Candida spp (",
"    <a class=\"graphic graphic_table graphicRef61023 \" href=\"UTD.htm?37/33/38428\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/18\">",
"     18",
"    </a>",
"    ]. C. albicans, C. glabrata, and C. tropicalis are highly susceptible to all three agents, whereas elevated MICs have been seen for C. parapsilosis and C. guilliermondii &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef82770 \" href=\"UTD.htm?16/47/17150\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Acquired resistance to the echinocandins remains sporadic [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/20,21\">",
"     20,21",
"    </a>",
"    ], but has been documented for individual cases of infection with C. albicans, C. glabrata, C. lusitaniae, C. tropicalis, and C. parapsilosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/21-27\">",
"     21-27",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Of note, there is increasing concern that some C. glabrata bloodstream isolates with resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    are also resistant to the echinocandins. In a surveillance study of the in vitro susceptibility of 1669 C. glabrata bloodstream isolates collected in the United States between 2006 and 2010, 162 isolates (9.7 percent) were resistant to fluconazole, of which 98.8 percent were also not susceptible to voriconazole (MIC &gt;0.5",
"    <span class=\"nowrap\">",
"     mcg/mL),",
"    </span>",
"    and 9.3, 9.3, and 8.0 percent were resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    , respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/19\">",
"     19",
"    </a>",
"    ]. Of the 162 isolates that were resistant to fluconazole, 18 (11.1 percent) were resistant to one or more of the echinocandins; all of these isolates contained an FKS1 or FKS2 mutation. In comparison, there were no echinocandin-resistant strains detected among 110 fluconazole-resistant C. glabrata isolates tested between 2001 and 2004, years in which only one echinocandin, caspofungin, was available and echinocandins were used sparingly. These findings argue for continued surveillance for resistance using standardized antifungal susceptibility testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\", section on 'Susceptibility patterns'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/21/29018?source=see_link&amp;anchor=H28#H28\">",
"     \"Antifungal susceptibility testing\", section on 'Echinocandins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239292445\">",
"    <span class=\"h3\">",
"     Candida biofilms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echinocandins are unique among the systemic antifungal agents in their activity against biofilm-embedded Candida species. Under sessile biofilm-like conditions, the MICs for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    may increase by 10- to 1000-fold [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Biofilm growth in C. albicans is associated with increased secretion of carbohydrates, including beta-1,3-D-glucan [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/30\">",
"     30",
"    </a>",
"    ], which has been shown to directly inhibit the activity of both fluconazole and amphotericin B [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. In contrast, echinocandin MICs are minimally affected when tested in biofilm versus non-biofilm conditions, and a biofilm-embedded inoculum of C. albicans can be reduced by &gt;99 percent at the echinocandin concentrations achieved in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These in vitro data suggest that echinocandins may be particularly useful antifungal agents for prosthetic device or catheter-associated infections, in which biofilm-embedded organisms can be associated with recurrent candidemia. However, this remains to be proven in clinical studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239292452\">",
"    <span class=\"h2\">",
"     Other yeasts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echinocandins lack clinically useful activity against Trichosporon spp, Cryptococcus neoformans, and Cryptococcus gattii, even though beta-1,3-D-glucan synthase from Cryptococcus spp is exquisitely sensitive to inhibition by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    and beta-1,3-D-glucan is present in the fungal cell wall [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/3\">",
"     3",
"    </a>",
"    ]. Compensatory cell wall mechanisms, melanin, and drug degradation pathways likely may contribute to the inherent resistance of this species to echinocandins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239292466\">",
"    <span class=\"h2\">",
"     Dimorphic fungi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echinocandins have only modest activity against the mycelial phase of the dimorphic fungi, Blastomyces dermatitidis, Histoplasma capsulatum, and Coccidioides spp. Echinocandins are not considered to be effective agents for therapy of dimorphic fungal infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239292473\">",
"    <span class=\"h2\">",
"     Aspergillus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth of Aspergillus species is inhibited at very low echinocandin concentrations in vitro, with the effects predominantly observed at apical and sub-apical branching points where cell wall remodeling and beta-glucan synthase are most active [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/10,34\">",
"     10,34",
"    </a>",
"    ]. As such, MIC endpoints for Aspergillus are determined differently for echinocandins than for other antifungals. The lowest echinocandin concentration resulting in grossly abnormal hyphal forms (small, compact highly-branched hyphae as compared to the normally elongated hyphal forms) are defined at the minimum effective concentration (MEC) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/12\">",
"     12",
"    </a>",
"    ]. MEC ranges for most Aspergillus species fall into what would be considered the susceptible range (",
"    <a class=\"graphic graphic_table graphicRef82768 \" href=\"UTD.htm?20/21/20828\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239292480\">",
"    <span class=\"h2\">",
"     Other molds",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echinocandins have only modest or weak activity against non-Aspergillus molds that is sometimes more apparent in vivo than in vitro, suggesting that their effects are partially mediated through unmasking of immunogenic epitopes on the fungal cell wall [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/35\">",
"     35",
"    </a>",
"    ]. Modest echinocandin activity has been reported in vitro for some phaeohyphomycetes, including Alternaria spp, Bipolaris spp, Cladophialophora bantiana, Phialophora spp, Exophiala spp, Fonsecaea pedrosi, Paecilomyces variotti, Acremonium strictum, and Scedosporium apiospermum [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/36-39\">",
"     36-39",
"    </a>",
"    ], but echinocandins are",
"    <strong>",
"     not",
"    </strong>",
"    used to treat infections due to these organisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12264177\">",
"    <span class=\"h2\">",
"     Pneumocystis jirovecii",
"    </span>",
"    &nbsp;&mdash;&nbsp;In experimental models of Pneumocystis jirovecii (formerly P. carinii) pneumonia (PCP), the echinocandins are effective agents for prophylaxis, but are less effective for established pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. The limited treatment efficacy of echinocandins can be explained by the fact that the glucan synthase target for echinocandin activity is expressed only during the cystic but not the trophic lifecycle of P. jirovecii [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Therefore, fungal clearance of established infection is relatively weak with echinocandins compared with established therapies such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/36,43\">",
"     36,43",
"    </a>",
"    ]. The echinocandins have no role for the treatment or prevention of PCP (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239292487\">",
"    <span class=\"h1\">",
"     RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although echinocandins are used extensively as a first-line treatment for invasive candidiasis and less commonly as part of salvage regimens for invasive aspergillosis, acquired echinocandin resistance has been relatively rare to date. (See",
"    <a class=\"local\" href=\"#H1239292438\">",
"     'Candida species'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Echinocandin resistance is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/21/29018?source=see_link&amp;anchor=H28#H28\">",
"     \"Antifungal susceptibility testing\", section on 'Echinocandins'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=see_link\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment and prevention of invasive aspergillosis\", section on 'Combination therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239292494\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the echinocandins share similar spectra of activity, each agent differs in its pathway of metabolism, resulting in distinguishable half-lives, drug interaction profiles, and dosing strategies (",
"    <a class=\"graphic graphic_table graphicRef56212 \" href=\"UTD.htm?5/2/5165\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/3,44\">",
"     3,44",
"    </a>",
"    ]. Due to their large molecular weights, echinocandins are minimally absorbed after oral administration and are available only in intravenous formulations. All three echinocandins exhibit a high degree of binding to plasma proteins and distribute minimally to cerebrospinal fluid, urine, and the eye. Echinocandins are not primarily metabolized by cytochrome P450, nor are they substrates or inhibitors of P-glycoprotein pumps, making them less likely targets of drug-drug interactions compared to other systemic antifungals.",
"    <strong>",
"    </strong>",
"    (See",
"    <a class=\"local\" href=\"#H1239298150\">",
"     'Dosing'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1239298206\">",
"     'Renal insufficiency'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1239299710\">",
"     'Hepatic insufficiency'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1239300816\">",
"     'Drug interactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22267050\">",
"    <span class=\"h2\">",
"     Caspofungin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     Caspofungin",
"    </a>",
"    <strong>",
"    </strong>",
"    exhibits triphasic non-linear pharmacokinetics [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/45\">",
"     45",
"    </a>",
"    ]. Following an initial intravenous infusion, tissue distribution accounts for an initial rapid fall in plasma levels, followed by gradual re-release of drug from extravascular tissues coupled with slow hepatic metabolism, yielding a net terminal half-life of 27 to 50 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/44,46-48\">",
"     44,46-48",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    A loading dose followed by a lower once daily dose is therefore required to attain an initial therapeutic plasma level and avoid drug accumulation. Caspofungin degrades spontaneously and is also metabolized via hydrolysis and N-acetylation to two inactive metabolites",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/45,47\">",
"     45,47",
"    </a>",
"    ]. It is non-dialyzable and less than 2 percent of active drug is excreted via the urinary tract.",
"   </p>",
"   <p>",
"    Dose adjustment is unnecessary for patients with renal insufficiency. However, dose reduction for severe hepatic insufficiency is recommended.",
"    <strong>",
"    </strong>",
"    (See",
"    <a class=\"local\" href=\"#H1239298150\">",
"     'Dosing'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1239301213\">",
"     'Caspofungin'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Several drugs have been shown to induce the metabolism of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    :",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    . An increased maintenance dose of caspofungin is therefore recommended when any of these agents are given concurrently with caspofungin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22267058\">",
"    <span class=\"h2\">",
"     Micafungin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     Micafungin",
"    </a>",
"    demonstrates linear elimination pharmacokinetics producing a terminal half-life of approximately 15 hours in adults",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/44,49\">",
"     44,49",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    It is metabolized hepatically by arylsulfatase, catechol O-methyltransferase, and hydroxylation. Less than 1 percent of unchanged drug is excreted in the urine. Like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    , it is non-dialyzable and dose adjustment for renal insufficiency is unnecessary. Elimination pharmacokinetics in advanced hepatic insufficiency are not well defined. Micafungin is subject to relatively few drug-drug interactions.",
"   </p>",
"   <p>",
"    Modest increases in exposure to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    have been described in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/50\">",
"     50",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    (See",
"    <a class=\"local\" href=\"#H1239298150\">",
"     'Dosing'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1239300837\">",
"     'Micafungin'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22267066\">",
"    <span class=\"h2\">",
"     Anidulafungin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     Anidulafungin",
"    </a>",
"    exhibits linear elimination pharmacokinetics that are predictable and relatively stable across a broad range of patient age, weight, gender, and disease states. Anidulafungin is not metabolized, but instead eliminated by slow spontaneous degradation, resulting in a terminal half-life of 40 to 50 hours",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/49\">",
"     49",
"    </a>",
"    ]. A loading dose is necessary to achieve rapid therapeutic concentrations. Less than one percent of unchanged drug is excreted in the urine. It is non-dialyzable and dose adjustment for renal or hepatic insufficiency is unnecessary. Few drug-drug interactions are expected.",
"    <strong>",
"    </strong>",
"    (See",
"    <a class=\"local\" href=\"#H1239298150\">",
"     'Dosing'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1239301205\">",
"     'Anidulafungin'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239298142\">",
"    <span class=\"h1\">",
"     PHARMACODYNAMICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The plasma drug concentration profile that optimizes the antifungal efficacy of echinocandins has been only partly elucidated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/51\">",
"     51",
"    </a>",
"    ]. Echinocandins appear to exhibit concentration-dependent killing against Candida spp based upon in vivo studies showing a fungicidal effect proportional to the maximum (peak) plasma drug concentration and a persistent antifungal effect after plasma drug concentration falls below MIC",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/51\">",
"     51",
"    </a>",
"    ]",
"    <strong>",
"     .",
"    </strong>",
"    Fungicidal efficacy against Candida spp also appears to correlate with the area under time-concentration curve to minimum inhibitory concentration (MIC) ratio (AUC:MIC)",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/47\">",
"     47",
"    </a>",
"    ]. The optimal pharmacodynamic parameters for killing or inhibiting Aspergillus spp, however, are not clearly defined",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Furthermore, therapeutic drug monitoring with standardized plasma drug concentration ranges or targets for echinocandins has not been established and revised dosing strategies evaluated in animal models have not identified promising dosing tools for further assessment in humans",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/47,51\">",
"     47,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239298150\">",
"    <span class=\"h1\">",
"     DOSING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18092677\">",
"    <span class=\"h2\">",
"     Adult dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dosing of echinocandins depends upon the indication. A brief overview of standard dosing approaches for echinocandins, including maintenance and loading doses, and needed dose adjustments, is provided here. Clinicians should consult individual topic reviews for each infection for more detailed information about the use of each drug. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=see_link\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link\">",
"     \"Treatment and prevention of invasive aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Esophageal candidiasis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"       Caspofungin",
"      </a>",
"      &mdash; 50 mg IV daily; no loading dose is required [",
"      <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/53\">",
"       53",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"       Micafungin",
"      </a>",
"      &mdash; 150 mg IV daily; no loading dose is required [",
"      <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/54\">",
"       54",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"       Anidulafungin",
"      </a>",
"      &mdash; 100 mg IV loading dose on day 1, followed by 50 mg IV daily thereafter [",
"      <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/55\">",
"       55",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Invasive candidiasis (including",
"    <strong>",
"    </strong>",
"    candidemia):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"       Caspofungin",
"      </a>",
"      &mdash; 70 mg IV loading dose on day 1, followed by 50 mg IV daily thereafter [",
"      <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/56\">",
"       56",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"       Micafungin",
"      </a>",
"      &mdash; 100 mg intravenous dose daily; no loading dose is required [6, 86]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"       Anidulafungin",
"      </a>",
"      &mdash; 200 mg IV loading dose on day 1, followed by 100 mg IV daily thereafter [",
"      <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/57\">",
"       57",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Salvage therapy for invasive aspergillosis &mdash; Only",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    has FDA approval for this indication:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"       Caspofungin",
"      </a>",
"      &mdash; 70 mg IV dose on day 1, followed by 50 mg IV",
"      <strong>",
"      </strong>",
"      daily thereafter; daily dose can be increased to 70 mg if response is inadequate [",
"      <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/58\">",
"       58",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"       Micafungin",
"      </a>",
"      &mdash; 100 to 150 mg IV dose daily; no loading dose is required [",
"      <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/59,60\">",
"       59,60",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"       Anidulafungin",
"      </a>",
"      &mdash; 200 mg IV loading dose on day 1, followed by 100 mg IV daily [",
"      <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/61\">",
"       61",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neutropenic fever (empiric therapy):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"       Caspofungin",
"      </a>",
"      &mdash; 70 mg IV loading dose on day 1, followed by 50 mg IV daily thereafter (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"       \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Candida prophylaxis in hematopoietic cell transplant recipients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"       Micafungin",
"      </a>",
"      <strong>",
"       &mdash;",
"      </strong>",
"      50 mg IV daily (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=see_link\">",
"       \"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239299702\">",
"    <span class=\"h2\">",
"     Pediatric dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacokinetic studies demonstrate an increased rate of clearance for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    among neonates, infants, and younger children compared with adolescents and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/62-69\">",
"     62-69",
"    </a>",
"    ]. Accordingly, larger doses of micafungin and caspofungin on the basis of milligrams per kilogram are required for small children and infants compared to adults. No large trials have evaluated dosing in low birth weight neonates, a population at high risk for developing invasive candidiasis.",
"    <strong>",
"    </strong>",
"    Only caspofungin has FDA approval for use in children; dosing instructions based upon body surface area for children aged three months or older are provided",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A brief overview of suggested pediatric dosing is presented here. Clinicians should consult individual topic reviews for each infection for more detailed information about the use of each drug. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3336?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of candidemia in children\", section on 'Antifungal agents and dosing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40760?source=see_link\">",
"     \"Treatment of Candida infection in neonates\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/47/21237?source=see_link\">",
"     \"Caspofungin: Pediatric drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/29/9686?source=see_link\">",
"     \"Micafungin: Pediatric drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For neutropenic fever (empiric therapy), invasive candidiasis (including candidemia), esophageal candidiasis, and salvage therapy of invasive aspergillosis, the following dosing regimen is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/45\">",
"     45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"       Caspofungin",
"      </a>",
"      &mdash; Age &ge;3 months: 70",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      (70 mg maximum) IV loading dose on day one, followed by 50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      (70 mg maximum) thereafter.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dosing regimens of the other echinocandins have not been standardized in children. The following general dosing guidelines for other echinocandins can be used [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/66,70-73\">",
"     66,70-73",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"       Micafungin",
"      </a>",
"      &mdash; 2 to 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, with doses as high as 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day suggested for neonates",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"       Anidulafungin",
"      </a>",
"      &mdash; 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239299694\">",
"    <span class=\"h2\">",
"     Dose adjustments",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1401995\">",
"    <span class=\"h3\">",
"     Enzyme induction",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased maintenance dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    of 70 mg daily is suggested for adult patients if treated concomitantly with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/45\">",
"     45",
"    </a>",
"    ]. For pediatric patients receiving rifampin, a dose of 70",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    (up to 70 mg) of caspofungin is suggested. A similar adjustment of caspofungin is recommended if the patient is concurrently receiving other drugs that are potent inducers of cytochrome P450 3A4 metabolism (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H1239300816\">",
"     'Drug interactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239298206\">",
"    <span class=\"h3\">",
"     Renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echinocandins are not extensively cleared by the kidney and are not dialyzable; therefore, dosage adjustment is",
"    <strong>",
"     not",
"    </strong>",
"    required in patients with renal insufficiency, including patients who are receiving dialysis",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/45,50,74\">",
"     45,50,74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239299710\">",
"    <span class=\"h3\">",
"     Hepatic insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     Caspofungin",
"    </a>",
"    maintenance dose should be reduced to 35 mg once daily for moderate hepatic insufficiency (Child-Pugh score 7 to 9). The loading dose is not reduced. No dose adjustment of caspofungin is needed for mild hepatic insufficiency (Child-Pugh score &le;6) and no recommendation is available for use in severe hepatic insufficiency (Child-Pugh score &gt;9)",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     Micafungin",
"    </a>",
"    does not require dose reduction for mild or moderate hepatic insufficiency and no recommendation is available for use in severe hepatic insufficiency",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     Anidulafungin",
"    </a>",
"    is inactivated by gradual spontaneous degradation and not metabolized hepatically. Therefore, dose adjustment for hepatic insufficiency is not needed",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239298213\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echinocandins are well tolerated, and all three members of the class have similar types of adverse effects. Serious adverse effects requiring drug discontinuation occur less frequently with the echinocandins than with other classes of systemic antifungals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239299718\">",
"    <span class=\"h2\">",
"     Hepatotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modest asymptomatic elevations of aminotransferases (in 7 to 14 percent) and alkaline phosphatase (in 4 to 12 percent) are the most frequently reported laboratory abnormalities in healthy volunteers and patients treated with echinocandins",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/45\">",
"     45",
"    </a>",
"    ]. Liver function test abnormalities are less common in patients treated with echinocandins compared with those receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    formulations or azoles. Although rare, clinically significant hepatitis, hepatomegaly, hyperbilirubinemia, and hepatic failure have been reported with the echinocandins, although causality has not been conclusively established. Regular monitoring of hepatic aminotransferases during echinocandin therapy is suggested.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239299726\">",
"    <span class=\"h2\">",
"     Infusion and hypersensitivity reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infusion-related histamine-release symptoms, including rash, pruritus, hypotension, bronchospasm, and angioedema, have been reported rarely with each of the echinocandins",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/3\">",
"     3",
"    </a>",
"    ]. Such reactions have been reported with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    when the drug is infused at a rate that exceeds 1.1",
"    <span class=\"nowrap\">",
"     mg/minute",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/74\">",
"     74",
"    </a>",
"    ]. In most patients, these effects are transient and are easily managed by slowing the infusion rate and supportive care.",
"   </p>",
"   <p>",
"    Delayed (type IV) hypersensitivity reactions manifesting as a maculopapular rash are rare, although eosinophilia has been observed in 3 percent of patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/75\">",
"     75",
"    </a>",
"    ]. Anaphylaxis has been reported rarely with each of the echinocandins. Postmarketing reports for caspofungin include rare cases consistent with a hypersensitivity syndrome, erythema multiforme, Stevens-Johnson syndrome, and skin exfoliation, although it is not clear that these reactions were caused by caspofungin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fever appears to be more common with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    than other echinocandins, with rates ranging from 4 to 26 percent in clinical trials compared with &lt;1 percent for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239298227\">",
"    <span class=\"h2\">",
"     Injection site pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injection site pain and phlebitis have been reported more frequently with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    (4 to 25 percent) than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    (1 to 14 percent) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    (&lt;1 percent), particularly when caspofungin is administered through a peripheral catheter. If these adverse effects occur, the infusion can be slowed down or the echinocandin can be administered in a more dilute solution.",
"   </p>",
"   <p>",
"    <strong>",
"     Gastrointestinal &mdash;",
"    </strong>",
"    Nausea, vomiting, diarrhea, and abdominal pain have been reported in approximately 1 to 3 percent of patients receiving echinocandin therapy, but rarely result in drug discontinuation",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/45,50,74\">",
"     45,50,74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239298234\">",
"    <span class=\"h2\">",
"     Renal toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;No significant drug-related nephrotoxicity was observed with any of the echinocandins in clinical trials or documented in postmarketing surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/45,50,74\">",
"     45,50,74",
"    </a>",
"    ]. Modest rates of hypokalemia have been observed with all three drugs (2 to 11 percent), which may represent renal wasting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239298248\">",
"    <span class=\"h2\">",
"     Hematologic effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia, leukopenia, neutropenia, and thrombocytopenia have been reported and are limited to rare case reports (&lt;1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/45,50,74\">",
"     45,50,74",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239298262\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239298269\">",
"    <span class=\"h2\">",
"     Fetal development",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no adequate studies of the echinocandins in pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/45,50,74\">",
"     45,50,74",
"    </a>",
"    ]. Embryo-fetal development studies in rats and mice performed with doses twofold higher than human exposures resulted in skeletal changes in rat fetuses and increased abortion and visceral abnormalities in rabbits. Echinocandins appear to cross the placental barrier in rats and could be detected in the plasma of the fetus.",
"   </p>",
"   <p>",
"    All three echinocandins are classified as pregnancy category class C agents; they should therefore only be used if the potential benefit justifies the risk to the fetus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239298276\">",
"    <span class=\"h2\">",
"     Breast milk",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not known whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    are excreted in human breast milk. However, all three echinocandins could be detected in the milk of lactating rats [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/45,50,74\">",
"     45,50,74",
"    </a>",
"    ]. Therefore, these drugs should only be administered to nursing mothers if the potential benefit justifies the risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239298283\">",
"    <span class=\"h2\">",
"     Mutagenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echinocandins do not show evidence of mutagenic or genotoxic potential when evaluated by the standard battery of in vitro and in vivo tests [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/45,50,74\">",
"     45,50,74",
"    </a>",
"    ]. Fertility in rats is not affected by intravenous administration of any of the echinocandins. Long-term studies in animals to evaluate the carcinogenic potential of these echinocandins have not been performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239300816\">",
"    <span class=\"h1\">",
"     DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echinocandins are not significant inhibitors or inducers of cytochrome P450 metabolism or p-glycoprotein drug efflux transporters. As a result, echinocandins generally have a lower risk for pharmacokinetic drug-drug interactions compared with other systemic antifungals. Of the comparatively few significant drug interactions involving echinocandins that have been identified to date, most involve the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    upon immunosuppressive agents, or the effect of other drugs upon caspofungin via enzyme induction.",
"   </p>",
"   <p>",
"    Echinocandin drug interactions will be briefly reviewed here. More comprehensive lists of drug interactions that can occur are presented separately. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     \"Caspofungin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     \"Micafungin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     \"Anidulafungin: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, specific interactions of echinocandins with other medications may be determined using the drug interaction tool (Lexi-Interact Online). This tool can be accessed from the UpToDate online search page or through the individual drug information topics, section on Drug interactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239301213\">",
"    <span class=\"h2\">",
"     Caspofungin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism(s) by which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    interacts with other drugs have not been firmly established. It has been suggested that organic anion transporting polypeptides, such as OATP-1B1, which mediate uptake of some drugs to hepatocytes, may play a role in drug interactions of caspofungin",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/48,77\">",
"     48,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    is a substrate of OATP-1B1 transporters and, when administered concurrently with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    , has been shown to increase caspofungin's total plasma concentration exposure (also known as area under curve [AUC]) by approximately 35 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/45\">",
"     45",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    On the other hand, caspofungin caused no significant alteration of cyclosporine time versus plasma concentration profile",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/45\">",
"     45",
"    </a>",
"    ]. The United States FDA-approved product information recommends caution when caspofungin and cyclosporine are given concurrently due to potentially increased risk of hepatotoxicity as evidenced by transient elevations in hepatic aminotransferases. Should the benefits of concurrent therapy outweigh the risks, monitoring of liver function tests is warranted",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/45,52\">",
"     45,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     Caspofungin",
"    </a>",
"    decreases",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    serum concentrations by approximately 20 percent, a clinically significant effect given the narrow therapeutic index for tacrolimus. Regular monitoring of tacrolimus blood levels is necessary to avoid effects of subtherapeutic levels, including acute graft rejection",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/45,52\">",
"     45,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    , an inhibitor of OATP-1, has been shown to induce",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/78\">",
"     78",
"    </a>",
"    ]. Therefore, an increased maintenance dose of 70 mg per",
"    <strong>",
"    </strong>",
"    day of caspofungin is recommended in patients who are receiving concomitant rifampin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/79\">",
"     79",
"    </a>",
"    ]. A similar dosage increase is recommended in patients receiving other enzyme inducers, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1401995\">",
"     'Enzyme induction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239300837\">",
"    <span class=\"h2\">",
"     Micafungin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     Micafungin",
"    </a>",
"    modestly reduces the clearance of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    (rapamycin), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/50\">",
"     50",
"    </a>",
"    ]. Routine dose adjustments of these agents are not necessary, but cyclosporine and sirolimus serum concentrations should be monitored. Unlike",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    , micafungin does not affect",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    serum concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/80\">",
"     80",
"    </a>",
"    ]. For patients receiving micafungin and nifedipine, blood pressure should be monitored and the dose of nifedipine can be reduced if necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239301205\">",
"    <span class=\"h2\">",
"     Anidulafungin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the echinocandins,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    is the least likely to be an object, or cause, of a pharmacokinetic drug interaction because it is not a substrate, inhibitor, or inducer of cytochrome P450 or P-glycoprotein. Anidulafungin does not alter the metabolism or clearance of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . A modest increase (22 percent) in the total drug plasma concentration exposure (AUC) of anidulafungin was observed when co-administered with cyclosporine [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/81\">",
"     81",
"    </a>",
"    ]. The modest degree of this effect does not require dose adjustment or other specific management.",
"   </p>",
"   <p>",
"    Concurrent administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    , or a variety of other substrates, inducers, or inhibitors of cytochrome P450 does not have a significant impact on the plasma drug concentration profile of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/7/9338/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239300844\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The development of echinocandins, the first systemic antifungal agents that selectively target the fungal cell wall, represents a major milestone in antifungal chemotherapy. Three semi-synthetic echinocandin derivatives have been developed for clinical use:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"       caspofungin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"       micafungin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"       anidulafungin",
"      </a>",
"      . Experience with this antifungal class suggests this it is the best tolerated and safest class available. (See",
"      <a class=\"local\" href=\"#H1239292403\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Echinocandins are widely used for the treatment of invasive candidiasis, especially in critically ill and neutropenic patients, and less commonly in salvage regimens for invasive aspergillosis. They are also used for empiric antifungal therapy in patients with febrile neutropenia. (See",
"      <a class=\"local\" href=\"#H1239292410\">",
"       'Overview of clinical uses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major advantages of echinocandins relative to other antifungal agents are their fungicidal activity against Candida spp, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      -resistant C. glabrata and C. krusei, combined with their relatively low potential for renal or hepatic toxicity or serious drug-drug interactions. (See",
"      <a class=\"local\" href=\"#H1239292410\">",
"       'Overview of clinical uses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because all three echinocandins share a similar spectrum of activity and mechanism of action, most experts consider these drugs to be interchangeable, particularly for the treatment of invasive candidiasis (",
"      <a class=\"graphic graphic_table graphicRef61023 \" href=\"UTD.htm?37/33/38428\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef82770 \" href=\"UTD.htm?16/47/17150\">",
"       table 2",
"      </a>",
"      ). However, the three echinocandins differ in terms of their dosing, pathways of metabolic elimination, and drug interaction profile. Therefore, it is important to appreciate these unique characteristics when selecting an echinocandin (",
"      <a class=\"graphic graphic_table graphicRef56212 \" href=\"UTD.htm?5/2/5165\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1239292410\">",
"       'Overview of clinical uses'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1239292494\">",
"       'Pharmacokinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Echinocandins target fungal cell beta-glucan synthesis by competitively inhibiting the beta-1,3-D-glucan synthase enzyme complex in susceptible fungi (",
"      <a class=\"graphic graphic_figure graphicRef67408 \" href=\"UTD.htm?36/25/37269\">",
"       figure 2",
"      </a>",
"      ). These agents are fungicidal for susceptible Candida spp, and fungistatic for Aspergillus spp. (See",
"      <a class=\"local\" href=\"#H1239299741\">",
"       'Mechanism of action'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1239292431\">",
"       'Microbiologic activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Echinocandins are well tolerated, and all three members of the class have similar types of adverse effects. Serious adverse effects requiring drug discontinuation occur less frequently with the echinocandins than with other classes of systemic antifungals. (See",
"      <a class=\"local\" href=\"#H1239298213\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/1\">",
"      Hector RF. Compounds active against cell walls of medically important fungi. Clin Microbiol Rev 1993; 6:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/2\">",
"      Debono M, Gordee RS. Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol 1994; 48:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/3\">",
"      Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/4\">",
"      Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/5\">",
"      Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/6\">",
"      Douglas CM. Fungal beta(1,3)-D-glucan synthesis. Med Mycol 2001; 39 Suppl 1:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/7\">",
"      Cabib E, Roh DH, Schmidt M, et al. The yeast cell wall and septum as paradigms of cell growth and morphogenesis. J Biol Chem 2001; 276:19679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/8\">",
"      Fleet GH. Composition and structure of yeast cell walls. Curr Top Med Mycol 1985; 1:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/9\">",
"      Bernard M, Latg&eacute; JP. Aspergillus fumigatus cell wall: composition and biosynthesis. Med Mycol 2001; 39 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/10\">",
"      Beauvais A, Bruneau JM, Mol PC, et al. Glucan synthase complex of Aspergillus fumigatus. J Bacteriol 2001; 183:2273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/11\">",
"      Beauvais A, Latg&eacute; JP. Membrane and cell wall targets in Aspergillus fumigatus. Drug Resist Updat 2001; 4:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/12\">",
"      Kurtz MB, Heath IB, Marrinan J, et al. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother 1994; 38:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/13\">",
"      Wheeler RT, Fink GR. A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog 2006; 2:e35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/14\">",
"      Wheeler RT, Kombe D, Agarwala SD, Fink GR. Dynamic, morphotype-specific Candida albicans beta-glucan exposure during infection and drug treatment. PLoS Pathog 2008; 4:e1000227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/15\">",
"      Hohl TM, Feldmesser M, Perlin DS, Pamer EG. Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure. J Infect Dis 2008; 198:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/16\">",
"      Ibrahim AS, Bowman JC, Avanessian V, et al. Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother 2005; 49:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/17\">",
"      Lamaris GA, Lewis RE, Chamilos G, et al. Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis 2008; 198:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/18\">",
"      Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/19\">",
"      Pfaller MA, Castanheira M, Lockhart SR, et al. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 2012; 50:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/20\">",
"      Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 2012; 125:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/21\">",
"      Zimbeck AJ, Iqbal N, Ahlquist AM, et al. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. Antimicrob Agents Chemother 2010; 54:5042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/22\">",
"      Chapeland-Leclerc F, Hennequin C, Papon N, et al. Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient. Antimicrob Agents Chemother 2010; 54:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/23\">",
"      Dannaoui E, Desnos-Ollivier M, Garcia-Hermoso D, et al. Candida spp. with acquired echinocandin resistance, France, 2004-2010. Emerg Infect Dis 2012; 18:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/24\">",
"      Dodgson KJ, Dodgson AR, Pujol C, et al. Caspofungin resistant C. glabrata. Clin Microbiol Infect 2005; 11 (Suppl 2):364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/25\">",
"      Kofteridis DP, Lewis RE, Kontoyiannis DP. Caspofungin-non-susceptible Candida isolates in cancer patients. J Antimicrob Chemother 2010; 65:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/26\">",
"      Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis 2006; 42:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/27\">",
"      Pfaller MA, Castanheira M, Lockhart SR, et al. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 2012; 50:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/28\">",
"      Ramage G, VandeWalle K, Bachmann SP, et al. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother 2002; 46:3634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/29\">",
"      Kuhn DM, George T, Chandra J, et al. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002; 46:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/30\">",
"      Nett J, Lincoln L, Marchillo K, Andes D. Beta -1,3 glucan as a test for central venous catheter biofilm infection. J Infect Dis 2007; 195:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/31\">",
"      Cassone A, Kerridge D, Gale EF. Ultrastructural changes in the cell wall of Candida albicans following cessation of growth and their possible relationship to the development of polyene resistance. J Gen Microbiol 1979; 110:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/32\">",
"      Gale EF, Ingram J, Kerridge D, et al. Reduction of amphotericin resistance in stationary phase cultures of Candida albicans by treatment with enzymes. J Gen Microbiol 1980; 117:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/33\">",
"      Nett J, Lincoln L, Marchillo K, et al. Putative role of beta-1,3 glucans in Candida albicans biofilm resistance. Antimicrob Agents Chemother 2007; 51:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/34\">",
"      Bowman JC, Hicks PS, Kurtz MB, et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002; 46:3001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/35\">",
"      Ben-Ami R, Lewis RE, Kontoyiannis DP. Immunocompromised hosts: immunopharmacology of modern antifungals. Clin Infect Dis 2008; 47:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/36\">",
"      Espinel-Ingroff A. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36:2950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/37\">",
"      Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000; 44:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/38\">",
"      Kahn JN, Hsu MJ, Racine F, et al. Caspofungin susceptibility in Aspergillus and non-Aspergillus molds: inhibition of glucan synthase and reduction of beta-D-1,3 glucan levels in culture. Antimicrob Agents Chemother 2006; 50:2214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/39\">",
"      Del Poeta M, Schell WA, Perfect JR. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob Agents Chemother 1997; 41:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/40\">",
"      Ito M, Nozu R, Kuramochi T, et al. Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice. Antimicrob Agents Chemother 2000; 44:2259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/41\">",
"      Schmatz DM, Powles M, McFadden DC, et al. Treatment and prevention of Pneumocystis carinii pneumonia and further elucidation of the P. carinii life cycle with 1,3-beta-glucan synthesis inhibitor L-671,329. J Protozool 1991; 38:151S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/42\">",
"      Kottom TJ, Limper AH. Cell wall assembly by Pneumocystis carinii. Evidence for a unique gsc-1 subunit mediating beta -1,3-glucan deposition. J Biol Chem 2000; 275:40628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/43\">",
"      Kohler S, Wheat LJ, Connolly P, et al. Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model. Antimicrob Agents Chemother 2000; 44:1850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/44\">",
"      Dodds Ashley ES, Lewis R, Lewis JS, et al. Pharmacology of Systemic Antifungal Agents. Clin Infect Dis 2006; 43 Suppl 1:S28.",
"     </a>",
"    </li>",
"    <li>",
"     Cancidas. Prescribing information-(caspofungin acetate) for injection. Merck &amp; Co Inc, Whitehouse Station, NJ 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/46\">",
"      Stone JA, Holland SD, Wickersham PJ, et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002; 46:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/47\">",
"      Sucher AJ, Chahine EB, Balcer HE. Echinocandins: the newest class of antifungals. Ann Pharmacother 2009; 43:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/48\">",
"      Stone JA, Xu X, Winchell GA, et al. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 2004; 48:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/49\">",
"      Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents : pharmacokinetics, safety and efficacy. Drugs 2004; 64:1997.",
"     </a>",
"    </li>",
"    <li>",
"     Mycamine. Prescribing information-micafungin for injection. In: Inc A, ed, Deerfield, IL 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/51\">",
"      Theuretzbacher U. Pharmacokinetics/pharmacodynamics of echinocandins. Eur J Clin Microbiol Infect Dis 2004; 23:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/52\">",
"      Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 2007; 27:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/53\">",
"      Villanueva A, Arathoon EG, Gotuzzo E, et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001; 33:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/54\">",
"      de Wet NT, Bester AJ, Viljoen JJ, et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 2005; 21:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/55\">",
"      Krause DS, Simjee AE, van Rensburg C, et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004; 39:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/56\">",
"      Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/57\">",
"      Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356:2472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/58\">",
"      Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006; 107:2888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/59\">",
"      Kontoyiannis DP, Ratanatharathorn V, Young JA, et al. Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transpl Infect Dis 2009; 11:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/60\">",
"      Kohno S, Masaoka T, Yamaguchi H, et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 2004; 36:372.",
"     </a>",
"    </li>",
"    <li>",
"     Anidulafungin plus voriconazole versus voriconazole for the treatment of invasive aspergillosis. In: Health NIo, ed, 2008. file://www.clinicaltrials.gov/ct2/show/NCT00531479 (Accessed on July 29, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/62\">",
"      Lehrnbecher T, Groll AH. Micafungin: a brief review of pharmacology, safety, and antifungal efficacy in pediatric patients. Pediatr Blood Cancer 2010; 55:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/63\">",
"      Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005; 49:4536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/64\">",
"      Neely M, Jafri HS, Seibel N, et al. Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother 2009; 53:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/65\">",
"      S&aacute;ez-Llorens X, Macias M, Maiya P, et al. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother 2009; 53:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/66\">",
"      Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005; 49:3317.",
"     </a>",
"    </li>",
"    <li>",
"     Heresi, GP, Gerstmann, DR, Blumer, JL, et al. Pharmacokinetic, safety, and tolerance study of micafungin (FK463) in premature infants. Pediat Res 2003; 53:317A.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/68\">",
"      Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis 2008; 197:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/69\">",
"      Hope WW, Smith PB, Arrieta A, et al. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother 2010; 54:2633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/70\">",
"      Benjamin DK Jr, Driscoll T, Seibel NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 2006; 50:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/71\">",
"      Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006; 25:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/72\">",
"      Queiroz-Telles F, Berezin E, Leverger G, et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J 2008; 27:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/73\">",
"      Cohen-Wolkowiez M, Moran C, Benjamin DK Jr, Smith PB. Pediatric antifungal agents. Curr Opin Infect Dis 2009; 22:553.",
"     </a>",
"    </li>",
"    <li>",
"     Eraxis. Prescribing information-(Anidulafungin) for injection. In: Pfizer I, ed. New York, NY 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/75\">",
"      Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003; 36:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/76\">",
"      Eschenauer G, Depestel DD, Carver PL. Comparison of echinocandin antifungals. Ther Clin Risk Manag 2007; 3:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/77\">",
"      Sandhu P, Lee W, Xu X, et al. Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos 2005; 33:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/78\">",
"      Meletiadis J, Chanock S, Walsh TJ. Human pharmacogenomic variations and their implications for antifungal efficacy. Clin Microbiol Rev 2006; 19:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/79\">",
"      Stone JA, Migoya EM, Hickey L, et al. Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother 2004; 48:4306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/80\">",
"      Hebert MF, Blough DK, Townsend RW, et al. Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005; 45:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/81\">",
"      Dowell JA, Stogniew M, Krause D, et al. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol 2005; 45:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/7/9338/abstract/82\">",
"      Dowell JA, Knebel W, Ludden T, et al. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 2004; 44:590.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13945 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-CCFD8525CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_7_9338=[""].join("\n");
var outline_f9_7_9338=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1239300844\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1239292403\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1239292410\">",
"      OVERVIEW OF CLINICAL USES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1239299741\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1239292431\">",
"      MICROBIOLOGIC ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1239292438\">",
"      Candida species",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1239292445\">",
"      - Candida biofilms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1239292452\">",
"      Other yeasts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1239292466\">",
"      Dimorphic fungi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1239292473\">",
"      Aspergillus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1239292480\">",
"      Other molds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12264177\">",
"      Pneumocystis jirovecii",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1239292487\">",
"      RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1239292494\">",
"      PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22267050\">",
"      Caspofungin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22267058\">",
"      Micafungin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22267066\">",
"      Anidulafungin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1239298142\">",
"      PHARMACODYNAMICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1239298150\">",
"      DOSING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18092677\">",
"      Adult dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1239299702\">",
"      Pediatric dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1239299694\">",
"      Dose adjustments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1401995\">",
"      - Enzyme induction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1239298206\">",
"      - Renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1239299710\">",
"      - Hepatic insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1239298213\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1239299718\">",
"      Hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1239299726\">",
"      Infusion and hypersensitivity reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1239298227\">",
"      Injection site pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1239298234\">",
"      Renal toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1239298248\">",
"      Hematologic effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1239298262\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1239298269\">",
"      Fetal development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1239298276\">",
"      Breast milk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1239298283\">",
"      Mutagenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1239300816\">",
"      DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1239301213\">",
"      Caspofungin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1239300837\">",
"      Micafungin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1239301205\">",
"      Anidulafungin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1239300844\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/13945\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/13945|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/59/25524\" title=\"figure 1\">",
"      Echinocandins structure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/25/37269\" title=\"figure 2\">",
"      Echinocandins target of activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/13945|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/33/38428\" title=\"table 1\">",
"      Candida spp susceptibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/47/17150\" title=\"table 2\">",
"      In vitro activity against Candida species",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/21/20828\" title=\"table 3\">",
"      In vitro activity against Aspergillus fumigatus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/2/5165\" title=\"table 4\">",
"      Echinocandins PK",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=related_link\">",
"      Anidulafungin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/21/29018?source=related_link\">",
"      Antifungal susceptibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=related_link\">",
"      Caspofungin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/47/21237?source=related_link\">",
"      Caspofungin: Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=related_link\">",
"      Micafungin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/29/9686?source=related_link\">",
"      Micafungin: Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=related_link\">",
"      Pharmacology of amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43190?source=related_link\">",
"      Pharmacology of flucytosine (5-FC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=related_link\">",
"      Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=related_link\">",
"      Treatment and prevention of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40760?source=related_link\">",
"      Treatment of Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=related_link\">",
"      Treatment of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3336?source=related_link\">",
"      Treatment of candidemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=related_link\">",
"      Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_7_9339="DSM-IV-TR diagnostic criteria for anorexia nervosa";
var content_f9_7_9339=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    DSM-IV-TR diagnostic criteria for anorexia nervosa",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Refusal to maintain body weight at or above a minimally normal weight for age and height (eg, weight loss or failure to gain weight that leads to a body weight less than 85 percent of that expected for age and height).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intense fear of gaining weight or becoming fat, even though underweight.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disturbed perception of one's body weight or shape, undue influence of weight or shape on self-evaluation, or denial of the seriousness of the current low body weight.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In postmenarcheal females, amenorrhea, ie, absence of at least three consecutive menstrual cycles. Menstruation that occurs only after hormonal treatment, eg, estrogen, is considered amenorrhea.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Ed, Text Revision, Washington, DC 2000. p.589.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_7_9339=[""].join("\n");
var outline_f9_7_9339=null;
var title_f9_7_9340="Ewings sarcoma chemo protocols";
var content_f9_7_9340=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F50917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F50917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Chemotherapy protocols for Ewing's sarcoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Dose",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Regimen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        VDCA",
"       </td>",
"       <td class=\"subtitle2\">",
"        VDCA/IE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vincristine",
"       </td>",
"       <td>",
"        2 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        (max 2 mg), day 1",
"       </td>",
"       <td>",
"        Cycles 1-17",
"       </td>",
"       <td>",
"        Cycles 1, 3, 5, 7, 9, 11, 13, 15, 17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Doxorubicin",
"       </td>",
"       <td>",
"        75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        , day 1",
"       </td>",
"       <td>",
"        Cycles 1-5*",
"       </td>",
"       <td>",
"        Cycles 1, 3, 5, 7, 9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclophosphamide plus mesna",
"       </td>",
"       <td>",
"        1200 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        , day 1",
"       </td>",
"       <td>",
"        Cycles 1-17",
"       </td>",
"       <td>",
"        Cycles 1, 3, 5, 7, 9, 11, 13, 15, 17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dactinomycin",
"       </td>",
"       <td>",
"        1.25 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        , day 1*",
"       </td>",
"       <td>",
"        Cycles 6-17*",
"       </td>",
"       <td>",
"        Cycles 11, 13, 15, 17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ifosfamide plus mesna",
"       </td>",
"       <td>",
"        1800 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        daily, days 1-5",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Cycles 2, 4, 6, 8, 10, 12, 14, 16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Etoposide",
"       </td>",
"       <td>",
"        100 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        daily, days 1-5",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Cycles 2, 4, 6, 8, 10, 12, 14, 16",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Courses administered every 21 days for 17 courses.",
"     <br>",
"      * Substitute dactinomycin for doxorubicin when cumulative doxorubicin dose is 375 mg/m",
"      <sup>",
"       2",
"      </sup>",
"      .",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Grier H, et al. N Engl J Med 2003; 348:694.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_7_9340=[""].join("\n");
var outline_f9_7_9340=null;
var title_f9_7_9341="Features giant cell arteritis";
var content_f9_7_9341=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F54634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F54634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Giant cell arteritis: clinical findings in 100 patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Finding",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Number",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sex (female/male)",
"       </td>",
"       <td>",
"        69/31",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duration of manifestations before diagnosis",
"       </td>",
"       <td>",
"        7*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Onset (gradual/sudden)",
"       </td>",
"       <td>",
"        64/36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weight loss or anorexia",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malaise, fatigue, or weakness",
"       </td>",
"       <td>",
"        40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever",
"       </td>",
"       <td>",
"        42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polymyalgia rheumatica",
"       </td>",
"       <td>",
"        39",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other musculoskeletal pains",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Synovitis",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sore throat",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Symptoms related to arteries",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        83",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Headache",
"       </td>",
"       <td class=\"sublist_other\">",
"        68",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"2\" rowspan=\"1\">",
"        Visual symptoms &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Transient",
"       </td>",
"       <td class=\"sublist_other\">",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Fixed",
"       </td>",
"       <td class=\"sublist_other\">",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Jaw claudication",
"       </td>",
"       <td class=\"sublist_other\">",
"        45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Swallowing claudication or dysphagia",
"       </td>",
"       <td class=\"sublist_other\">",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Tongue claudication",
"       </td>",
"       <td class=\"sublist_other\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Limb claudication",
"       </td>",
"       <td class=\"sublist_other\">",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Signs related to arteries",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        66",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Artery tenderness",
"       </td>",
"       <td class=\"sublist_other\">",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Decreased temporal artery pulsations",
"       </td>",
"       <td class=\"sublist_other\">",
"        46",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Erythematous, nodular, or swollen scalp arteries",
"       </td>",
"       <td class=\"sublist_other\">",
"        23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Large artery bruits",
"       </td>",
"       <td class=\"sublist_other\">",
"        21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Decreased large artery pulses",
"       </td>",
"       <td class=\"sublist_other\">",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Visual loss",
"       </td>",
"       <td class=\"sublist_other\">",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ophthalmoscopic abnormalities",
"       </td>",
"       <td class=\"sublist_other\">",
"        18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Extraocular muscle weakness",
"       </td>",
"       <td class=\"sublist_other\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Raynaud's phenomenon",
"       </td>",
"       <td class=\"sublist_other\">",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central nervous system abnormalities",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Range 1 to 48 months before diagnosis",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Calamia, KT, Hunder, GG. Clin Rheum Dis 1980; 6:389.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_7_9341=[""].join("\n");
var outline_f9_7_9341=null;
var title_f9_7_9342="Normal response to metyrapone";
var content_f9_7_9342=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F81918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F81918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal response to metyrapone",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 362px; height: 432px; background-image: url(data:image/gif;base64,R0lGODlhagGwAfcAAP////8AAAAzmQAAAO7u7hERERBAn6qqqv9XV/+oqKi53P94eP+Pj//Dw/8EBHiTycPP54iIiI+l0szMzAQ2myIiInd3d/8ICGOCwf8GBv8XF/9mZru7u//d3f8yMjMzM/8dHVd2wf8QELvJ5JmZmVVVVf8vL0RERP+Zmd3d3f8zMyNPp/+IiDJVuRhGo+Dm82ZmZmaFwhFBoP83Nzddsj9lsv8iIpmt1u7x+P9VVf/u7v+7u4igz//g4CJOp/9ERP8MDC9Vsv8REf8BAQM1mt3k8QE0mSdNsszW63eSyVBzuURptP8CAgI1mjNcraq73f/MzB1Jpww9nv+qqlV3u/9paQo6n0Zpuf8NDf9xcTxfuQMyn52u3P9QUP8PD/9jY//f3//ExAg3n/8nJ/8KCv+SkgY2n/9ra9/l8v88PP/Pz7/M5f9+fhdFo2uB0g08nws8nQ4+oA8/n+/y+QwrwIiZ3P86Oml63AY4m19/v/93dwE0mqu83f8DAxVEoQQ0nVx9vv8VFUFns8/P/x9MpQg5nE9yuf8ODv8HB3+ZzAk5n36P3J+y2S1Xq9/f/5Ok3HGMyf9GRi9ZrAAwnwM1m1BwwR9Lp6u35wk5ngc5nX6Yy0xwtxRDoc/Z7P9MTAk6nf8pKZKe5/9ubgEzmgU3mwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABqAbABAAj/AAEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcu2rdu3FA8MmDugQASTcguUlUvX7sO8GgnMnQDXpdwPAFJUGMChJGCyhxMvbtzwMUbBAwgXZhkZwIcBJCwMOHFiAIEJpQdUOGBwQt0SdQ/ALsCaAOy5EVzTtbCYcIQBMPLCGHBA9NwCJACI/rC4QgoAto8nF45bIInFo5/D7Pw5+e+5Fqxj/89Md0B4gq4LzJYdW+D3ASUAFKD7AfZdDqoxi7bAFzyAvKmxBsB74ek3X3wAXDfXCdqlFVkKBRRAgHFzEVBBBafV1VpdBJDA4W8nAFBaY5M9th8AvfVH3ED4DZDCcgOO5tkAd312QF4EAIZfiCDG9GCEE8IHwHAWpEfAQJahx6GHEvb42132YUZYZMNFgJl/AlkIGo746SVafERidgAB83GwY4whqqXiB6x9aV15g803WHr/aZhXCnDS+JhrFeCHmGUT3DaYm+nh6aJywAGmGwHDlafXduWxiSJodTp3nAXTaQiAoLnZ6ale481VgpQC9QYkqdBRqKemZS6WKYaDyf9HXKN9rdXZQG4mqJpCdAJ251wN1vmoiKpRatl8Vg4qZJeGPidacBouOhwMNd1aqrG7FicnCUkO1OunkyY3EKq/LUYtqqXF91kEj7WKLayZyXrAtG9ZiyiCZNKY2AlHKqmXrxp+hmAJB3Q5kIe7CpvlXGYqC6aQ6854Y7QV5jUlgi/Z6yaRBLlq8Ib/grvckRGEV6ZAhsaL6rpasquhhxXcO6R5pM43cQEX2zoAYgTlCgBqdGHsLbiAMUoXg8Sad+1dCrs312eZiYYdv9DdhpzCiyYItb6Q8kwQgXXSxXRq5w0d8tnuyblajDsLBFuaqB4w34WrFrDYB5qBXfOKJGz/zfRmKuEp4UM+Aw7RYgJWpqnhQxXOkOOMLyRXzH8tHvnlmGeu+eacd+7556CHLvropJdu+umop6766qy37vrrV/3wQ0MdBNCB6bLTbntXRcgwAkG9/36QAMQLQAUSA93gA/FLFDEQDzIQ78QNI20QwPU5QMGQDShEVPvtIwUPvO8IFW888gIpz7zzAkEvPfUhWY+99gtx7/3uW8VAvPAA6C8A/wX5HwBwQAUZOO8JAuCBQJYgAxwAAHrCS0IMRPIDFdyuAznoXv00+JDvjcR//ANh+X5HQAMCAIEKBAADHQhBgUgwJBW8YAa3x0GHeLArAiRIDg2ywxhM0AlJIIgP/3iAAxnAjyQ7wB9BcnA9FegAABvYAAsCMMXrsSCKAECBEK7XvR3YgIsAuOFIdigQMuowhD8M4kCGWMQjiiSJ4FtiE58YxSlWkYpY1CIYvQhGMW7FjGYcyA6VBwABPIEgPkSCABxYEhaowCAssMHtVLABKKpAg/aDYiWF0D0U6EEHQmABAKZgOz+GBJAAPGPyfFDIQw4kkYts5CMLEslJVnIDlxRIJrHIySx+MpSjLKUS/5jKHI6geL8bJCsNicgYKJKRJHGkQX4gylEKQZMD2WUlK7iBLgZgICpggSlBgkqBHHN/heQfIZn5SmfGMpqzJAg1BTKFa2JRlxrEIje9Cf9OcQ5TK+UcHhoBAEQhEtGIJoFjQeZpTWziUyD3RAEuc5DEfo7zIwHl4UALusaDujEkCpVnNevpUABoUyASVQFFvymQcF70KhkNIAkLeMAELrCBAEgCQnM6wZCoQAXawyAKaqkDSpY0nBDdQAeACgBHglKUKBBmHEUSU1WWsKYpXGFOd/pCkPw0qBkkqlHvCQCkanKp2nMqMKPagZdSxX/EEwhcBTC84i0BfQBQnwDu+rzoCWB6ItGB/AKQPQAwMQBOLGlU8bgBHRzWBjsAAB8D0D23amSucjVfXZmHV73ytX1+BSxIBHs9wmrvsIkl62Kv2NjHRnaylf0n7GZL29r/2va2uPXcAHLLW53strfArclvg0tcmAy3uMhdyXGTy1yTLLe50A3Jc6NLXY5MVy1VmEEXelDdp1z3LGAAQmmHkICfKOAIV3iBQiDQAho8ALrfNUsZSns9EfgkBObjAkLwWzwKKIC58S3LGeh7vZ5AwHwC2MJBDoxgAwD4LWwgsAN6IgEE09UgFbbwg92iBgJ/oScKQDARDhJiBFNgw24JgwYu4IUF/MQA5sMAQlaA4PcmN8DdHcgLamAAA9gYAOx170Aw0GMXSKC5OM7xfs3n3xwnWckFYbD5HNzdJ0N5IBlGsJOvDJESM3nLXH4Ijc33Y+paOcwA2AQliACHI4MZ/80M4S/xmlxlODNEysWjcnXPfOUsa7bOdlaIl/v75kDPuMaFNvRBiGwAIyuZz1wOcpn3rOiEyFkAdKZ0pQ2CZ+Lp2cybxrCFL6zpUA9k0HNOtKnHXLxJw9fUBmG0o1UN6zBDutY3xnWgb61r4vK618D9NbB5K+xh47bYxrYtspNN22UzG3bOfrbrok2VBnhgBi6W9kyoLRUE0NcB5dW2cdvSAAIHwL7i9kh06iIuDsynAJQRCLehwgBzszTdHEkB3hAlEL9EYFgAmPdTEmDuCeMbJByImWsGEi95uwUEBM72wT0Cg+dcZyBrc7hZrI1tgthhCEwIBAMGwnGJ1+S86f+9c3td7brciAfjiRP4UbxdWnADgObXCzfOA2Bzmlz6v5ZmMtBfd4LELRw6DQ94WcpNYBEwvbRkAMDTS4tumXTaCgnptAA+vTp9/63fd/k3QWRelHqb2+z0BQDa0z4TP8cVIW5/e+taRJfkuLsu8VY6WQguYb6PFwB+rzlNUD1ihKAa0ygeC8Tp62Is0BcBAll8aU0eExgXT8YJYTXxWN5bshsFARm4gAZGDoAezCD0WSAI6EVPeprsuMecJ4is3ZzriSfe9r4GtqSh7PneXjrToMa11rn+alzHndTBr/XhTwxoXGteALFHbu97O/tH477218/9W0qe/ZRMfyk773n/90ny/aRMvb7jL0n5kbL20qaf/G4J/PUM/n7pvkXy16N8UHZv/besfvRG8XtDl3ywNny0VmnHd4CKtnwKqGjPF33FtX63VX0NWH/TBhfcZ4EiIYEz923hpoEewYFFcX7nBoIfIYJE0X4FVhT8V4FjIX88VxQC6IKKF3FEYYDN1xb/13pCkYA5aGoM+INrkYFF8YA0KBbh94FDQYFCiBYkWHUmuBEoOBQqeG9RqBFTKBQwSH9XmBFZKBT4FwD614UV8YVCsYNkKIVp+DpmGBRE6BMQoAQ1AIGlxhZJ6BMYIHRZt3JI5hZPaGAWRnwCMYPS5xZVSGGjtmCBiH1rsYUg/2ZhzFcQPhiB92eDPREFiGYQQUiJ/hd6AHgTeRKKojiKcNJ54saEnLiGrNOGqtgVrMg6LViHtUaIBFiAiyiLpjaJ0fWKqbOJuwhsRoiLavGGRYGKv+gWd2hgfDgQsRiLqTiE5gaFOTGD1KiHhdgWh7gTw7eNt/iMauGIO3F84piI19gWYTiGJweJy+eLwcWLPYGGPWGE8piJ3mhnTHiPRUZ79diKpuOOmdOMy4gQzohy6kVsYVaN/TWAA0GIl6ZfueWPkcONDcZpi9hpCvaQXDaOGiaJiRh3Bnll6wiJmiiShJc6EBJvqcEwDBdm80hmBxGMlkc8mGc6jYKSX7eSYf+Gj42mjwXBhK/nY6vDGANxAjepcX54bejIjwGHkmIzdv7ngUppEEJZEB6iGXrHFn8YlWOXdwwXbxCJE9molfJGGfr2HP/WL1fZiAUnljNDF9CRGn3ilA9niWzpEF+ZE/BYl3a5ac7Ygs6ofYbGkEJHi4BpZwaodVLQjYUJZwl4fOS4j1zGgIfXBCJZjoEWjA8YjJCZk/koe50JAMbYjnpJOncJE2+YAGMQCdwlEMSojEJ2hFlxhztXXsnYE4RZfGTxhOdHBlnJEzhYi2FRhSoYluH4mMe4dwUnf+S1lo9oYqETAV4DEqXpEucIAI5XWpBXnT6hmZ4jGmh5gmgBj6b/h3oDkZd4+Jmg450bOGx/eTkE8J7wqZ7212u3yThXAiffGYJgQYr82Z9zgRO/6Z6imJ8dMZ2ho4vuCZ8KOhIGCjrsmDkKSqAFCoz0qDm0UiHrCWyheTl0RxcSqoZn8YYiipTahh9WAp8MehayCZW1mWxEuaAZmpvRqJvRKG0XahoxOhbCaW/EORMESRCx+KOM06EYOp/I2XfJyZw+l1+DqIcNOaQ0AqNGShbVWaV0aXUIpmASWTwXaTgfcKLvmaIq6omtl5fmKRMeqZF/Bjj3WaTSWWklGZLmU3hsmicfioWbFpMCgHlGqKczyaYRKqYhSqKsSaiF2nE38ZNlRoGK/3p7Y5GEK1pzSqgT7YmbMkpg4tV0vakT9dmHZlGFPGpvvqmYmjMBN2KVOfqC5sYESSphPIGglzMBoVIBqAqeZ3GOVsp4PPGgkTM3H8AclmOrY8p6AmGmZLqdFXo5cvF1v5E4wkpuHmACSfkTG8o4ciEub+Ks+omMUMmCLRAEdFgYglMCFmABJTAfwbKtWFmjRNGpjPMeTZmqadGjPxGgmTMBJWMBLieoaumqQwGrmGOqB1CrbzqXujoUvMo4sloetMqvdnisRZisl+OrwApwz1pr1Wo4y/o1KzKlWBmt05ps10oQHqKtE8qtknoUClADSlCQmjOu5Xquh+KxabGpQv+Rh8RjBAp5OfBaHfKKFvRarxPJOfharvv6s2cBjv+6kcKIFtqJsM75nNF5sWtxpkLhp5wToUFyp14IbI26OW3qoUgLFtYmrQRRtpSHts8WKmJLs2ERqfOnc93KE4ywBp/jGmPynvJZsJdKX05XozZ7E2hACMRTA3PgOR8Qb9DpsMEZquamdqK6E2tgPpLQf0fqgWuptDkxucWTB5xDAkUJf2aRq5MXeVeKE51QPHKABpwjNRaQrmP7FcZKrOUJsTyBBnmQCIfbOSSQGiXAlXw7mlcRKPNBlIwrvFVBABHQHKGLp8jLFb07tdb1vF4BuyBKvVShtceLvU0RtvsWvNz/+xRhG6zTG75RQSZ5WwInIBom67zm+xQjOzMlC77vuxTpAQMwECFy0b5dW79PcaERsLj0679KURwWALzqSsBLcSMMzL8McZIs8m5516AKDBFhy7UIUZMD4W8AR8EV/BC/+qsVYLEQMZVHF3BW6cEfHBEegsANMZUXVyoxt8JKoaC/MQEYjBAwTDkoMsM0fBTj27ElTBlHJxgp/MNALIoOnBBTKR9h18FIDMRam8MFcaECcXfwJpdR3BYqvMUv0cVe3BJgHMbKRcZrMcZmjBJonMbOxcZoscZuvL1x7BVwvBJqW8F1nBIt+r55fBKBG759bBJBy72BXBKay8eVeLD+/1vIJmG15svIc+y+0Gq2ePyUKWs6dyx1IFsQd5zJ3uWH7Eo6kNqt4WcHc9sUkCwSg9w5JJipfit19tZ0UJHKIXHIoAOqj4vLbOcUtBwSTys6MMiqrgqDSorKcOHIoIOrlhiGh3C6S9HLcAaP5omGyJwU0BzJFHHNpubJWqHNm7bHV+HNivbHVSHOhrbKU2HOgWbLVqHOgfbLWOHOEYGaabCahUrJ9xyyoFPNVCHPDzGbxcqipyy8/twQuwnLmhrKmLzJrvipuey4BIY64NzOZqGcgNeq33Y65NzPZ3Gd1wN5AEC6+Xc66CwVBd0Q43kBqVe7tHtztls67FzO2AzP4f+MzS7d0t1s02Jx0jotlT29nz/9FTwd1EZJ1Dlt1Fsx1NHFzQbB1LNsxhN9cwP9yWH8xxv9zGQctCVtzWTMzjHNFErdXDRtuoocFWHdXPzMz1iN1EcdyU5d05Ec1Rw9x1dt0pG81U89x1+tFCnZxGfdXWPNFMbr09is1kkx2AXx12ackl+n2GxclTjJ1unslZL9FGU5IINT1JVdw3A5wZsN158919hcBSawXQ29fQwNO+E1XpMK2nY41aozX6+c1KAsy68zYBFN29gYua4TYRmt22yx16bTYfT1YcDNFoGdOirGYvps1sf80vXr2NX11jJd2LAt2pPc3KVT13mtg9f/jTp4zcu1PduuI9zdvRbhPTrJbddtYd6mY9jnvRbr/bzSzRDwTdChXd35zd777dw07J8ALoribcakbdpkUd+9tdrXQ14LUeD2zN9bLNtUlxAKHgAMns5kjNu7bBASjn4YHsa+LXgIoeHu9+FeTNyl5QmpTc+i4K8QvsXL7QWg4IE752HYTcatTGCIsGItpt9mrMsl7tpdvaoENgRZgeDFdY4eHQAgLeQbEYdzaHgs67L1h4YpvdLx/BE4O2cKueU6e32Z7MlhntrxnREB2mmCqG2jnLJrHrf+zRG66JETl+MJjakKbcwd4YuoFon4BuSl5ecrSNUdgYkuSRBYO3HB/4zRpSXMvy3oHRECZiAGbcCTAPC1tqfMuorppVvmKyzNtuvpOD3gbk3mbf3kcvhjK9uyzPit4Wp7cm3iGrHlmKYAXv5f7grmd+7kFoGYDWav45feeK4RjolgAJt97u3oGDGZCDYKCZt98/3mGkHorfYG5lMJAMCdVQ7dWf7okT7plU4DkQ4JQ4aeYE7mY47PN47EcMtzCfDqa40R7AWuA3EHQaDqQMbqnHbqcz6j5ubKE57uE/F7j0AHxaOztCjrwCdtOxrLuQ3rFKF1mIBgiTm0vs5sW5joLv7iEzHso/ZnxZ5sIi2Gz87VF6Hs5kOZUdvsyTa7n3jfSLFsDxgHMf+mmdK+ef19vRchCBRACn5wZHzACRRQCDZGZHCAB41A5SHwB02QCZpw8zhfEbWO8EBX60NW8DsLbHfs4ARBz/Ys5qSuFMjWaXBQkQgmBwJxCUO78vTVBxfA2gFdWrQp0Jf87hXB8cUDAHLuBkw7bCQoy7tJo7ZN9xSBantAkgi2BwKxCFFrbH4OuQS28A0P9hlB7cUTAjUPfQJB+cQTAgIxCJMQYxbP8PN30fS1nEia8SQ/EQG++uXBbGFo49b5eCFtgyMPFPMW79F368O2gzEucVfO0p9408Ev+BjRqRXffdTt4w5xXlrgsvEOCKQqEB+Pe+4O7Q3xpJc2aj8W74b/YGFGsP34bnvczelZl6VaN2r+lf3orwC6z/i8feQQEXd2XzwTbz54oAgWVv95hujFDBAABA4kWNDgQYQJFS5kqHBAw4EKBEycSEQixYlGPmHkyNFNR5ACII4kWdLkSZQpVa4kCSLAy5cLWM6kWfIhSQMYMQBYwfHBRYxNOlKo01EoRwo1lS5l2tTpTAQZLmhg8NQqzZsjX9QwYODBQAxdXUgQ2BPjA7MUv1rymXbi16tx5c6lW9fu06wHISipAbdkWANjBQIWPFgsWQCEEd9l3NjxY8hO8xbEgJGCAoEKjmh5EXFzZ4EQWgTxm/kzQdGkPXMeeCeIEtCRZc+u28CD/wmZAm3jHrg7N22rkwdC6GgAQAiMmJFTVG4Z8/HkApdPvDxdgAJHdCgaeQ7c+3eaCGAGcJBAPMzy51+WB89UuEAJIIljtDKfYv3iAOxPtKK/oxSOrAiFI+PaM/BAiBoY7yUgFgygwQVFQBArhICiiIL4OMoQow0xAqDDiT4MyaOOJjTxxIEYcHBFFlFU6T2BovDJQgEs4shGpACgkQgdjbqxKMtcFNLABBxkwkgHHRjyJBilM0OMNhDLiaKdppxoJ7cEgMtKAXbiyScud4pDpyXLBM6l8RZAEyY1F/zNzIaaRGirruCi0yuwDhvoztIUA4BPgQCFc1DIopqqKgAMpWtKIEURJZShASKVdFJKK7X0Ukwz1XRTTjv19FNQQxV1VFJLNZXUR1NVdVVWW3X1VVhjlXVWWmu19VZcc9V1V1579fVXYIMVdlhiizX2WGSTVXZZZpt19lloo5V2WmqrtfZabLPVdltuu10yIAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Serum concentrations of 11-deoxycortisol (11-DOC) and cortisol before and after the administration of metyrapone (750 mg every four hours for six doses) in normal subjects. The fall in serum cortisol concentrations stimulates the secretion of ACTH, leading to a marked increase in serum 11-DOC concentrations. To convert serum deoxycortisol values to nmol/L multiply by 28.9.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Spark RF. Simplified assessment of pituitary-adrenal reserve. Measurement of serum 11-deoxycortisol and cortisol after metyrapone. Ann Intern Med 1971; 75:717.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_7_9342=[""].join("\n");
var outline_f9_7_9342=null;
var title_f9_7_9343="Beta hemolysis 1";
var content_f9_7_9343=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Listeria monocytogenes on blood agar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 365px; height: 246px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The clear areas around each colony of Listeria monocytogenes are characteristic small zones of beta-hemolysis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_7_9343=[""].join("\n");
var outline_f9_7_9343=null;
